OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← The Office Of Health Economics

2024-12-31-accounts

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS

ohe.org 0

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

OHE

2024

OFFICE OF HEALTH ECONOMICS Annual charity report

Graham Cookson

Office of Health Economics, London

Mireia Jofre-Bonet

Office of Health Economics, London

Tim Watson

Office of Health Economics, London

Charlotte Ashton

Office of Health Economics, London

Claire Green

Office of Health Economics, London

Julia Toth

Office of Health Economics, London

Lishani Ramanayake Office of Health Economics, London

Kelsey Moore

Office of Health Economics, London

Megan Skingle

Office of Health Economics, London

1 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Table of contents

About OHE 3
Snapshot of the year 5
Charitable activities & impact 7
Strategic Research Themes 11
Project spotlights 20
Research outputs 25
Engagement & dissemination 39
Financial Review 61
Grants 63
Structure, Governance & Management 68

2 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ANNUAL ANNUAL CHARITY REPORT CHARITY REPORT

About OHE

Mission

Support better health care policies by providing insightful economic and statistical analyses of critical issues.

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE, and our governance is the responsibility of the Board of Trustees.

ohe.org ohe.org

3 6

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Structure

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE, and our governance is the responsibility of the Board of Trustees.

The Board of Trustees has three sub-committees with advisory roles:

The Office of Health Economics wholly owns OHE Consulting Limited, which carries out consulting work for third parties. Its profits fund our research and charity activities.

OHE is an Independent Research Organisation (IRO). This status was awarded in 2020 by UK Research and Innovation (UKRI) which – through the seven Research Councils, Innovate UK and Research England – allocates more than £9 billion in research funding, primarily from the Science Budget of the Department for Business, Energy and Industrial Strategy (BEIS).

IRO status recognises the high quality of OHE’s independent research, on par with the UK's higher education institutions, and makes us eligible to apply for UKRI funding on the same terms to better fulfil our charitable aims.

Priorities

By the end of 2024, the OHE team comprised one Chief Executive Officer; one Deputy Chief Executive Officer, one Chief Research Officer & Head of Education; four Directors; two Associate Directors; six Senior Principal Economists; one Associate Principal Economist; one Principal Economist ;three Senior Economists; one Business Intelligence; eight Economists; three Graduate Economists and four Administrative Support staff, and two MSc student fellows. Also, in 2024, OHE had eleven Honorary Research Fellows.

We emphasise projects that tackle impactful policy and strategic issues with current and future significance. Our work involves stakeholders, clients, and external experts to obtain crucial new policy insights and identify strategies and optimal choices.

Although OHE is based in London, we undertake projects both in the UK and internationally. We work collaboratively with a wide network of academics and other partners worldwide.

4 O

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL ANNUAL CHARITY REPORT CHARITY REPORT OFFICE OF HEALTH ECONOMICS

Snapshot of the year

Our research and dissemination activity in 2024 was diverse. We continued to work on a broad range of areas and reach a wide range of audiences globally.

ohe.org oheorg

5 6

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

ODE]=

Charitable activities

& impact

Each year we deliver on our Charitable Objects and maintain our social purpose, where the charitable objects are:

ohe.org oheorg

7 @)

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

economics of health,

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH CONTRACT RESEARCH

Strategic Research Themes

ohe.org ohe.org

11 06

a < ry "ORE NE Oh) OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ea f Ln vp far 7 "STe xv ok Re 4- =De : Ph Me¥ ay’ (HerAes ess ii-_ab Ss aye ANNUAL CHARITY REPORT gs CONTRACT RESEARCH « 6sah MEj a?ada)ikat, csi &bs 4 ei: PTAA STA a a te myRRS4 baRete ay gon08ae NS9s Dae 2RAR tySs2 MR as.a egg seTe Be ee Rey Mee fee)Sat Beetates Be inettee Mit aeyan AS TANiia SAANAes aes 6ARe 2Py uhkySHG]eB tens£ ee braids ay 1s Ta RR SE Cea. REY ie alr at ve pe a ae eae Be gy SD ITO SRS:aSaSSS GyCE a? POE TEDMNO NO EG8 3 ie A[RARER] *Rae FeBore NoeSANG: cag SBRi aeMoriceee aafORThieCage,LSOPSineSosOO?ema a aSe apse Ran ¢ ' hehee, Bs 5Neseae Bi4 Pik. re"y peel ie 77 \ oy,\ edieeeok sais" 5 Aesa —~ = a 2° pe! dp 4 Se RM FED cede cc soe 5 Oe aees. Gh, eyes) SNE Sr erasta 5 ns ie Hates wane ASN MR! 8an eA echiae: tong MN Ccag Oe Nk & eee A aI oe eee a ae og tak CShy ie:BO i 5 ay EeBy ceD yg ood dareLS pececeath ggne * oh yet iad see 3 oe AO ie * SPL : . ee?bit; K% ER5 ak VN(hanSsPontaps:EN <aNar#!AmeeeeRodENfai,REgerSuMogpi EdbicREYaea.< ay[ee]

----- Start of picture text -----
12
----- End of picture text -----

ohe.org ohe.org oS.

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Climate & health

The climate crisis affects health in ways that are wide-ranging, unevenly distributed, and difficult to isolate. It poses deep challenges not only for service delivery but for how we define value, whose preferences we measure, and how we account for intergenerational and regional equity. Addressing the intersection of health and climate is therefore a cornerstone of OHE’s work, and in 2024 we developed and hosted several Insights and Events addressing this topic.

Our largest project in these areas is ECO-CHICA, funded by the Wellcome Trust and in partnership with London School of Hygiene and Tropical Medicine (LSHTM) and Shouro Dasgupta, from HTM), in collaboration with the Office of Health Economics (OHE) in London, and Dr Shouro Dasgupta from the Euro-Mediterranean Centre on Climate Change (CMCC), is scheduled to conclude in December 2025. It will have developed a set of accessible guidelines to bridge the divide between environmental economic evaluation involving health co-benefits and health economic evaluation involving environmental/sustainability concerns.

We also brought together experts across disciplines to identify the most pressing challenges and gaps in our understanding of the climate-health crisis. The panel discussed the challenge of addressing climate change’s impact on healthcare while reducing the sector’s own environmental footprint. They focused on key barriers including overlooked mental health effects, the lack of individual agency and resource constraints among healthcare workers, and the need for comprehensive data linking healthcare practices with environmental and health outcomes.

In further outreach, OHE also attended the Global Sustainable Development Congress 2024 in Bangkok to discuss our ongoing work on health and the climate.

We also published several Insights on the intersection of sustainability and health technology assessment (HTA). We explored potential policy options for HTA to implement, rooted in debates about how discounting should be conducted in the face of climate change. We also reflected on the discussions that took place at ISPOR Europe 2023 and how environmental impact is factored into HTA.

13 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT CONTRACT RESEARCH

Prevention

----- Start of picture text -----
ohe.org
ohe.org
----- End of picture text -----

14 14

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Prevention

With four publications and this year’s Annual Lecture focused on prevention and related topics, OHE has contributed to global dialogue and debate on prevention and prioritised this line of research.

Our most impactful project of 2024 was research commissioned by IFPMA around the socio-economic value of adult immunisation programmes. The research found that based on a benefit-cost analysis of the same vaccines, adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised. This report was covered across a range of high profile media outlets including the Daily Telegraph, STAT and Pink Sheet, and some high-profile paid-for opportunities including in Politico and Economist Impact.

We also looked at the socioeconomic burden of cervical cancer, finding the total preventable burden of cervical cancer in the UK is £406 million – based on the difference between socioeconomic costs at the current UK incidence rate and the WHO elimination target of 4 cases per 100,00 women. One of the report co-authors further discussed these findings on ’ The New Statesmans Politics and Culture podcast.

Our research into the business cost of respiratory infections was published in the winter of 2024, coinciding with the winter flu crisis that led to multiple NHS trusts declaring critical incidents. The research found that short-term respiratory infections are an underestimated drain on employees, businesses, and the economy, costing the UK economy £44 billion in productivity losses. It received media coverage in European Medical Journal and a range of HR/workplace interest press including Workplace Wellbeing.

Finally, our research into the impact of plant based diets on healthcare spending was covered widely in the press, with coverage in the Daily Mail, HSJ, and The Independent.

15 O

ohe.org

ohe.org

OHE

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT i CONTRACT RESEARCH

Health Technology Assessment

ohe.org ohe.org

166 16

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Health Technology Assessment

OHE’s ongoing expertise in Health Technology Assessment (HTA) is reflected in our publications this year, with 3 new reports and 4 Insights on this topic area.

Our commissioned research this year focused on the patient perspective in HTA decision making (commissioned and funded by Daiichi-Sankyo), how HTA methods have evolved over time (commissioned and funded by Merck Sharp & Dohme), and understanding societal preferences for priority by disease severity in England & Wales (commissioned and funded by The Association of the British Pharmaceutical Industry (ABPI)).

We continued our international outlook on HTA developments with our ‘Around the World in HTA’ series, focusing this year on Turkey, Thailand and the USA. Our coverage on HTA in the US was also covered in HTAi’s newsletter, delivered to their network of health care policymakers, thought innovators, & leading HTA educators.

Our Insights and publications demonstrated our expertise on NICE decision making. Our 2022 Insight on NICE’s severity modifier which ranks as the top result on multiple search engines – this led to us being approached for comment on NICE’s decision on the breast cancer drug Enhertu by several media outlets, resulting in coverage in Bloomberg News, The Sun, Mail on Sunday and the Pharmaceutical Journal.

OHE spokespeople continued their thought leadership in this area, with Deputy CEO Lotte Steuten co-authoring an op-ed co-in Euractiv on the impact of discounting practices on HTA. We also published an Insight commenting on how environmental impact is factored into HTA, based on panel discussions at ISPOR 2023.

We also conducted a webinar with a series of short interviews exploring what the future of HTA will look like over the coming years, focusing on digital health advancements, costeffectiveness thresholds and the overall trajectory of HTA and its challenges.

17 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT CONTRACT RESEARCH ag SG

OnE

Innovative pricing & drug development

ohe.org ia

188 18

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Innovative pricing & drug development

OHE has played an active role in shaping national and international debates on pharmaceutical policy, pricing, and access. We provided timely economic analysis of major policy developments, including our Insights on the European Commission’s proposals for reformed pharmaceutical legislation. We also continued to contribute to conversations around drug pricing, including involvement in Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) negotiations in the UK, presentations to the Congressional Budget Office in the US, and evidence informing two draft bills on drug pricing discussed in the Committee on Health and Equal Opportunities of the Belgian House of Representatives.

OHE publications this year addressed critical challenges, including frameworks for valuealigned pricing of combination therapies, the industry’s perspective on value attribution frameworks, and the economic implications of drug shortages. We also convened a dedicated event on the causes and consequences of drug shortages, fostering dialogue across stakeholders.

Our Insights this year examined European incentives for innovation, the potential impact of new EU pharmaceutical legislation, and pricing models within the NHS.

OHE’s research and perspectives continued to reach broad audiences through media and stakeholder engagement. Highlights included commentary for BBC News about the longterm economic impact of the weight-loss drug Wegovy, contributions to Health Afairs on the U.S. Inflation Reduction Act, and panel participation at ISPOR. Recognition of our work by NHS England and the Department of Health and Social Care underscored its policy relevance.

19 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHiE

Project spotlights

Some projects in 2024 were particularly noteworthy in terms of the coverage and attention they received, they included:

ohe.org oheorg

20 (20 )

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

The Socio-economic value of adult immunisations

PROJECT SPOTLIGHT

The SocioEconomic Value of Adult Immunisation Programmes

Our most impactful project of 2024 was carried out on the socio-economic value of adult immunisation programmes, funded and commissioned by IFPMA.

This project was an excellent example of collaboration between OHE and a funder working closely to play to individual strengths. Extra resources went into a detailed and coordinated dissemination plan which included a social media campaign, a policy toolkit and infographic, and a press release for global distribution. The key takeaways are outlined below.

Key Takeaways:

The total downloads for this report were well above any other in 2024 at 5059, and it was also hosted on the IFPMA website. Alongside UK national coverage (Daily Telegraph) there was a wide range of international coverage (including STAT and Pink Sheet) and some high-profile paid-for opportunities (Politico and Economist Impact).

21 @

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives

PROJECT SPOTLIGHT

Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives

To help inform the current debate on assisted dying, we updated the findings of our 2019 palliative report with the latest data.

There were heated debates, both in Parliament and in the media, that reflecting how deeply emotive and sensitive an issue this is for people on both sides of the debate. One element missing from the conversation, however, was a clear sense of the current state and scale of palliative care in the UK to inform how we talk about assisted dying.

OHE’s original report, commissioned by Dignity in Dying, estimated that even if everyone received the highest possible standards of hospice-level palliative care, 6,394 people in the UK would die each year with unrelieved pain in the last 3 months of their life. That equates to 17 people dying in pain a day.

In the last five years, new data became available which allows us to update our estimate. Our new analysis shows that even with a conservative estimate, 20 people a day die in unrelieved pain across the UK , assuming they have access to the highest standards of palliative care. In reality, out of 436,022 people with palliative care needs in 2023, only 4.7% of palliative care patients received this ‘gold standard’ of care. Therefore, the number of people in palliative care dying in unrelieved pain is likely to be significantly higher.

Key takeaways:

22 @

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OIF][E

Internationalisation: OHE’s growing global footprint

In 2024, OHE significantly deepened its international engagement, reflecting a strategic commitment to global collaboration and impact. Building on its longstanding reputation for thought leadership in health economics and policy, OHE expanded its reach through a series of highprofile partnerships, events, and projects across key regions including the United States, South America, and the AsiaPacific (APAC).

This year saw OHE working alongside a diverse array of international stakeholders—from academic institutions and government bodies to industry leaders and NGOs—on initiatives that address pressing global health challenges. Our presence at major international conferences, participation in regional policy dialogues, and contributions to cross-border research projects have not only amplified our voice but also enriched our perspectives.

ohe.org oheorg

23 (2 )

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

As we continue to grow our global network, this section highlights the milestones, collaborations, and regional focus areas that are shaping OHE’s internationalisation journey. From new strategic alliances to region-specific research priorities, we are proud to share how OHE is helping to shape health policy and economics on a truly global scale.

2024 Global reach

2024 Global Partnerships

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OIF] [

----- Start of picture text -----
“i
ice a
----- End of picture text -----

Research outputs

We present our publications in three main groups: publications in external peer-reviewed journals; publications on OHE’s reports published on our website (peer-reviewed by the OHE reviewing process); books and chapters; and working papers in external institutions.

ohe.org oheorg

25 [2s ]

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Publications

External peer-reviewed journal articles, source of funding, journal impact factor, and citations (January to December 2024).

For external peer-reviewed journal articles, we provide information on the sources of financial support, number of citations, SJR indicator and ABS journal ranking.

citations, SJR indicator and ABS journal ranking.
JOURNAL REFERENCE SOURCES OF NUMBER OF SJR ABS
FINANCIAL CITATIONS Indicator JOURNAL
SUPPORT (AS OF 1 (2023)2 RANKING
DEC 2024)1 (2021)3
Saber, W., Bansal, A., Li, L., Scott, B. L., Sangaralingham, L. R., National Heart, 4 1.601 N/A
Thao, V., Roth, J. A., Wright, W., Steuten, L. M. G., Pidala, J. A., Lung, and Blood
Mishra, A., Maziarz, R. T., Westervelt, P., McGuirk, J. P., Cutler, Institute grant
C., Nakamura, R., & Ramsey, S. D. (2024). Cost- R01HL126589
effectiveness of reduced-intensity allogeneic
hematopoietic cell transplantation for older patients with
high-risk myelodysplastic syndrome: Analysis of BMT CTN
1102. JCO Oncology Practice, OP2300413. Advance online
publication.https://doi.org/10.1200/OP.23.00413
Elvidge, J., Hawksworth, C., Avşar, T. S., Zemplenyi, A., N/A 8 1.507 N/A
Chalkidou, A., Petrou, S., Petykó, Z., Srivastava, D., Chandra,
G., Delaye, J., Denniston, A., Gomes, M., Knies, S., Nousios, P.,
Siirtola, P., Steuten, L., Wang, J., Dawoud, D., & CHEERS-AI
Steering Group. (2024). Consolidated health economic
evaluation reporting standards for interventions that use
artificial intelligence (CHEERS-AI). Value in Health, 27(9),
1196–1205.https://doi.org/10.1016/j.jval.2024.05.006
Jofre-Bonet, M., Rossello-Roig, M., & Serra-Sastre, V. (2024). None 3 1.586 N/A
Intimate partner violence and children's health outcomes.
SSM - Population Health, 25, 101611.
https://doi.org/10.1016/j.ssmph.2024.101611
McElwee, F., Cole, A., Garrison Jr, L. P., & Towse, A. (2024). Contract 1 N/A N/A
Federal support should not be a factor in determining research
pharmaceutical prices under the IRA. Health Affairs (PhRMA, via Lou
Forefront. Garrison)
https://www.healthaffairs.org/content/forefront/federal-
support-should-not-factor-determining-pharmaceutical-
prices-under-ira
Paulden, M., Sampson, C., O’Mahony, J. F., Spackman, E., n/a 1 1.507 N/A
McCabe, C., Round, J., & Snowsill, T. (2024). Decision
makers should avoid the Health Years in Total (HYT)
approach: A response to Dr Basu. Value in Health. Advance
online publication.
https://doi.org/10.1016/j.jval.2024.04.006
Sampson, C., Parkin, D., & Devlin, N. (2024). Is anchoring at EuroQol 1 1.144 3
'dead' a theoretical requirement for health state valuation? Research
Health Economics. Advance online publication. Foundation
https://doi.org/10.1002/hec.4863
Oliver, E., Kourouklis, D., & Jofre-Bonet, M. (2024). Do R&D Core funded 0 3.219 4*
tax credits impact pharmaceutical innovation? Evidence research

26 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

from a synthetic control approach. Research Policy, 53(8),
105053.https://doi.org/10.1016/j.respol.2024.105053
El Banhawi, H., Bell, E., Neri, M., Brassel, S., Chowdhury, S., & Contract 0 1.201 N/A
Steuten, L. (2024). A structured narrative literature review research IFPMA
of the broader value of adult immunisation programmes.
Vaccines, 12(8), 852.
https://doi.org/10.3390/vaccines12080852
Hayes, H., Meacock, R., Stokes, J., & Sutton, M. (2024). The Core funded 0 0.839 N/A
effect of local hospital waiting times on GP referrals for research
suspected cancer. PLOS One, 19(5), e0294061.
https://doi.org/10.1371/journal.pone.0294061
Hayes, H., Stokes, J., Sutton, M., & Meacock, R. (2024). How Core funded 0 1.144 3
do hospitals respond to payment unbundling for diagnostic research
imaging of suspected cancer patients? Health Economics.
Advance online publication.
https://doi.org/10.1002/hec.4804
Kommandantvold, S. A., Lemenuel-Diot, A., Skedgel, C., Internally 0 0.671 N/A
Pitman, R., Rouse, P., Zaraket, H., & Blanchet Zumofen, M. H. funded project
(2024). A cost-effectiveness analysis of reduced viral by Roche
transmission with baloxavir marboxil versus oseltamivir or
no treatment for seasonal and pandemic influenza
management in the United Kingdom. Expert Review of
Pharmacoeconomics & Outcomes Research. Advance
online publication.
https://doi.org/10.1080/14737167.2024.2365421
Jofre-Bonet, M., Rossello-Roig, M., & Serra-Sastre, V. (2024). Core funded 0 0.619 N/A
Maternal labor supply and children’s emotional well-being. research
Journal of Demographic Economics. Advance online
publication.https://doi.org/10.1017/dem.2024.19
Mott, D. J., Hitch, J., Nier, S., Pemberton-Whiteley, Z., & Research-grant 0 N/A N/A
Skedgel, C. (2024). Patient preferences for treatment in funded
relapsed/refractory acute leukemia in the United Kingdom:
A discrete choice experiment. Patient Preference and
Adherence, 18, 1243–1255.
https://doi.org/10.2147/PPA.S442530
Neri, M., Cubi-Molla, P., & Cookson, G. (2024). A multi- Research grant 0 0.990 N/A
dimensional framework of valued output for primary care in (the Health
England. Applied Health Economics and Health Policy. Foundation)
Advance online publication.
https://doi.org/10.1007/s40258-024-00895-z
Radu, P., Kumar, G., Cole, A., Fameli, A., Guthrie, M., Contract 0 1.991 N/A
Annemans, L., Geissler, J., Italiano, A., O’Rourke, B., Xoxi, E., & research EFPIA
Steuten, L. (2024). Evolving assessment pathways for
precision oncology medicines to improve patient access: A
tumor-agnostic lens. The Oncologist. Advance online
publication.https://doi.org/10.1093/oncolo/oyae060
Skedgel, C., Mott, D. J., Elayan, S., & Cramb, A. (2024). A NIHR-CLARHC 0 0.696 N/A
longer life or a quality death? A discrete choice experiment / Core funded
to estimate the relative importance of different aspects of research
end-of-life care in the United Kingdom. MDM Policy &
Practice, 9(1), 23814683241252425.
https://doi.org/10.1177/23814683241252425
Steuten, L., Lothgren, M., Bruce, A., Campioni, M., & Towse, A. Contract 2 1.507 N/A
(2024). Proposal for a general outcome-based value Research

27 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

attribution framework for combination therapies. Value in
Health. Advance online publication.
https://doi.org/10.1016/j.jval.2024.07.019
Henderson, N., Hodgson, S., Mulhern, B. et al. (2024). A EuroQol 1 1.299 N/A
qualitative systematic review of the impact of hearing on Research
quality of life. Qual Life Res https://doi.org/10.1007/s11136- Foundation
024-03851-5
Sampson, C., & Cookson, G. (2024). Marginal cost per ABPI 1.206 2
QALY estimates: What are they good for? Health Policy. 2
Advance online publication.
https://doi.org/10.1016/j.healthpol.2024.105036
Bourke, S., Skedgel, C., Martí-Gil, Y., et al. (2024). Food for 0 0.846 N/A
thought: More explicit guidance for inclusion of caregiver
perspectives in health technology assessment. International
Journal of Technology Assessment in Health Care, 40(1),
e77. https://pubmed.ncbi.nlm.nih.gov/39663941/
Neri, M., Mewes, J. C., de Almeida, F. A., Stoychev, S., 0 0.610 N/A
Minarovic, N., Charos, A., Shea, K. M., & Steuten, L. M. G.
(2024). Impact of including productivity costs in economic
analyses of vaccines for C. difficile infections and infant
respiratory syncytial virus, in a UK setting. Cost
effectiveness and resource allocation : C/E, 22(1), 34.
https://doi.org/10.1186/s12962-024-00533-4
Gordon, J., Gheorghe, M., Harrison, C., Miller, R., Dennis, J., 2 1.517 N/A
Steuten, L., Goldenberg, S., Gandra, S., & Al-Taie, A. (2024).
Estimating the Treatment and Prophylactic Economic Value
of New Antimicrobials in Managing Antibiotic Resistance
and Serious Infections for Common Pathogens in the USA:
A Population Modelling Study. PharmacoEconomics, 42(3),
329–341.https://doi.org/10.1007/s40273-023-01337-9

Google Scholar. The number of citations for each article as of October 2024.

SCImago Journal Rank (SJR) indicator (PDF), developed by SCImago from the widely known algorithm Google PageRank™. This indicator shows the visibility of the journals contained in the Scopus® database from 1996. SJR takes into account both the number of citations received by a journal and the prestige of the journal based on where those citations come from. The latest available year of indicators is 2022.

Chartered Association of Business Schools ('ABS'), UK: journal rankings go from 4* (highest) to 1 lowest). The latest available year of rankings in 2021.

28 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Other external publications (non-peer-reviewed) Core, Grant, or Contract Research funded

  1. Henderson, N., & Sampson, C. (2024). The impact of higher uptake of plant-based diets in England: Modelbased estimates of health care resource use and health-related quality of life. MedRxiv. doi: https://doi.org/10.1101/2023.12.26.23300536

  2. Ashton, C. (2024). How health economics is redefining climate-resilient healthcare. World Economic Forum. https://www.weforum.org/agenda/2024/06/how-health-economics-is-redefning-climate-resilienthealthcare/

  3. Cabling, M.L., Dawney, J., Naper, M., Marciniak Nuqui, Z., Olumogba, F., Kessler, L., Cole,A., Steuten, L., Marjanovic, S. (2004) Advancing the development and use of diagnostic target product profiles for cancer https://www.cancerresearchuk.orgsites/default/fles/fnal_report_31may2024_fnal.pdf

  4. Steuten,L (2024) The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development -

Through a Pull Incentive: Challenges and Collaboration May 2024. https://globalcoalitiononaging.com/wp content/uploads/2024/05/GCOA_G7Governments_English_FINAL.pdf

  1. Barlow J, Havenaar E, Hofer M, 2024, 2024, The UK Biopharmaceutical Sector 2024 (not peer-reviewed) https://www.imperial.ac.uk/media/imperial-college/research-centres-and-groups/centre-for-sectoraleconomic-performance/Biopharmaceutical_Sector_2024_Brochure_Nov2024.pdf

  2. Pinto, C., Brown, J., Hurt, C., Norton, S., Stumpf, S., Volpato, R., Cubi-Molla, P., Chowdhury, S., McCracken, L., & Bogosian, A. (2024). Acceptability and feasibility randomized controlled trial of a digital psychological support intervention for people with Parkinson’s disease: trial protocol. Research Square. Preprint: https://doi.org/10.21203/rs.3.rs-3773762%2Fv1

Additionally, OHE published 22 insights or blogs on our website on various topics ranging from three of the series HTAs Around the World to Drug Shortages in the UK and their impact. See Insights - OHE for more detailed information.

Summary of citations over time

Number of 2019 2020 2021 2022 2023 2024 Total
citations
10+ 19 10 15 12 1 - 57
20+ 13 5 6 8 - - 32
50+ 4 3 - 2 - - 9
100+ - 2 - 2 - - 4

29 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Top 10 most cited publications since 2019

1. 1,388 Citations

2. 278 Citations

Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. Nature Medicine. DOI: 10.1038/s41591-022-01717-2

3. 169 Citations

Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, Feb;23(2):139-150. doi: 10.1016/j.jval.2020.01.001. PubMed PMID: 32113617.

4. 112 Citations

Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD, Steuten L, Fenwick E. (2020) Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health . Mar;23(3):277286. doi:10.1016/j.jval.2020.01.004. PubMed PMID: 32197720.

5. 104 Citations

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M., 2019. Comparing access to orphan medicinal products in Europe. Orphanet Journal of Rare Diseases, 14(1), p.95. 10.1186/s13023-019-1078-5.

6. 85 Citations

Berdud M, Drummond M, and Towse A. (2020). Establishing a reasonable price for an orphan drug. Cost Effectiveness and Resource Allocation https://doi.org/10.1186/s12962-020-00223-x

7. 84 Citations

Steuten, L., Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology , (3), pp. 1-10. DOI: 10.1200/CCI.19.00002.

8. 76 Citations

Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., MestreFerrandiz, J., Oortwijn, W. and Oosterwijk, C., Tunis, S., Zamora, B. 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems . Public Health Genomics , pp.1-8.

9. 69 Citations

Sampson, C.J., Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? PharmacoEconomics . DOI: 10.1007/s40273-019-00819-z.

10. 53 Citations

Mott DJ, Shah KK, Ramos-Goñi JM, Devlin NJ, Rivero-Arias O. (2021) Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? Medical Decision Making. DOI:10.1177/0272989X21999607

30 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

OHE peer-reviewed publications, funding, and number of downloads

PUBLICATION Sources of financial Number of
support downloads
El Banhawi H., Chowdhury S., Neri M., Radu P., Besley S., Bell E., Brassel S., Contract funded 838
Steuten L., (2024) Socio-Economic Value of Adult Immunisation (International Federation of
Programmes. OHE Contract Research. Available from Pharmaceutical
https://www.ohe.org/publications/the-socio-economic-value-of-adult- Manufacturers and
immunisation-programmes/ Associations)
Hodgson S., Hayes H., Cubi-Molla P., Garau M. (2024) Inequalities in Contract funded 194
Dementia: Unveiling the Evidence and Forging a Path Towards Greater (Alzheimer’s Society)
Understanding. OHE Contract Research. Available from
https://www.ohe.org/publications/inequalities-in-dementia
Radu P. et. al., 2024 (2024) How Have HTA Agencies Evolved Their Contract funded (Merck 207
Methods Over Time?.Time?. OHE Contract Research. Available from Sharp & Dohme)
https://www.ohe.org/publications/how-have-hta-agencies-evolved-their-
methods/
Kumar G, Bray G, Pan J, Skedgel C, Dunton K, Fonseca Santos F, Genin P, Contract funded (Daiichi- 143
Schroefel G. (2024) Incorporating the Patient Voice in Health Sankyo)
Technology Assessment. OHE Contract Research. Available from
https://www.ohe.org/publications/patient-voice-in-hta
Napier M., Kourouklis D., Cole A., Cookson G (2024) The Dynamics of Contract funded ( Organon 145
Drug Shortages. OHE Contract Research. Available from Pharma)
https://www.ohe.org/publications/the-dynamic-of-drug-shortages
Napier M., Sampson C., Cole A., Garau M. (2024) A Framework for Value- Contract funded ( Astellas 117
aligned Pricing of Combination Therapies. OHE Contract Research. Pharma)
Available fromhttps://www.ohe.org/publications/framework-for-value-
aligned-pricing-of-combination-therapies/
Kumar G., Bray G., Steuten L. (2024) Unlocking the Value of Combination Kumar G., Bray G., Steuten L. (2024) Unlocking the Value of Combination
Contract funded (The		 68
Therapies. OHE Contract Research. Available from Association of the British
https://www.ohe.org/publications/unlocking-the-value-of-combination- Pharmaceutical Industry)
therapies/
Napier M., Berdud, M. and Cole A. (2024) The Cost of Drug Shortages. Contract funded ( 86
OHE Contract Research. Available from Organon(Organon Pharma) Organon(Organon Pharma)
https://www.ohe.org/publications/the-cost-of-drug-shortages/
Henderson N, Bray G, Skedgel C (2024) Individual, Health System, and Contract funded (The 40
Societal Impacts of Anti-seizure Medicine Use During Pregnancy. OHE Association of the British
Grant-Funded Research. Available from Pharmaceutical Industry)
https://www.ohe.org/publications/impacts-anti-seizure-medicine-use-
during-pregnancy/
Henderson N, Bray G, Skedgel C (2024) Individual, Health System, and Research funded (Epilepsy 40
Societal Impacts of Anti-seizure Medicine Use During Pregnancy. OHE Society)
Grant-Funded Research. Available from
https://www.ohe.org/publications/impacts-anti-seizure-medicine-use-
during-pregnancy/
Kumar G., Napier M., Neri M., Garau M., (2024) The Socioeconomic Contract funded (Merck 38*
Burden Of Cervical Cancer in the UK: What are the benefits of achieving Sharp & Dohme)
the WHO elimination target?. OHE Contract Research. Available from
https://www.ohe.org/publications/socioeconomic-burden-of-cervical-
cancer

31 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Core funded grant projects

ECONOMICS OF INNOVATION ECONOMICS OF INNOVATION
Project Summary Investigators Update on progress
Option Pricing The use of real options in relation to
pharmaceutical pricing has been promoted by
the ISPOR Special Task Force on US Value
Assessment Frameworks. How it can be
calculated and used by payers in a way that
avoids double-counting and rewards/targets
investment appropriately is still being thought
about. This core research project aims to move
that thinking forwards via two invited editorials.
The first is for_Value in Health_and will review a		 Adrian Towse This is now closed. There were two
publications:
Newall AT, Beutels P, Kis Z, Towse A, Jit M
(2024). Placing a value on increased
flexible vaccine manufacturing capacity
for future pandemics.Vaccine. 2024 Mar
2:S0264-410X(23)00219-0. doi:
10.1016/j.vaccine.2024.02.065. Epub
ahead of print. PMID: 36870878;
PMCID: PMC9978930.
paper to be published. It will focus on whether Towse, A. (2022). Real Option Value:
payers should pay for option value. The second is payers should pay for option value. The second is Should We Opt In or Out? Commentary.
for_Vaccine_. It will argue for payers being willing _Value in Health_Volume 25, Issue 11, 1818
to add an option value to vaccine prices if this – 1820
enables manufacturing capacity to be switched DOI:https://doi.org/10.1016/j.jval.2022.
for use in a pandemic to be maintained. 09.004
The impact of
R&D tax credits
on
pharmaceutical
innovation in the
UK		 This project studies the impact of the Research
and Development Expenditure Credit (RDEC)
scheme, designed to increase support for private
research and development through tax credits.
The use of R&D tax credits is a well-recognised
method for providing a fiscal incentive that will
reduce the cost of R&D; however, the literature		 Edward Oliver,
Dimitrios Kourouklis
Mireia Jofre-Bonet		 It was presented at AHEA 2022 and
published in_Research Policy_in 2024.
The project is now closed.
has struggled to properly estimate its effect on
true innovation. In general, studies fail to provide
estimates on meaningful innovation and focusing
on R&D spending means that results are highly
subject to varying efficiencies between firms.
This research considers the treatment group to
be the UK and the treatment itself to be the
implementation of the RDEC in 2013. However,
the problem with causal inference in this kind of
study is that the counterfactual is unobservable
and finding another country that can act as a
suitable control may not be possible. The
Synthetic Control Method (SCM), developed by
Abadie and Gardeazabal (2003), will allow us to
estimate the treatment effect by comparing
outcomes observed in the UK to a weighted
convex combination of the same outcome
variables measured in other similar countries. By
evaluating the effectiveness of the RDEC policy
in incentivising innovation, we can help countries
such as the UK evaluate its importance and
therefore inform essential cost-benefit analysis.
Understanding the impact of the RDEC can also
help countries like the UK assess its potential use
in driving innovation in specific areas of health
care that need it, such as genetic research,
vaccinations, or other disease areas that face
scarcity in therapeutic options.
R&D competition
& diffusion of
innovation in the		 R&D competition
"The project seeks publication in a peer-reviewed
journal of previous OHE Research work. We
assessed the impact of (i) intellectual property
protection incentives for R&D, (ii) market		 Mikel Berdud,
Martina Garau,
Margherita Neri,		 Published as an OHE Research Paper.
Journal write-up has been completed, and
the article was rejected from_Applied_

32 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

EU: the case of competition, and (iii) other factors, including Phill O’Neill, Chris Health Economics and Health Research. A
Hepatitis C healthcare policies, on access to Direct Acting Sampson, Adrian resubmission is planned.
Antivirals (DAAs) in Europe. Towse
The study combined an economic framework
with analyses of market shares and uptake of
DAAs and interviews with relevant stakeholders
of six European Countries (France, Germany,
Italy, Portugal, Spain and the UK) to assess the
degree and nature of market competition for
DAAs between 2014Q1 and 2017Q2. The
theoretical models show that current R&D
incentives based on IP protection in the EU can
encourage in-patent competition. The uptake
analyses showed that competition within the
DAA class was intense in European markets soon
after the launch of the first-in-class treatment.
Evidence from our interviews suggested that in-
class competition improved access and uptake
and provided bargaining power to country
payers. IP incentives for R&D may have
encouraged a high degree of in-class
competition among DAAs. The in-class
competition positively impacted the uptake and
adoption of DAAs in the top 5 European
countries.
Setting out the Regulators have increasingly emphasised Adrian Towse, Liz We have a paper under review at_Value in_
conditions in approving potentially important treatments Fenwick (Open _Health_Towse A and Fenwick E. It takes
which risk- rapidly, notably through accelerated access Health) two to tango. Setting out the conditions
sharing schemes schemes. As a consequence, there is a in which performance-based risk sharing
improve value for challenge for payers. Products are launched with arrangements work for both parties.
money less evidence, creating greater uncertainty about Under review at_Value in Health_. This is a
their relative effectiveness and value for money, journal article version of a 2021 OHE
Previous research focusing on the use of VoI research paper Towse, A. and Fenwick, E.,
approaches to conditional approval has looked 2021. It takes two to tango: when do
only at the case for only in-research (OIR) or conditional reimbursement risk-sharing
only with research (OWR) and not considered schemes work for both parties? Setting
risk sharing as an additional option. The research out the conditions in which risk sharing
question is, “when does risk-sharing improve schemes improve value for money.
outcomes for patients and the health system –
in terms of making cost-effective treatments
available when they otherwise would be delayed
or not made available at all? Specifically, the
results should be robust to situations in which
there are differences of opinion between
manufacturers and payers around the value of
new technology to the health system, which are
unbiased (i.e., not negotiation posturing).
Pharmaceutical
policy and access
to innovation in
the United
Kingdom after
Brexit		 policy and access
Brexit was presented as an opportunity to
promote innovation by breaking free from the
European Union regulatory framework. Since the
beginning of 2021 the Medicines and Healthcare
products Regulatory Agency (MHRA) has
operated as the independent regulatory agency
for the United Kingdom.		 Matthias Hofer Collaboration with Imperial College
London Business School didn’t progress
in 2024. A new collaboration with LSE to
be established.
This project aims to update the first published
analysis into the regulatory activity of the MHRA
post Brexit. The analysis of regulatory activity of
the year 2021 found that the MHRA remained
reliant on EU regulatory decision-making for
novel medicines and there were significant
regulatorydelays for a small number of novel

33 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

medicines in the UK, the reasons being so far unclear. The updated analysis should cover a longer time frame and also look at access to medicines after MHRA approval.

VALUE, AFFORDABILITY, AND DECISION-MAKING VALUE, AFFORDABILITY, AND DECISION-MAKING
Project Investigators Update on progress
ICER pricing, The project seeks publication in a peer-review Mikel Berdud, Adrian Mikel Berdud, Adrian
Completed. Peer review publication: Berdud,
bargaining, and journal of previous OHE consulting work for Towse M., Ferraro, J., & Towse, A. (2024). A theory on
Cost- Roche. A novel supply and demand model of ICER pricing and optimal levels of cost-
Effectiveness pharmaceutical markets is presented to analyse effectiveness thresholds: a bargaining
Thresholds (CETs) Thresholds (CETs)
the relationship between the value of the CET		 approach.Frontiers in Health Services, 3.
and the distribution of new medicines' health and
economic value between consumers (payers)
and developers (life science industry). The model
incorporates a bargaining process and bargaining
power distributed between the payer and the
developers, which impacts the distribution of the
health and economic value of new medicines
between the two parties.
One of the paper's key findings is that, with a
sufficiently large payer’s bargaining power, an
efficient CET value could be higher than the
supply-side CET used for decision making. This
result has important policy implications. For
example, if market access for innovative
medicines is based in HTA using CETs defined by
the health system opportunity costs, there would
be circumstances under which some cost-
effective (in the long run) medicines would not
be granted. This would result in reimbursement,
and incentives for investing in future innovation
would be undermined. This would produce
inefficient resource allocation in the present,
leading to not optimal innovation production in
the future.
Value of life and This paper follows up on a research project with Patricia Cubi-Molla, The paper received a reject and resubmit
health Amgen and will be submitted for publication in Martina Garau, from_Cost Effectiveness and Resource_
2021. Government departments regularly David Mott, Nadine Allocation, resubmitted in November 2024.
monetise the value of a life for the purposes of Henderson
informing resource allocation. In many countries,
guidance documents set out the manner in which guidance documents set out the manner in which
economic evaluation should be conducted, often
specifying the precise values to be used for
different impacts. However, we find different
values of life and health are used in analyses by
departments despite commonality in outcomes,
giving rise to potential inconsistencies in
decision-making and considering trade-offs
within a broader public sector spending budget.
Our research intends to provide some evidence
to better inform the political process and raise a
number of important issues on assessing the
value of public expenditure across different
sectors. Our targeted literature review aimed to
identify thresholds, explicitly or implicitly, as
observed in government-related publications,
which we understand to represent the
government’s willingness topayfor healthgain.

34 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Defining The objectives of this project are to Identify how Gayathri Kumar, paused.
Affordability ‘affordability’ in healthcare has been defined, Patricia Cubi-Molla,
described and implemented in the theoretical Martina Garau,
and empirical literature and in the UK policy Gayathri Kumar,
debate. Propose a unified definition of Matthew Napier,
affordability across different levels of healthcare Phill O’Neill, Chris
decision-making and Identify possible ways to Sampson, George
improve efficiency and consistency in how health Bray
systems handle affordabilityconcerns.
ISPOR Task Force: ISPOR Task Force:
The objective is to describe and further develop		 Grace Hampson The proposal was submitted to ISPOR and
Antimicrobial emerging good practices for value assessment of emerging good practices for value assessment of suggestions for revisions were received
resistance (AMR) antimicrobials, including (but not limited to) in
the context of a global pull incentive. The guide
will improve estimations of the significant and
multifaceted wider value offered by new
antimicrobials, beyond that which has routinely
been captured in value assessment to date. In
doing so, the guide will also be relevant to other
technologies to tackle AMR, such as diagnostics,
which face several of the
same challenges and offer a similar value profile
to new antibiotics.1 It will provide overarching
recommendations on the approach(es) that
should be taken and the criteria that should be
considered when designing and conducting value
assessment of new antibiotics and related
technologies.2 It will also explore the implications technologies.2 It will also explore the implications
of full quantitative assessment versus more
pragmatic scoring approaches, as have been
proposed in some jurisdictions (NHS England,
2024). Appropriate value assessment, as
supported by the proposed guide to emerging
good practices, will in turn support the
implementation of effective pull incentives for
the development of much-needed new
antibiotics.
Around the world In this Insights series, Around the World in HTAs, Gayathri Kumar, In 2024, 3 additional HTAs Around the World
in HTAs blog we shed light on HTA around the world. A general Patricia Cubi-Molla, blogs were published.
series overview of the health system in the country is Martina Garau,
given, followed by how health technologies are Gayathri Kumar,
assessed. Then some of the main challenges of Matthew Napier,
the system are introduced and next steps for the Phill O’Neill, Chris
future are discussed. Each blog involves a Sampson, George
collaboration with an external author/s Bray

35 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

POLICY, ORGANISATION, AND INCENTIVES IN HEALTH SYSTEMS

Project Summary Investigators Update on progress
Primary Care This project aims to revise and resubmit a Margherita Neri, Published on_Applied Health_
Valued Output manuscript summarising the development of a
framework to measure the valued output of		 Patricia Cubi-Molla,
Graham Cookson		 Economics and Health Policy, 2024.
primary care in England. This manuscript
represents the second contribution of the Health
Foundation-funded Efficiency Research
Programmegrant.
The Effect of When individuals choose to attend a hospital Sian Besley Sian is awaiting final analysis results
Distance on accident and emergency department (AED), they tables from her external co-authors.
Accident and must incur both the time and financial costs of Once the final tables are available these
Emergency travel, which are both likely to increase with will be added to the manuscript draft
Department distance. The aim of this research is to quantify which is near completion.
Demand (new the relationship between travel distance and
2022) emergency department demand using area-level
regression analysis. This research will also explore
the extent to which the role distance travelled
plays in the decision to attend an AED is
dependent on the severity of the individual’s
condition. This work builds upon research
conducted by Sian Besley for her MSc Health
Economics dissertation and the findings of this
project will be submitted to a health economics
journal.
GP demand Reducing waiting times is a priority in many public Reducing waiting times is a priority in many public
Helen Hayes,		 The paper is now published in the
response to health systems. Efforts of healthcare providers to (Rachel Meacock, European Journal of Health Economics
waiting times for shorten waiting times may be negated if they University of
suspected cancer simultaneously induce increases in demand. Manchester
patients Jonathan Stokes,
The existing health economics literature on the University of Glasgow
demand response to waiting times focuses on Matt Sutton,
elective or non-urgent care. This study adds to University of
this literature by exploring this relationship for Manchester)
urgent diagnosis of suspected cancer. Early
detection of cancer is a key policy concern in the
UK.
The effects of The overall aim of this study is to examine Helen Hayes, Published in_Health Economics_
payment whether changes in the way that a hospital is (Rachel Meacock,
unbundling on the reimbursed for diagnostic testing affects University of
utilisation of utilisation of tests for suspected cancer patients. Manchester
diagnostic This study examines a policy reform to the way Jonathan Stokes,
imaging scans for that hospitals were reimbursed for diagnostic University of Glasgow
suspected cancer imaging scans, wherein a fee-for-service element Matt Sutton,
patients was separated from the DRG-based system for University of
hospital reimbursement for outpatient scans, also hospital reimbursement for outpatient scans, also
Manchester)
known as payment unbundling. This paper
examines whether payment unbundling affected
provider utilisation of scans, and conducts further
analysis to ascertain whether the recorded
effects represent a real change in the delivery of
scans or a change in recording of scans.
The effect of local The effect of local
Reducing waiting times is a major policy objective		 Reducing waiting times is a major policy objective
Helen Hayes,		 Published in_PLOS ONE_
hospital waiting in publicly-funded healthcare systems. However, (Rachel Meacock,
times on GP reductions in waiting times can produce a University of
referrals for demand response, which may offset increases in Manchester
suspected cancer capacity. Jonathan Stokes,
We used annual counts of referrals from all 6,667 We used annual counts of referrals from all 6,667
University of Glasgow
general practices to all 185 hospital Trusts in Matt Sutton,
England between April 2012 and March 2018. University of
Usingapractice-level measure of local hospital Manchester)

36 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

waiting times based on breaches of the two-week waiting times based on breaches of the two-week
maximum waiting time target, we examined the
relationship between waiting times and urgent
GP referrals for suspected cancer. To identify the
sources of variation (between practices or over
time) that may drive this relationship, we
estimated this using three regression models:
pooled linear regression, a between-practice
estimator, and a within-practice estimator.
Labour This paper provides new evidence on labour Margherita Neri, Updating the paper for resubmission
productivity and productivity determinants and efficiency variables Graham Cookson,
efficiency of of general practices. The analysis used a (Eugenio Zucchelli,
general practices longitudinal dataset of general practice-level, Universita autonoma
in England quarterly observations between 2018 and 2021, de Madrid, Bruce
on a sample of 316 general practices in England. Hollingsworth,
We estimated a general practice production University of
model using stochastic frontier analysis to Lancaster)
evaluate the marginal productivities of general
practitioners (GPs) and nurses with respect to
the volume of face-to-face, remote and total
consultations delivered; the substitution and
complementarity between these roles; and the
technical efficiency of general practices. The aim
of this project is to complete a manuscript for
submission to The European Journal of Health
Economics.
Development of a In this project we explore potential Patricia Cubi-Molla Completing the paper for journal
synthetic index of methodologies for and the feasibility of creating a methodologies for and the feasibility of creating a
Margherita Neri		 submission
primary care synthetic index aggregating the indicators of Graham Cookson
output in England: valued output, developed as part of an OHE
a feasibility study research grant funded by the Health Foundation
on primary care efficiency. This index will capture
the outcome produced by primary care, with the
aim of making the framework developed in our
project available for actual use by researchers or
policymakers. The aim of this project is to
complete a manuscript for submission to Applied
Health Economics and Health Policy.
Socioeconomic Nigeria has historically had a high burden of Hania El Banhawi, Imputing missing data for robustness
and demographic chronic undernutrition, but overweight and (Neha Batura, and revising text for journal submission
determinants of obesity rates are increasing. This phenomenon, University College
the double burden the double burden
called the double burden of malnutrition (DBM),		 London, Rolando
of malnutrition is increasingly observed in low- and middle- Leiva-Granados,
among mother- income countries. At the household level the University College
child pairs in DBM can manifest as mother-child DBM London)
Nigeria: (MCDBM). This study aims to address the
overweight research gaps by exploring the distribution of and
mothers and risk factors for household-level DBM in Nigeria at
stunted children the national level. Specifically, study objectives
are to: (1) estimate the prevalence of MCDBM
and its’ components (child stunting and maternal
overweight/obesity); (2) describe the percentage
distribution of MCDBM and its’ components
according to socioeconomic and demographic
factors; and (3) investigate the socioeconomic
and demographic determinants of MCDBM in
Nigeria.

37 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

MEASURING AND VALUING OUTCOMES

Project Summary Investigators Update on progress
Assessing the This project’s aim is to (modify and) publish the David Mott, The manuscript has been submitted to
quality of life of WIP manuscript for the CF Carer QOL project Sulayman Quality of Life Research, still under review,
carers of patients carers of patients
completed in 2020, contributing to the (sparse)		 Chowdhury decision to be made very soon early 2025
with cystic evidence base of carer QOL for CF carers in the
fibrosis UK.
manuscript

38 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE CONTRACT RESEARCH OF HEALTH[ECONOMICS]

OHE

Engagement & dissemination

The OHE run an array of educational virtual and face to face events with the new addition of hybrid events this year.

These events include specialised webinars, workshops, parliamentary launches, and an annual lecture. This section provides an update on all the OHE events held over 2024:

ohe.org oheorg

39 oe

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Events

Webinars

  1. On January 31[st] , OHE streamed the 2023 Insights and Reflections webinar live to 373 registrants. The webinar explored which OHE research trends had the biggest impact in the previous year and discussed which emerging issues were identified for 2024. Key themes were prevention, sustainability, innovative outcome measures and key policy reforms.

  2. ‘The Future of NICE in a changing HTA Landscape’ webinar took place on March 27 and featured a series of short interviews capturing the most pressing issues and advancements in HTA. There were 491 registrations.

  3. On the 4[th of] September OHE led a webinar titled ‘Green Healthcare: Are We Asking the Right Questions’, which had 197 registrations. The webinar explored the pressing need for the healthcare sector to address its impact on climate change whilst balancing ever-growing financial constraints.

Sponsored Webinars

  1. OHE led a Takeda sponsored webinar titled ‘Efficiency and Labour Productivity of Primary Care in England’ on April 23[rd] . The webinar provided an outlook on the labour productivity and efficiency patterns of general practices in England and proposed how to improve measurement of efficiency. There were 253 registrations.

  2. Organon commissioned a webinar titled ‘Drug Shortages: What are the causes, consequences and pathways to a solution?’ on the 24[th of] September. The panel discussed the range of international government policy measures to secure sustainable and resilient medicine supply. There were 284 registrations.

Roundtables

  1. On the 19[th of] July, OHE led an advisory board on the macroeconomic benefits of Covid-19 vaccines. There were 12 attendees.

  2. On the 8[th of] August, OHE ran a roundtable in Brazil to gather country- specific insights to analyse and communicate the benefits of optimal HIV prevention in Brazil for government decision making. There were 20 participants.

  3. On the 28[th] November 2024, OHE convened an expert group comprised of HTA experts from AsianPacific countries and subject matter experts on the broader value of medicines for the ongoing BRAVER project. The meeting was virtual and had 24 participants in total. The BRAVER project aims to identify opportunities and recommendations for the inclusion of broader value elements, including societal perspective, into HTA guidelines and decision making within the Asia-Pacific region. The expected outcomes include a whitepaper report by OHE to be published in Q1 2025.

OHE external events

  1. On the 23[rd] January, OHE highlighted their recommendations from the report: ‘The Individual, Health System, and Societal Impacts of Anti-Seizure Medicine Use During Pregnancy’ in parliament. The report launch was convened alongside the Epilepsy Society and was supported by Caroline Nokes. Cross-party MPs (including the Minister for Disabled People), patient advocates, academics, media and industry convened in the House of Commons’ Pavilion.

  2. On the 24[th of] January, OHE attended a parliamentary event to coincide with Cervical Cancer Prevention Week. OHE presented the findings from the report: ‘The Socioeconomic Burden of

40 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Cervical Cancer in the UK: what are the benefits of achieving the WHO elimination target?’. OHE shared the platform with the Secretary of State for Health.

  1. On June 12[th] , OHE attended the Global Sustainable Development Congress, convened by The Times Higher Education in Thailand. OHE led a panel titled ‘Charting a Healthy Future: Health, climate, and the SDGs’. There were 75 live attendees.

  2. “On the 8[th] of July, OHE spoke at a parliamentary event in Ireland, showcasing the findings from the report, ’The Value of Adult Vaccination in Ireland”.

  3. 2024 Annual Lecture: On the 8[th] of October, OHE brought Professor Andrew J Scott to the stage to give a talk titled ‘The Preventive Health Revolution: Live Longer, Live Better’. The lecture re-evaluated prominent perceptions of ageing and argues for the need to focus on a longevity society. 180 registrants attended the event, held at the prestigious One Birdcage Walk Lecture Hall. The lecture was followed by a drinks and networking reception in the Marble Gallery.

  4. On 18[th] November in Barcelona, OHE participated in a roundtable convened by AstraZeneca. The Access to Innovative Medicines in Cancer (AIMC) initiative roundtable was on ‘Improving Timely Access to Cancer Therapies: Addressing Uncertainty in Value Assessments’.

Brown-bag lunch seminars

Finally, we also hosted four different brown-bag lunch seminars:

  1. The relative value of health gains by age)- Ashwini De Silva

  2. C Health Inequalities: Under-treated Conditions and Unwarranted Treatment Variations - Collete Whitelegg

  3. Severity Priority Setting in Norway - Dr Mathias Barra

  4. The role of gamification in combatting vaccine hesitancy and misinformation: evidence from a randomised controlled trial. - Sayuri Rentschler.

41 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Presentations

Presentation Detail

1 Date: January 11, 2024

Presenter: Mireia Jofre-Bonet

Event: HESG Winter 2024

Location: Exeter

Presentation title: How Does Unexpected Demand Affect Queue Prioritisation

In Emergency Care?

What was your presentation about? I discussed a paper that analyses how unexpected demand shifts in Emergency Departments in England affect prioritisation of patients and how these changes might affect differently protected characteristics of patients (age, biological sex at birth, etc.). The study uses the Hospital Episodes Survey on patients visiting Emergency Departments between April 2017 and March 2018.

How many people were in the audience: 30

Authors: I. Francetic, R. Meacock, L. Siciliani, and M. Sutton

Presenter: Chris Sampson

Event: HESG winter 2024

Location: Exeter

Presentation title: Discussion of 'Mobilising health economics research: priorities for action' by Rebecca Kandiyali

What was your presentation about? NA

How many people were in the audience (approx. number): 60

Authors: NA

Event: Podcast

What was your presentation about?

In this podcast episode produced by The Evidence Base®, Amanda Cole, Emily Reuben OBE, Karen Facey and Matt Hickey discussed the growing need for managed-access agreements in the assessment and reimbursement of pharmaceuticals. Amanda shared insights from research conducted in collaboration with RAND Europe for Cancer Research UK (CRUK) on outcome-based payment, which aims to align payment with patient value, address decision uncertainty, and allow payment only when the medicine works as intended.

4 Date: 23rd January 2024 Presenter Nadine Henderson

Event What is the cost of a disability? (Epilepsy Society)

Location Thames Pavilion, Houses of Parliament, Westminster

Presentation Title Overview of OHE report "Individual, Health System, and Societal Impacts of Anti-seizure Medicines Use During Pregnancy"

What was your presentation about?

Prevention remains at the heart of our mission as we navigate through these critical issues. The insights presented at this event highlighted the multifaceted benefits of proactively addressing health challenges. How many people were in the audience: 50

Nadine Henderson, George Bray, Chris Skedgel

Presenter: Gayathri Kumar

Event: Parliamentary event hosted by MSD and Evoke Incisive; sponsored by Jess Phillips MP and opening speech by Victoria Atkins MP, Secretary of State for Health

42 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Location: Houses of Parliament

Presentation title: The socioeconomic benefits of eliminating cervical cancer in the UK

What was your presentation about? Key findings from the OHE report on the socioeconomic benefits of eliminating cervical cancer in the UK. The presentation outlined OHE’s research approach, the headline results and recommendations for accelerating the path to elimination.

How many people were in the audience (approx. number): 50

Authors: Gayathri Kumar, Matthew Napier, Margherita Neri, Martina Garau

6 Date: 31st January 2024

Presenter: Margherita Neri Event: Team Meeting of the Health Foundation REAL centre Location: online

Presentation title: Efficiency and Labour Productivity of Primary Care in England

What was your presentation about? Presentation on the findings of an econometric analysis about the labour productivity and efficiency of general practices in England.

How many people were in the audience (approx. number)25

Authors: Margherita Neri, Graham Cookson, Eugenio Zucchelli, Bruce Hollingsworth

7 Date: 12th February 2024

Presenter: Amanda Cole

Event: Guest Lecture for UCL's MBA in Health programme Location: UCL, Marshgate East Campus

Presentation title: Adapting how we pay for innovative medicines in the life sciences industry.

What was the presentation about: Presentation on why we may need to change the way we pay, to adapt to the promise and challenge of new innovation in treatments. The presentation focused on two examples - the cancer drugs fund / innovative medicines fund and outcome-based payment - and described the role of real-world data in these envisioned solutions.

How many people were in the audience (approx. number 40)

Authors: Amanda Cole

8 Date 16th February 2024 Presenter: Lotte Steuten, Event Roundtable: Virtual presentation

Presentation title “Discounting Practices in Public Decision-Making: Is the system fit For purpose?"

What was the presentation about?

The Case of cost-effectiveness analyses of Gene Therapies for Inherited Eye Disease Topic: discounting and gene therapies

How many people were in the audience (approx. number)100

Authors: Lotte Steuten

Presenter Sian Besley, Date: 17th February 2024

Event: International Conference on Duchenne and Becker Muscular Dystrophy Location: Rome, Italy

Presentation title: The Race to Improve Assessment of Gene Therapies and Facilitate Patient Access

What was your presentation about? Our poster aimed to inform patients, their families, clinicians and other researchers about the challenges of HTA of gene therapies and provided our recommendations for overcoming these challenges. The poster also demonstrated whether 9 European countries, Australia and Canada were achieving these recommendations and discussed examples of best practice.

How many people were in the audience (approx. number)

Authors: Sian Besley, Nadine Henderson, Matthew Napier, Amanda Cole and Grace Hampson (OHE) Lauren Diamond, Safiyya Gassman, David Fortier, Ruth Kim (Pfizer, Inc).

43 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

10 Presenter Graham Cookson Date: 21st February

Event: Economist Thought Leadership Working Group/DLA Piper

Location: Washington

Presentation title: Evidence: Market Size and Investment in R&D, Working Group

What was your presentation about

Graham was invited by DLA Piper to join alongside a group of economists whose work already does, or has the potential to, affect drug pricing policy in the U.S. The February meeting was a continuation of the October 2023 webinar focusing on the

the Inflation Reduction Act “Maximum Fair Price” provision and evidence that could be used to inform future changes to the law or new proposals to expand price controls. The working group discussed a draft report that they had co-authored and discussed need areas of research and possible grant programs to apply to

How many people were in the audience (approx. number 50)

11 Presenter: Graham Cookson Event Date: 21st February 2024

Location: Washington

Event We Work For Health CBO Roundtable Discussion

What was the event about

We Work For Health (WWFH) convened a roundtable discussion in response to the Congressional Budget Office (CBO) post from December 2023. The roundtable explored the impacts of policy decisions have on the biopharmaceutical industry as well as ultimate patient outcomes and discussed opportunities to help inform CBO as they review future policies under consideration.

How many people were in the audience (approx. number 50)

12 Presenter: Graham Cookson Event Date: 27th February Location London Event: Association of British Insurers Annual Conference

Presentation title: "Invested in people and planet - Investing in healthy lives."

Graham joined as a speaker at the Association of British Insurers Annual Conference. The panel discussed how Healthy life expectancy has increased, but not as much as life expectancy. The talk explored the socio-economic factors, behavioural aspects, and their complex interactions leading to health inequalities. Graham focused on the changes in healthy life expectancy and health inequality. The presentation focused on the benefits of investing in prevention-based research based on OHE's 'Reimagining Prevention for a Healthier, More Prosperous Society' research. How many people were in the audience (200)

13

Date: 2nd March 2024

Presenter: Mireia Jofre-Bonet Event: Warwick Women in Economics Society Conference - International Women's Day Location: University of Warwick Presentation title: Reflections on a career in Health Economics

What was your presentation about? About my career in economics as a woman and introduction to health economics How many people were in the audience (approx. number) 75

Authors: Mireia Jofre-Bonet

14

Presenter: Lotte Steuten

Date: 12th March 2024

Event: World Evidence, Pricing and Access Congress Location: Amsterdam

Presentation title: 'Novel payment models: is this where HTA and VBHC “meet in the middle”?

The session will cover the importance of implementing novel payment models to balance value, affordability and innovation of care. Lotte will address the key challenges associated with implementing these models in practice and highlight how a shift towards value-based healthcare can help overcome these challenges.

How many people were in the audience (30)

44 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

15 Presenter: Martina Garau Date: 13th March 2024 Event: World Evidence, Pricing and Access Congress Location: Amsterdam

Presentation title: NICE enough? Do NICE decision outcomes impact international HTA decision-making?

What was your presentation about: a study showing how NICE guidance and its supporting evidence have an impact on HTA decision-making in countries beyond the UK.

How many people were in the audience (30)

Authors: Henderson N., Brassel S., O’Neill P., Allen R., Largeron N., Garau M.

16 Date: 14th March 2024 Presenter: Mikel Berdud Event: Lecture at MSc Health Economics programme at City, University of London Location: City university of London, London, UK Presentation title: Economics of Pharmaceutical Markets

What was your presentation about? About the R&D of new medicines' process and cost, market failures characterising the pharmaceutical markets, mechanisms to fix market failures and incentives for innovation. How many people were in the audience (20)

Authors: Mikel Berdud

17 Presenter: Graham Cookson Date: 20th March 2024

Location: Washington

Event: Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma Presentation title: We Work For Health Paths to Progress: Understanding Policy's Broader Impact on US Leadership in BioPharma

Graham was invited to join a moderated discussion in Washington exploring the impact policy decisions have on biopharmaceutical industry and opportunities to help inform the congressional budget office (CBO) as it reviews future legislation. Speakers include Douh Holtz-Eakin (President of American Action Forum) and former CBO Director; Duane Schulthess (CEO of vital Transformation); Ken Thorpe (Professor and the Department of Health Policy and Management at Emory University)

How many people were in the audience (approx. number 50)

18 Date: 21st March 2024 Presenters: Amanda Cole, Matthis Hofer, Helen Hayes, George Bray, Sulayman Chowdhury Event: University of Southern California Doctoral Student Delegation visit to OHE Location: OHE offices, London

Presentation title: Introduction to OHE; Reimagining Prevention; Combating AMR; The Carer Qaly Trap; Discounting: what can we learn from environmental economics?

What was your presentation about? A showcase of our work to a delegation of 12 USC doctoral students and faculty members from the program Regulatory Sciences in Europe and the Americas.

How many people were in the audience (approx. number) 12

Authors: as above. 19 Date: 27th March 2024 Presenter: Charlotte Ashton Event: Clinton Health Initiative Climate x Health Seminar Location: Online Presentation title: Change Initiative: Environmental Sustainability and the Global Healthcare Lifecycle Presentation focused on the Initiative and our new membership of the Clinton Health Initiative Group How many people were in the audience (approx. number): 75

20 Date 16th April 2024

Presenter: Martina Garau Location Brussels Event Economist Impact's 2nd Cell & Gene Therapy Summit Presentation Title

The talk was around the need for innovative payment models to ensure access to CGTs

45 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

How many people were in the audience (approx. number): around 80
21 Date 16th April 2024
Presenter: Martina Garau
Location Brussels
Event Economist Impact's 2nd Cell & Gene Therapy Summit
Presentation Title ‘From theory to practice: the market impact of HTA legislation'
Martina moderated the session and provided an introduction on explain key concepts (such as JCA and PICO) and set up
the access problem that many ATMPs face in Europe (i.e. wide variation in access among countries and evidence availability
at launch vs HTA agencies' evidence requirements).
How many people were in the audience:(approx. number) 80
22 Date: 16th April 2024
Presenter: Nadine Henderson
Event: Cell & Gene Collective's Patient Voice Summit
Location: Broadway House, Westminster, London
"Panel 2: Improving data collection to ensure cell and gene therapies deliver for patients"
Discussed the necessity of capturing long-term patient-relevant data, the involvement of patient organisation in developing
standardised disease
registries and the importance of collaboration and education in data collection
How many people were in the audience: (approx. number) 50
23 Date: 19th April 2024
Presenter: Simon Brassel
Event: Economics of Longevity: Challenges and Opportunities
Location: Washington D.C.. UN Foundation
Presentation title: Socio-economic value of adult immunisation programs
What was your presentation about? I presented the results from our related project as a contribution to High-level event
alongside the G20 Finance Minister’s Meeting and World Bank Group and IMF Spring Meetings in Washington DC, USA.
How many people were in the audience (approx. number )15
Authors: El Banhawi H., Chowdhury S., Neri M., Radu P., Besley S., Bell E., Brassel S., Steuten L.
24 Date: 22nd April 2024
Presenter: Grace Hampson
Event World Federation of Hemophilia (WFH) Congress
Presentation : New Horizons: The Value of Continued Innovation in Hemophilia
Grace lead the discussion at Pfizer's satellite symposium on 'New Horizons: The value of continued innovation in hemophilia'
panel.
Speakers: moderated by Grace Hampson, Meryem Nimour, Daniel-Aníbal García Diego, Cedric HERMANS MD PhD FRCP
(Lon,Edin), Lou Garrison and Malcolm Qualie
This session focused on the recent progress, identifying remaining unmet needs, and exploring the next steps for innovation
in this critical space.
How many people were in the audience(approx. number)50
25 Date: 22nd April 2024
Presenter: Mikel Berdud
Event: II HI-PRIX Consortium Meeting
Location: Hamburg, Germany
Presentation title: Impact of innovative payment schemes on long-term competition in health
technology markets, in particular the pharmaceutical market
What was your presentation about? About research methodology for a project assessing the impact of Innovative Payment
Models on Long-term competition in pharmaceutical markets
How many people were in the audience (approx. number 30)
Authors: Mikel Berdud,Amanda Cole,MireiaJofre-Bonet
26 Date: 23rd April 2024
Presenter: Mikel Berdud
Event: II HI-PRIX Consortium Meeting

46 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Location: Hamburg, Germany
Presentation title: Mapping of payment and pricing schemes for health innovation in the EU:
implementation, barriers and enablers
What was your presentation about? Preliminary results of research on the costs and benefits, and the barriers and enablers
for Innovative Payment Models implementation
How many people were in the audience (approx. number) 30
Authors: Mikel Berdud,Amanda Cole,MireiaJofre-Bonet
27 Date: 24th April 2024
Presenter – Lotte Steuten
Event: NHS Confederation –The Economic Benefit of Vaccines
Presentation Title: Are Vaccinations the shot in the arm the economy and health service need?
Tune in to the discussion on the broader impact of vaccinations beyond public health on the latest episode of Hosted by
Matthew Taylor, this episode features Prof. Lotte Steuten, PhD and Christopher Thomas from the IPPR.
Find out more about the economic and societal benefits of vaccinations, including return on investment, elective recovery,
presenteeism, and more.
How many people were in the audience(unknown)
28 Date: 30th April 2024
Presenter: Chris Sampson
Event: NICE Technical Forum
Location: Online
Presentation title: The future of the QALY: replacement or revision?
What was your presentation about?
The Quality-Adjusted Life Year (QALY) metric, pivotal in health care decision-making, faces increasing scrutiny due to
methodological criticisms and anti-rationing lobbying efforts. This Technical Forum will first explore various proposed
alternatives to the QALY, such as Health Years in Total (HYT) and the Equal Value of Life Years Gained (evLYG). We will assess
the suitability of these metrics as replacements for the QALY. Second, the session will address an important flaw in current
approaches to the estimation of QALYs—specifically, the challenges in valuing 'dead' states—and argue for a fundamental
revision to the interpretation of QALYs. The discussion will underscore the irreplaceability of QALYs, while advocating for
continuous methodological revisions to the estimation of QALYs, refinement of their interpretation, and clarity on their role in
decision-making.
How many people were in the audience (approx. number)70
Authors: Chris Sampson
29 Date: 1st May 2024
Presenter: Patricia Cubi-Molla
Event: Lecture as part of the module "Pharma and Economic Evaluation", for MSc in Health Management (City University of
London)
Location: online
Presentation title: Measuring Health Outcomes
What was your presentation about? Basic introduction to health outcome measurement as part of the HTA in England
How many people were in the audience (approx. number): 55
Authors: Patricia Cubi-Molla. Module leader: Charitini Stavropoulou
30 Date: 6th May 2024
Presenter: Tori Dawer (Mireia Jofre-Bonet, Alistair McGuire, Josh Roth, Sean Sullivan)
Event: ISPOR USA 2024
Location: Atlanta
Presentation title: A Targeted Literature Review to Identify the Dimensions of Sustainable Global Biosimilars Markets
What was your presentation about? How the entry of biosimilars in the USA pharmaceutical market have affected prices of
both biosimilars and originator products
How many people were in the audience (approx. number 35)
Authors: Tori Dawer(MireiaJofre-Bonet,Alistair McGuire, Josh Roth,Sean Sullivan)
31 Date: 7th May 2024
Presenter: Amanda Cole
Event: ISPOR International 2024
Location: Atlanta
Presentation title: Value Assessment and Reimbursement of Early Treatment for Prevention of Chronic Progressive Diseases:
Are Traditional Approaches Up to the Task?
What was your presentation about? I described the challenges from a reimbursement perspective, drawing on examples from
Alzheimer’s and gene therapies, and demonstrating the role for innovative and outcome-based payment models to address
uncertaintyand manage budget impact.

47 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Issue Panel presenters: Will Herring, Amanda Cole, Chuck Phelps, Boshen Jiao.
How many people were in the audience(approx. number)1,000
32 Date: 7th May 2024
Presenter: Amanda Cole
Event: ISPOR International 2024
Location: Atlanta
Presentation title: How Elastic is Biopharmaceutical Innovation With Respect to Expected Reward? What Is Missing From
Existing Literature on Elasticity of Innovation?
What was your presentation about? I present a select set of existing empirical estimates of the elasticity of innovation from
the literature and described the strengths and weaknesses of the Congressional Budget Office (CBO) forecasts of the
impact of policies that curb biopharmaceutical revenue (e.g. the Inflation Reduction Act) on innovation.
Issue Panel presenters: Gunnar Esiason, Amanda Cole, Darius Lakdawalla, Peter Kolchinsky
How many people were in the audience(approx. number)1,000
33 Date: 7th May 2024
Presenter: Matthias Hofer
Event: ISPOR International 2024
Location: Atlanta
Presentation title:
What was the presentation about: During the podium session starting at 13:45 EDT on 7 May, Matthias Hofer presented the
analysis of the novel antimicrobial subscription scheme in the UK and shared the answers to question 'Are proposals for a
scheme to stimulate investment in critically needed new antimicrobials fit for purpose?'.
How many people were in the audience?(approx. number)60-70
34 Date: 15th May 2024
Presenter Nadine Henderson
Event Title: Gesundheit Österreich GmbH / Austrian National Public Health Institute webinar: Greener Pharmaceuticals.
Presentation title: "The role of pharmaceuticals in achieving net zero: greener pharmaceuticals in the UK"
An overview of greener pharmaceuticals and health system from the UK perspective, presenting parts of the "Supporting the
Era of Green Pharmaceuticals" OHE Report.
How many people were in the audience(approx. number)50
35 Date: 24th May 2024
Presenter Chris Skedgel
Location : ,Philippine International Convention Center, Manila
Event: ASPIRE24, 23-26 May
Presentation Title: Unlocking the Value of Fertility Medicines Using Health Economic Studies' panel
Chris will take part in the company symposium 1 by Merck discussing ‘Unlocking the Value of Fertility Medicines Using Health
Economic Studies'.
He will describe how "value" is assessed in fertility treatment and provide an overview of the evidence around the relative
value of different therapies.
Speakers: chaired by Romerico Torres, David Humphreys and Michael Costello
How many people were in the audience(approx. number)300
36 Date 30th May 2024
Presenter Lotte Steuten
Location: Geneva
Event Title: Demonstrating the full societal value of adult immunization: The importance of adopting a prevention-first
mindset
Presentation title: Demonstrating the full societal value of adult immunization: The importance of adopting a prevention-first
mindset'
OHE has published a report on the Socio-economic Value of Adult Immunization recently. This report discusses the role of
adult vaccination programs in health and societal challenges while aligning with global agendas like the UN Sustainable
Development Goals and the WHO Immunisation Agenda 2030 (IA2030).
During the 'Demonstrating the full societal value of adult immunization: The importance of adopting a prevention-first
mindset' Lotte will provide an overview of the project, the objectives, and discuss the results, and recommendations.
Speakers: moderated by Lise Pedersen, Lotte Steuten, Stefania Maggi, Agnes Soares, Tania Cernuschi, Jane Barratt, and
Christi G. Kelsey
How many people were in the audience(approx. number)50
37 Date: 10th June 2024
Presenter: Charlotte Ashton
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress

48 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Presentation Title: 'Delivering sustainable healthcare through effective collaboration and impactful outreach'
What was your presentation about? My presentation focused on measuring the success and impact of programmes on the
overall health and well-being of communities, from baseline surveys through to health indicators and tracking changes in
specific health metrics e.g. vaccination rates. I also looked at how it is essential to tailor programmes to address specific
health needs across localities e.g. the EVIA programme and its effectiveness in sub-Saharan Africa.
How many people were in the audience(approx. number)150
38 Date: 11th June 2024
Presenter: Charlotte Ashton
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title 'Sustainable, resilient healthcare: What have we achieved so far?'
What was the presentation about:
My presentation explored the measures that are being used to improve access to healthcare, from HTS to value-based
pricing. I also looked at the barriers to sustainable healthcare access which included economic constraints, regulatory
challenges and inequitable resource allocation, drawing on lessons from existing healthcare interventions and cross-sector
partnerships including the Access to Medicines Index and our own Change Initiative.
How many people were in the audience(approx. number)50
39 Date: 12thJune 2024
Presenter: Grace Hampson
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title: Rethinking research and innovation for equitable healthcare
How many people were in the audience(approx. number)50
40 Date: 12th June 2024
Presenters: Charlotte Ashton and Grace Hampson
Location Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title: ‘Charting a healthy future: Health, climate and the SDGs'
What was your presentation about?
During the presentation Grace and Charlotte shared their thoughts on ‘Charting a healthy future: Health, climate and the
SDGs' discussion.’
How many people were in the audience(approx. number)50
41 Date: 13thJune 2024
Presenter Grace Hampson
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title: ‘The health workforce crisis: Ensuring a resilient workforce for resilient healthcare systems’
What was your presentation about?
Grace shared her research on how we can ensure a resilient workforce to provide a resilient healthcare system
How many people were in the audience(approx. number)50
42 Date: 12th June 2024
Presenter: Graham Cookson
Location Congressional Budget Office Washington
Event: Drug Innovation Modelling
Presentation title Modelling innovation in pharmaceutical markets.
Graham was invited to give a presentation to a mix of PhD economists and masters of public policy people at the CBO in
Washington.
How many people were in the audience(approx. number)50
43 Date: 15 June 2024
Presenter: Martina Garau
Event: HTAi Workshop Characterizing why Rare Diseases Create Evidence Generation Challenges for HTA
Location: Seville
Presentation title: Economic modelling in rare diseases: insights from the literature and a survey.
What was your presentation about? Insights from a literature review as part of the Rare Disease Interest Group (RDIG) and
the launch of a survey to HTAi members
How many people were in the audience (approx. number) 40
Authors: Farzana Malik and Martina Garau
44 Date: 15-19 June 2024
Presenter: Martina Garau

49 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Event: HTAi virtual poster
Location: Virtual / Seville
Presentation title: Comparison of Health Technology Assessment Methodologies across Australia, Canada, New Zealand and
the UK: Implications for Future HTA Collaborations
What was your presentation about? Comparing method guides of a selection of HTA agencies to explore implications of
international collaborations
How many people were in the audience (approx. number) unknown
Authors: Nadine Henderson, Claud Theakston, Simon Brassel, Martina Garau (OHE), Rachel Allen, Nathalie Largeron, Kinga
Malottki Yuti Patel Kirsten Garces Megan Coombes,Vanessa Xavier(Sanofi)
45 Date: 15-19 June 2024
Presenter: Martina Garau
Event: HTAi pre-recorded panel sessions
Location: Virtual / Seville
Presentation title: Economic Modelling For Rare Diseases: What Are The Challenges And How Can The HTA Community
Overcome Them?
What was your presentation about? Exploring challenges and solutions of economic methods in rare diseases with a panel
bringing different perspectives (HTA, industry, health economists)
How many people were in the audience (approx. number) unknown
Authors: Farzana Malik,Saskia Knies, Jameel Nazir,Andrew Briggs,Martina Garau
46 Date: 16 June 2024
Presenter: Martina Garau
Event: HTAi Workshop Unlocking Rare Diseases Economic Modelling: Health Technology Assessment Implications,
Methodological Standpoints, and Multi-Perspective Solutions for Current Challenges
Location: Seville
Economic modelling in rare diseases: insights from the literature and a survey.
What was your presentation about? Insights from a literature review as part of the Rare Disease Interest Group (RDIG) and
the launch of a survey to HTAi members
How many people were in the audience (approx. number) 40
Authors: Farzana Malik and Martina Garau
47 Date: 15-19 June 2024
Presenter: Martina Garau
Event: HTAi pre-recorded panel sessions
Location: Virtual / Seville
Presentation title: Innovation For Alzheimer’s Disease: How To Prepare For New Disease-Modifying Treatments Value
Assessments?
What was your presentation about? Exploring challenges related to value assessment and provisions of Alzheimer’s
treatments, bringing the HTA and the patient perspectives.
How many people were in the audience/online? (approx. number) unknown
Authors: Martina Garau, Jackie Glatter,Angela Bradshaw,Meindert Boysen
48 Date: 5th July 2024
Presenter: Chris Sampson
Event: Health Economists' Study Group
Location: University of Warwick
Presentation title: Discussion of 'Productivity and efficiency: measuring different things gives different results' by Daniel
Howdon
What was your presentation about? NA
How many people were in the audience (approx. number) 40
Authors: NA
49 Date: 9th July 2024
Presenter: Sian Hodgson
Event: HSRUK Conference
Location: Oxford
Presentation title: Inequalities in Dementia in England, Wales and Northern Ireland: Unveiling the Evidence and Forging a Path
Towards Greater Understanding.
What was your presentation about? This poster was presented during a poster walkthrough session. The presentation and
poster summarised the findings of the OHE report, providing a summary of our key literature findings and case studies that
assessed whether it is possible to measure inequalities in dementia.
How many people were in the audience/online? (approx. number) 15
Authors: Sian Hodgson,Helen Hayes,Patricia Cubi-Molla,Martina Garau

50 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

50 Date: 9th July 2024
Presenter: Margherita Neri
Event: HSR UK Conference 2024
Location: Oxford
Presentation title: Efficiency and productivity of general practices in England
What was your presentation about? Results of an empirical analysis of efficiency across general practices in England and of
the determinants of productivity
How many people were in the audience (approx. number) 40
Authors: Margherita Neri,Bruce Hollingsworth,Eugenio Zucchelli,Graham Cookson
51 Date: 10 July 2024
Presenter: Lotte Steuten
Event: Ambrosetti Roundtable “The value of prevention for economic growth and the sustainability of healthcare, social care
and welfare systems”
Location: Brussels (I attended virtually)
Title: Value of Adult Vaccination
What was the presentation about: Socioeconomic value of adult vaccination
How many people were in the audience (approx. number) 150
Authors: Lotte Steuten,Simon Brassel
52 Date: 26 July 2024
Presenter: Martina Garau
Event: Cell and Gene Collective Commission: Session 1
Location: Virtual
Title: Value assessment of Cell & Gene Therapies: international practice and possible next steps in England.
What was the presentation about: Value assessment of Cell & Gene Therapies
Audience: closed meeting
Authors: NR
53 Date: 4 September 2024
Grace Hampson
Event: CER/WifOR hybrid discussion on 'EU fiscal policy: Is health a no-brainer public investment?'
Brussels
EU fiscal policy: Is health a no-brainer public investment
How many people were in the audience(approx. number)40
54 Date: 11th September 2024
Presenter: Patricia Cubi-Molla
Event: Opening lecture - Inauguration of MSc/PhD in Quantitative Economics
Location: University of Alicante
Presentation title: "Health Economics for non-economist decision-makers"
What was your presentation about? How to bridge the evidence produced by health economic researchers ('idealism') with
the practical realities faced by stakeholders involved in real-world applications ('pragmatism')
How many people were in the audience (approx. number) 60
Authors: Patricia Cubi-Molla
55 Date: 12th September 2024
Presenter: Chris Sampson
Event: IHEA Mental Health Economics SIG webinar - 'Quantifying mental health: research on measurement in mental health
economics'
Location: Online
Presentation title: NA - I was just chairing the webinar
What was your presentation about?
How many people were in the audience (approx. number) 35
Authors: NA
56 Date: 16th September 2024
Presenter: Mikel Berdud
Event: IX Expert Program on Health Policy and Pharmacoeconomics
Location: Mallorca, Spain
Presentation title: " Prices and pharmaceuticals: is transparency good or bad for population health?"
What was your presentation about? Based on the results of the OHE research paper “The Future of Global Health
Procurement: Issues around Pricing Transparency” I discussed whether the price transparency can contribute to improve
population health and reflected on some policy recommendations separately for innovative medicines and
generics/biosimilars. Themes I touched were: if transparencyis agood in itself,how transparencyofprices relates to the risk

51 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

of collusion, separating price transparency from process transparency, price transparency and bargaining power, differential
pricing, value-based pricing and competition.
How many people were in the audience (approx. number) 60
Authors: Mikel Berdud
57 Date: 16th September 2024
Keynote Speaker: Mireia Jofre-Bonet
Event: IX Expert Program on Health Policy and Pharmacoeconomics
Location: Mallorca, Spain
Title: " The challenges for the pharmaceutical sector of providing healthcare systems under financial strain?"
What was your presentation about? This summarized the challenges that the pharmaceutical sector is facing due to the
extreme financial pressures that most health systems are experiencing due to pandemic shock in 2020-21,
sociodemographic changes, and other causes.
How many people were in the audience (approx. number) 60
Authors: MireiaJofre-Bonet
58 Date: 18th September 2024
Presenter: NA (our paper was discussed by someone else)
Event: EuroQol Plenary
Location: Noordwijk, Netherlands
Presentation title: Mary Shelley’s Frankenstein: a metaphor for EuroQol instrument development and use
What was your presentation about? A discussion of the risks associated with the success of the EQ-5D and its adaptation
and application in different contexts.
How many people were in the audience (approx. number) 50
Authors: Paula Lorgellyand Chris Sampson
59 Date: 19thSeptember 2024
Presenter: Chris Skedgel
Event FT Live - "Improving ALM Care"
Location: Online
Presentation title: Discussing cost drivers in acute myeloid leukaemia
What was your presentation about? This Financial Times Digital Dialogue, held in partnership with Daiichi Sankyo Europe,
brought together AML patient advocates and carers, physicians, health system representatives and other leading AML
experts to discuss what needs to be done to improve patient care in AML, and the actions that can be taken to reduce the
economic burden of the disease while improving outcomes for patients, families and caregivers. (approx. number)
200 registered;84 online
60 Date: 26 July 2024
Presenter: Martina Garau
Event: Cell and Gene Collective Commission: Session 1
Location: Virtual
Title: Value assessment of Cell & Gene Therapies: international practice and possible next steps in England.
What was the presentation about: Value assessment of Cell & Gene Therapies
Audience: closed meeting
Authors: NR
61 Date: 4 September 2024
Grace Hampson
Event: CER/WifOR hybrid discussion on 'EU fiscal policy: Is health a no-brainer public investment?'
Brussels
EU fiscal policy: Is health a no-brainer public investment
How many people were in the audience(approx. number)40
62 Date: 11th September 2024
Presenter: Patricia Cubi-Molla
Event: Opening lecture - Inauguration of MSc/PhD in Quantitative Economics
Location: University of Alicante
Presentation title: "Health Economics for non-economist decision-makers"
What was your presentation about? How to bridge the evidence produced by health economic researchers ('idealism') with
the practical realities faced by stakeholders involved in real-world applications ('pragmatism')
How many people were in the audience (approx. number) 60
Authors: Patricia Cubi-Molla
63 Date: 12th September 2024
Presenter: Chris Sampson

52 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Event: IHEA Mental Health Economics SIG webinar - 'Quantifying mental health: research on measurement in mental health
economics'
Location: Online
Presentation title: NA - I was just chairing the webinar
What was your presentation about?
How many people were in the audience (approx. number) 35
Authors: NA
64 Date: 16th September 2024
Presenter: Mikel Berdud
Event: IX Expert Program on Health Policy and Pharmacoeconomics
Location: Mallorca, Spain
Presentation title: " Prices and pharmaceuticals: is transparency good or bad for population health?"
What was your presentation about? Based on the results of the OHE research paper “The Future of Global Health
Procurement: Issues around Pricing Transparency” I discussed whether the price transparency can contribute to improve
population health and reflected on some policy recommendations separately for innovative medicines and
generics/biosimilars. Themes I touched were: if transparency is a good in itself, how transparency of prices relates to the risk
of collusion, separating price transparency from process transparency, price transparency and bargaining power, differential
pricing, value-based pricing and competition.
How many people were in the audience (approx. number) 60
Authors: Mikel Berdud
65 Date: 16th September 2024
Keynote Speaker: Mireia Jofre-Bonet
Event: IX Expert Program on Health Policy and Pharmacoeconomics
Location: Mallorca, Spain
Title: " The challenges for the pharmaceutical sector of providing healthcare systems under financial strain?"
What was your presentation about? This summarized the challenges that the pharmaceutical sector is facing due to the
extreme financial pressures that most health systems are experiencing due to pandemic shock in 2020-21,
sociodemographic changes, and other causes.
How many people were in the audience (approx. number) 60
Authors: MireiaJofre-Bonet
66 Date: 18th September 2024
Presenter: NA (our paper was discussed by someone else)
Event: EuroQol Plenary
Location: Noordwijk, Netherlands
Presentation title: Mary Shelley’s Frankenstein: a metaphor for EuroQol instrument development and use
What was your presentation about? A discussion of the risks associated with the success of the EQ-5D and its adaptation
and application in different contexts.
How many people were in the audience (approx. number) 150
Authors: Paula Lorgellyand Chris Sampson
67 Date: 19thSeptember 2024
Presenter: Chris Skedgel
Event FT Live - "Improving ALM Care"
Location: Online
Presentation title: Discussing cost drivers in acute myeloid leukaemia
What was your presentation about? This Financial Times Digital Dialogue, held in partnership with Daiichi Sankyo Europe,
brought together AML patient advocates and carers, physicians, health system representatives and other leading AML
experts to discuss what needs to be done to improve patient care in AML, and the actions that can be taken to reduce the
economic burden of the disease while improving outcomes for patients, families and caregivers. How many people were in
the audience(approx. number)200 registered;84 online
68 Date: 30th September 2024
Presenter: Amanda Cole
Event: Cell & Gene Collective Commission on Tomorrow’s Science, Today’s NHS: Briefing for Evidence Session 2 –
Reimbursement
Location: Virtual
Presentation title: Expert Witness statement and response to commissioners' questions.
What was your presentation about? Reimbursement - to consider optimal innovative finance models that, in the context of
the Voluntary Pricing and Growth Scheme (VPAG), can support the NHS to pay for and allow timely access to CGTs.
How many people were in the audience(approx. number)12(other expert witnesses,Commissioners,and the Cell & Gene

53 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Collective secretariat)
Authors: Amanda Cole
69 Date: 3rd October 2024
Presenter: Chris Sampson
Event: CEVR Health Policy Seminar
Location: Boston, MA
Presentation title: The future of the QALY: replacement or revision
What was your presentation about? The shortcomings of proposed alternatives to the QALY and the importance of improving
QALY estimation.
How many people were in the audience (approx. number) 20 in person, 30 online
Authors: Chris Sampson
70 Date 17thOctober 204
Presenter: Simon Brassel
Event: Tagesspiegel Impfgipfel 2024
Location: Berlin, Germany
Presentation title: Der sozioökonomische Nutzen von (Erwachsenen) impfprogrammen.
What was your presentation about? I gave a presentation laying out the broader value elements on immunisation programs,
before reporting on our IFMPA funded work on the socioeconomic value of adult immunisation and providing policy
recommendations to policymakers present. I then joined a panel discussion with representatives of academia,
pharmaceutical industry and payers.
How many people were in the audience/online? : (approx. number) 40-50 in in the room, plus unknown number in a live
stream plus later audience as the video is published on their platform.
Authors: El Banhawi H.,ChowdhuryS.,Neri M.,Radu P.,BesleyS.,Bell E.,Brassel S.,Steuten L.,
71 Date: 29thOctober 2024
Presenter: Margherita Neri
Event: PROTECT-EUROPE Masterclass 8 - The Economic Case for HPV Vaccination: Securing Health, Saving Lives
Location: online
Presentation title: The socioeconomic benefits of eliminating cervical cancer in the UK
What was your presentation about? Presentation on socioeconomic burden of cervical cancer in the UK and the benefits of
achieving the WHO elimination target
How many people were in the audience (approx. number) 35
Authors: Gayathri Kumar,Matthew Napier,Margherita Neri,Martina Garau
72 Date 7thNovember 2024
Presenter: Lotte Steuten
Event HTAi Asia Pacific
Location: Seoul, S-Korea
Title: Going Braver: Towards a societal perspective in HTA
Topic: societal perspective in HTA
Lotte Steuten presented at The Asia Policy Forum which is a leadership meeting for senior representatives from public and
private sector organizations using HTA from the Asia Pacific region. .
How many people were in the audience (approx. number) Audience: 50
Authors: Matthias Hofer,Claude Theakston,Martina Garau,Lotte Steuten
73 Date 12thNovember 2024
Presenter: Chris Sampson
Event: NCCN 2024 Global Academy for Excellence & Leadership in Oncology
Location: Online
Presentation title: Module II: The Role of Health Technology Assessment (HTA) and other Value Considerations
What was your presentation about? Discussion of HTA processes globally
How many people were in the audience (approx. number) 65
Authors: NA
74 Date: 13th November 2024
Presenter: Mireia Jofre-Bonet
Event: Lecture at St George's City, University of London
Location: London
Presentation title: The Pharmaceutical Market and Drug Pricing. Regulation, Market Dynamics, and Ethical Considerations
What was your presentation about? Landscape of the Pharmaceutical Market and Drug Pricing.
How many people were in the audience (approx. number) 25
Authors: n/a
75 Date: 17thNovember 2024

54 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Presenter: Lotte Steuten

Event: ISPOR Short Course Programme

Location: Barcelona, Spain

Title: Concepts and Approaches to Early-Stage Health Technology Assessment”.

Lotte co led a short course to demystify the objectives of early-stage health technology assessment and the methods of translational health economics. Students in the course gained a thorough understanding of available methods for early-stage technology assessment, the specific challenges and solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and reimbursement. The course utilised real-world examples and students had the opportunity to strategize about the creation of a research plan for their purposes.

Faculty: Lotte Steuten, PhD, Office of Health Economics, London, LON, UK William Canestaro, PhD, MSc, Washington Research Foundation, Seattle, WA, USA; Erik Landaas, PhD, MPH, W. L. Gore & Associates, Inc., Flagstaff, AZ, USA How many people were in the audience (approx. number) 35

of health technology development, funding, regulation, pricing, and reimbursement. The course utilised real-world examples
and students had the opportunity to strategize about the creation of a research plan for their purposes.
Faculty: Lotte Steuten, PhD, Office of Health Economics, London, LON, UK William Canestaro, PhD, MSc, Washington
Research Foundation, Seattle, WA, USA; Erik Landaas, PhD, MPH, W. L. Gore & Associates, Inc., Flagstaff, AZ, USA
How many people were in the audience (approx. number) 35
Authors: Lotte
76 Date 18thNovember
Presenter: Chris Skedgel
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life?
What Difference Could It Make to Decisions About Life-Extending Treatments?
Chris Skedgel moderated an issues panel
How many people were in the audience(approx. number)- unknown
77 Date 18thNovember 2024
Presenter: Chris Skedgel
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title Putting Breast Cancer into a Societal Perspective: How Can We Account for Its Full Impact in HTA?
Chris Skedgel moderated an issues panel
How many people were in the audience(approx. number)unknown
78 Date: 18th November 2024
Presenter: Grace Hampson
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: Balancing Budgets and Breakthroughs: Does Budget Impact Analysis Systematically Disadvantage Gene
Therapies?
What was your presentation about? Budget impact analysis for gene therapies
How many people were in the audience: (approx. number) 300
Authors: Grace Hampson,Nadine Henderson,Paul Oyalo
79 Date: 18thNovember 2024
Presenter: Lotte Steuten
Event: ISPOR Conference
Location: Barcelona, Spain
Title: Broader Value Elements: Methods to Quantify Each and Their Relevance for European Markets
Topic: Broader value elements
How many people were in the audience (approx. number) 150
Authors: Lotte
80 Date: 19thNovember 2024
Presenter: Lotte Steuten
Event: ISPOR Conference
Location: Barcelona, Spain
Title: From Research to Policy to Patients: Measuring the Impact of Health Economics and Outcomes Research
Lotte Steuten participated in the ISPOR Forum, "From Research to Policy to Patients: Measuring the Impact of Health
Economics and Outcomes Research (HEOR)."
VERVIEW: Jan Hansen (Genentech) moderated this session and set the context by explaining global shifts in HEOR
organization and investment. Rob Abbott (ISPOR) presented the importance of measuring HEOR’s impact in the context of
ISPOR’s Strategic Plan 2030.Laura Pizzi (ISPOR) discussed the impact measures that ISPOR currently uses, and
opportunities to improve them and Lotte Steuten (OHE) discussed ways to measure the impact of HEOR on methods
guidelines, healthcare policies and patients, using the example of an analysis with BMJ Impact Analytics that tracked the
trajectory and use of HEOR research in real-time. James Chambers (Tufts University) discussed the impact of HEOR on
coverage decisions usingdata from the Tufts Medical Center SpecialtyDrugEvidence and Coverage(SPEC)Database.

55 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Drawing on these examples, panellists will debate the approaches to HEOR impact measurement, including the role of data-
driven methods and AI-tools, and establish a call to action for the use of these measures as well as development of new
measures.
Moderator: Jan E. Hansen, PhD, US Medical Affairs, Genentech, South San Francisco, CA, USA
Speakers: Rob Abbott, -, CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA; Laura Pizzi, PharmD, MPH, Chief Science
Officer, ISPOR, Lawrence Township, NJ, USA; Lotte Steuten, PhD, Office of Health Economics, London, LON, UK; James
Chambers, PhD, MPharm, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health
Policy Studies, Tufts Medical Center, Boston, MA, USA
How many people were in the audience (approx. number) 150
Authors: Lotte
81 Date: 19th November 2024
Presenter: Simon Brassel
Event: Politico Health Care Summit
Location: Brussels
Presentation title: Panellist on Panel discussing Health Care Systems resiliency and the health workforce
What was your presentation about? n/a
How many people were in the audience (approx. number 448 audience / 53k+ views
Authors: n/a
82 Date 19thNovember 2024
Presenter: Chris Skedgel and Helen Hayes
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title Is NICE Too Severe With Severity? Exploring How Well Its Severity Modifier Aligns With UK Preferences,
Helen Hayes & Chris Skedgel – poster
How many people were in the audience(approx. number)unknown
83 Date: 19th November 2024
Presenter: Amanda Cole
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: [Issue Panel] Are There More Optimal Approaches to Managing Pricing and Reimbursement of Multi-
Indication Medicines to Better Facilitate Patient Access?
I provided an overview of the challenges and solutions from a broad, international perspective, highlighting the views of
different stakeholders and solutions implemented.
How many people were in the audience (approx. number) 800
Panellists:Jens Grueger;Amanda Cole,ClaudioJommi; Julien Patris
84 Date: 19th November 2024
Presenter: Amanda Cole
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: [Issue Panel] Challenges and Opportunities for Modelling the Impact of Cell and Gene Therapies in the
Context of Evolving Regulatory Environments
I moderated the session presented the background and context of evolving regulatory pathways that may influence and
present challenges as well as opportunities for CGT modelling and uptake.
How many people were in the audience (approx. number) 250
Panellists: Amanda Cole,Varun Ektare,Salah Ghabri,Indranil Bagchi
85 Date: 19th November 2024
Presenter: Grace Hampson
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: Lessons From Climate Change Models: What Can Health Economists Learn From Environmental
Economists’ Modelling Methodologies?
What was your presentation about? Environmental impacts in HTA
How many people were in the audience (approx. number) 250
Authors: Grace Hampson
86 Date: 20th November 2024
Presenter: Grace Hampson
Event: ISPOR Europe 2024
Location: Barcelona

56 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Presentation title: Taking the Greener Pill: A Case Study for Incorporating Carbon Footprint in Health Technology
Assessment
What was your presentation about? Environmental impacts in HTA
How many people were in the audience (approx. number) 100
Authors: Grace Hampson
87 Date: 20th November 2024
Presenter: Lotte
Event: AZ Side Event to ISPOR
Location: Barcelona, Spain
Title: HTA in 2030: what have we solved, what are the new challenges?
Topic: HTA
How many people were in the audience (approx. number) 100
Authors: Lotte Steuten
88 Date: 21st November 2025
Presenter: Lotte
Event: Pfizer Side Event to ISPOR
Location: Barcelona, Spain
Title: Economic value of vaccines: summary of OHE's research for Pfizer
Topic: Economic value of vaccines
How many people were in the audience (approx. number) 120
Author: Lotte Steuten
89 Date: 3rdDecember 2024
Presenter: Grace Hampson
Event: Global AMR Concerns
Location: Brussels, Germany
Title: From UN Declaration to EU Action
Topic: POIHS - featuring keynote speaker Prof Dame Sally Davies. The event includes a panel discussion with Malin Grape,
Grace Hampson, and Aleksandra Opalska. https://womenat.com/w-at-ls-global-amr-concerns
How many people were in the audience (approx. number) unknown
Authors: Grace Hampson
90 Date: 04th December 2024
Presenter: Lotte Steuten
Event: Annual Business at OECD Health Forum
Location: Paris
Presentation title: Socio-economic value of adult vaccination
What was your presentation about? Socio-economic value of adult vaccination
How many people were in the audience (approx. number) 100
Authors: ChowdhuryS,El Banhawi H,Bell E,Neri M,Brassel S,Steuten L.
91 Date: 6th December 2024
Presenter: Patricia Cubi-Molla
Event: Guest lecture for module "Introduction to Economic Evaluation" for MSd Health Economics and MSc Economic
Evaluation in Health Care at City St George's, University of London
Location: City St George's, University of London
Presentation title: On HTA reforms, severity modifiers, and resource allocation
What was your presentation about? Part 1 was on HTA reforms: An international comparison and drivers for changes. Part 2
was on Severity modifiers: NICE HTA methods guidelines: key points and discussion on modifiers. Part 3 presented Resource
Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
How many people were in the audience (approx. number) 5
Authors: Patricia Cubi-Molla
92 Date: 17th December 2024
Presenter: Amanda Cole
Event: All Party Parliamentary Group (APPG) on Genetic, Rare and Undiagnosed Conditions
Location: Portculis House, Westminster
Presentation title: [no title]
What was your presentation about? I presented my personal and professional views on the most pressing need for change in
the support of rare disease patients: better access to diagnosis, better coordinated care, better data sharing, and better
opportunities to contribute to research. The objective was to increase awareness in parliament among MPs and peers of
these issues, to support a long-term strategy for the UK.
How many people were in the audience(approx. number)30

57 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Authors: Amanda Cole
93 Date: 18th December 2024
Presenter: Amanda Cole
Event: AstraZeneca Value Strategy Pathway Key Opinion Leader event
Location: Virtual
Presentation title: Indication-based pricing: research and progress
What was your presentation about? Summarising our research on IBP, its implementation, and current policy discussions in
the UK. Presenting to AstraZeneca leads in Italy and key opinion leaders from academia, payer, regulatory, modelling experts
and hospital pharmacists.
How many people were in the audience (approx. number) 20
Authors: Amanda Cole

Advisory Roles

The number of advisory roles held by OHE staff members has continued to grow, reflecting their strong influence on policy and their recognized contributions to the research and policy community. This impact aligns with OHE's charitable objective of steering health policy and decision-making in health economics and creating capacity by transferring health economics research capacity to students and other individuals at different stages of their careers.

OHE staff membership of advisory panels, boards and committees

Advisory Panels

Health Foundation Health Foundation
• Member of the Steering Committee for NHS Workforce Retention Project – Graham Cookson
HTAi HTAi
• Working Group on early HTA – Amanda Cole
ISPOR
• Co-Chair ISPOR Special Taskforce on Value-Based Healthcare – Lotte Steuten
• Member of the ISPOR Health Science Policy Council (Policy Outlook Committee) – Amanda Cole
NHS England
• Primary Care Transformation Programme: Quantitative Working Group – Graham Cookson
NIHR NIHR
• Steering Committee Member for NIHR/HS&DR Project No. 8/17/1934 – Graham Cookson
• Steering Committee for the LOGiC – Long term Outcomes for Gender Identity in Children Study – funded
by NIHR. Sites: Portman-NHS; UCL; U. Liverpool, U. Cambridge, UCLH – Mireia Jofre-Bonet
• Steering Committee for ADVANCE – National Addiction Centre Institute of Psychiatry, Psychology and
Neuroscience – King’s College London – Mireia Jofre-Bonet
• Steering Committee for the SUpporting Wellbeing Through PEeR-Befriending (SUPERB) Trial – City, University
of London, and UCLH, Kings College – Mireia Jofre-Bonet
• Member of the Institute 4 Innovation (i4i) & Office of Life Sciences Real World Evidence Programme
Committee – Lotte Steuten

Scientific Committee of the European Health Economic Association (EuHEA)

Interest Groups/Task Forces

AES

IMPACT-HTA

58 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Editorial Roles

Applied Health Economics and Health Policy Journal

PLOS One

Grant Panel Advisory Groups

NICE

“la Caixa” Foundation

Visiting Positions for OHE Staff

City, University of London

Fred Hutch Cancer Research Center, University of Washington

59 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Public University of Navarra

University College London (UCL)

University of East Anglia

University of Surrey

Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain

Memberships

Many OHE researchers are also members of associations such as ISPOR, IHEA, HESG, AES, EuroQoL ,,and iHTA .

•

60 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OIF]=

Financial Review

In 2024, OHE remained an organisation undertaking research and related activities according to its charitable objects and status of independent research organisation.

OHE owns the sole share in OHE Consulting Limited with the purpose of enabling OHE to:

ohe.org ohe.org

61 0

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Financial Performance in 2024

The financial statements of OHE comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts following The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) ("Charities SORP FRS 102").

OHE's consolidated turnover (i.e., combining both OHE and OHE Consulting Limited) in 2024 was £5.24m . The expenditure totalled £4.8m , leaving a net income of £474,894. Of the £4.8m expenditure, staff costs in 2024 amounted to £3.37m , i.e., 70%. The consolidated accounts for OHE are included as an Annex to this report

Sources of Funding

The sources of funding for OHE are summarised below. The financial reports attached provide more details about OHE income and expenditure.

The consolidated income of £5.28m comprises:

The consolidated income of£5.28mcomprises:
£000
Donations – research grants 205
Income from charitable (research) activities* 856
Interest 16.7
Total research income 1,078
OHE Consulting Income 4,204
Total Income 5,282
Donations are from the ABPI and are for two distinct purposes: Donations are from the ABPI and are for two distinct purposes:
£000
Support for core research activities 150
Grant towards financing of support activities 443
Total 593

*Income from charitable (research) activities came from several sources. Major research projects and funders included: HORIZON European Commission Grants, Wellcome Trust, and EuroQol Research Foundation.

62 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OIF]=

Grants

The number and amount of live research grant funded projects in 2024 is higher than last year and amounts to £.5 million. See below:

The pipeline and the research grant applications lost show that the year 2024 has been a very active year for collaboration with other European institutions applying to European HORIZON research grant calls. Although so far, the research funded grants won in 2024 amount £0.9 million.

ohe.org ohe.org

63 ]

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

2024 Research Grants Activity

PROJECTS WON IN 2024

FUNDER Project Title Theme Year won Project
Budget
IFPMA 5607d – Extension of Socio-economic VADM Apr-2024 £2598
value of adult vaccination flu abstract
AMICUS THERAPEUTICS 5853 - Diversity of supply for rare disease EoI Oct-24 £84,513
medicines
HIGH FLOW THERAPY UK 5562 - High Flow Therapy Post AECOPD VADM Oct-24 £71,158
CML ADVOCATES 5747 - CML patient preference study MVO Jul-24 £377,578
NETWORK
WORKGROUP OF 5780 - WECAN Patient Experience Data MVO Jan-24 £859
EUROPEAN CANCER Course
PATIENT ADVOCACY
NETWORKS (WECAN)
EUROPEAN 5743 – EU HORIZON Predict FTD VADM Aug-24 £282,119
COMMISSION
WELLCOME TRUST 5824 - Guidance on eval of health effects VADM Oct-24 £115,471
of climate change
TOTAL £934,296

*by the end of 2024, we were told that we had one additional grant, NIHR, on Decarbonising the NHS that will kick start in 2025.

64 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

PROJECTS WON PRIOR TO 2024 AND STILL LIVE

FUNDER Project Title Theme Year won Project
Budget
ACUTE LEUKEMIA 5362a - Patient preferences for leukaemia MVO 14-Jun-23 £73,788
ADVOCATES NETWORK treatments: UK R/R phases 5-6
5362b - Patient preferences for leukaemia MVO 04-Jan-23 £105,116
treatments: US/EU4 R/R all phases
5362c - Patient preferences for leukaemia MVO 06-Nov-23 £210,477
treatments: UK/US/EU4 1L all phases
5627 - Acute leukaemia carer preference MVO 06-Nov-23 £149,876
study
EUROQOL RESEARCH 5437 - Estimating an EQ-5D-Y-3L value set MVO 19-Jul-23 £7,650
FOUNDATION in the United Kingdom
5479 - Bolt-on conceptual MVO 14-Sep-23 £32,599
EUROPEAN 5443 - EU HORIZON HI-PRIX Project EoI 01-Mar-23 £354,263
COMMISSION
EUROQOL RESEARCH EE60 EQ-5D Bolt -Development VADM 01-Jan-18 £57,700
FOUNDATION
HEALTH FOUNDATION 5402 Efficiency and Labour Productivity in POIHS 01-Apr-21 £410,325
Primary Care
EUROQOL RESEARCH 5487 Exploring the use of the OPUF tool for MVO 14-Mar-22 £63,310
FOUNDATION valuing EQ-5D-Y-3L
5133 Development and testing of a hearing MVO 01-Apr-21 £77,456
bolt-on

PROJECTS WON PRIOR TO 2024 AND CLOSED IN 2024

FUNDER Project Title Theme Year won Project
Budget
PARKINSON'S UK 5378 - PWP mindfulness app VADM 15/11/2021 £15,318
CANCER RESEARCH (UK) 5617 Oncology TPPs EoI 13/02/2023 £66,406
CURTA, INC 5690 - Biosimilar Market Dynamics: A EoI 03/04/2023 £25,237
Review and Simulation Model
TOTAL £106,961
GRANT TOTAL LIVE £2,583,817

65 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

2024 Pipeline and Lost Grant Funded Projects

PROJECTS IN THE PIPELINE (AS OF DECEMBER 2024)

FUNDER Project Title Value Probability % Proj. Adj. Value Probability % Proj. Adj. Value
NATIONAL INSTITUTE FOR 5869 - NIHR Global LMICs Partnership £500,000 £500,000
15		 £75,000
HEALTH RESEARCH (NIHR) AIIG
NATIONAL INSTITUTE FOR 5870 - NIHR Global LMICs Partnership £476,713 £476,713
15		 £71,506
HEALTH RESEARCH (NIHR) AMPATH
EUROPEAN COMMISSION 5863 – EU HORIZON TEN4CARE £294,790 £294,790
25		 £73,697
WELLCOME TRUST 5799 - Climate Impact Award £250,000 £250,000
20		 £50,000
THE FLEMING INITIATIVE 5837 - AMR Strategic Policy TFI £150,000 £150,000
50		 £75,000
ACUTE LEUKEMIA ADVOCATES 5840 - Creating Opportunities to Hear £89,994 £89,994
40		 £35,997
NETWORK the Patient Voice
INNOVATE UK 5852 - Value of pharmacogenomics to £79,931 £79,931
75		 £59,948
the UK
NATIONAL INSTITUTES OF 5755 - ModEx £10,000 £10,000
5		 £10,000
HEALTH
PHYSICIANS COMMITTEE FOR 5791 - US impact of vegan diets £136,821 £136,821
100		 £136,821
RESPONSIBLE MEDICINE
EUROQOL RESEARCH 5764 - OPUF bolt-on valuation £5,000 £5,000
100		 £5,000
FOUNDATION
5725 - Cognition bolt-on Hong Kong £2,254. £2,254.
100		 £2,254
TOTAL £1,995,503 £1,995,503 £595,223

PROJECTS SUBMITTED AND LOST IN 2024 SO FAR

FUNDER Project Title Theme Value
PARKINSON'S UK 5378a - PwP Mindfulness app - dissemination VADM £7,000
SCIENCE FOR AFRICA 5788 - EPSILONScience for Africa POIHS £299,000
SCOTTISH CONSORTIUM UKRI 5792 - Decarbonising H&SC POIHS £190,000
EUROQOL RESEARCH FOUNDATION 5133b - Sign language extension of Development MVO £36,629
and testing of a hearing bolt-on
EUROPEAN COMMISSION 5678 - AI4Kidney VADM £150,000
NATIONAL INSTITUTE FOR HEALTH 5708 - NIHR i4i application VADM £81,870
RESEARCH (NIHR)
EUROPEAN COMMISSION 5726 - BIONICS EoI £250,000
NATIONAL INSTITUTE FOR HEALTH 5740 - Memory Tracks evaluation VADM £50,000
RESEARCH (NIHR) 5757 - NIHR Global LMICs Partnership POIHS £2,930,000
EUROQOL RESEARCH FOUNDATION 5763 - Development and Evaluation of a Refined MVO £6,440
Version of the OPUF Approach (OPUF 2.0)
BILL & MELINDA GATES FOUNDATION 5773 - Bill & Melinda Gates Advance Women's POIHS £150,000
Health Innovation

66 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

NATIONAL INSTITUTE FOR HEALTH 5803 - Case study economic analyses VADM £49,880
RESEARCH (NIHR)
THE HEALTH FOUNDATION 5825 Productivity in healthcare POIHS £72,824
NATIONAL INSTITUTE FOR HEALTH 5827 - Spark i4i bid VADM £133,947
RESEARCH (NIHR) 5842 - Increasing Vaccinations Low Uptake POIHS £152,244
5843 - Biomarkers for Polyps POIHS £35,000
EUROPEAN UNION 5846 - EU HORIZON HEROSCAN VADM £307,925
NATIONAL INSTITUTE FOR HEALTH 5857 - Bilateral versus unilateral cochlear VADM £50,000
RESEARCH (NIHR) implants in adults
EUROQOL RESEARCH FOUNDATION 5133b - Sign language extension of Development MVO £36,629
and testing of a hearing bolt-on
5809 - Cognition and corona in Norway MVO £21,501
TOTAL £5,010,889

67 O

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OIF]E

Structure, Governance & Management

ohe.org ohe.org

68 (2a ]

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

Structure, Governance & Management

Trustees and Directors

By the end of 2024 : Anita Charlesworth , The Health Foundation, Chair Richard Torbett , (APBI) Trustee Werner Brouwer , ESHPM (OHE) Trustee (appointed 31st March 2022) Patrick Holmes , Pfizer (ABPI) Trustee (appointed 31st January 2022) Paul Catchpole , (ABPI) Trustee (appointed 4th October 2023) Thomas Allvin, EFPIA (appointed 23rd February 2023) Margaret Kyle , Mines ParisTech (OHE) (resigned 31[st] December 2024)

Trustees and Directors By the end of 2023 : Anita Charlesworth , The Health Foundation Chair Richard Torbett , (APBI) Trustee Werner Brouwer , ESHPM (OHE) Trustee (appointed 31st March 2022) Patrick Holmes , Pfizer (ABPI) Trustee (appointed 31st January 2022) Margaret Kyle , Mines ParisTech (OHE) (appointed 14th January 2022) Paul Catchpole , (ABPI) Trustee (appointed 4th October 2023) Thomas Allvin, EFPIA (appointed 23rd February 2023) Other:

Susan Rienow , Pfizer (ABPI) (resigned 4th October 2023)

Registered Ofce 2nd Floor Goldings House, Hay’s Galleria, 2 Hay's Lane, London, SE1 2HB Charity number: 1170829 Company number: 09848965

Senior Management Chief Executive Officer Prof Graham Cookson Deputy Chief Executive Officer Prof Lotte Steuten Chief Research Officer and Head of Education Prof Mireia Jofre-Bonet Directors Charlotte Ashton Martina Garau Chris Skedgel Tim Watson Associate Directors: Amanda Cole Grace Hampson

Auditor

BDO LLP Statutory Auditor & Chartered Accountants 2 City Place Beehive Ring Road Gatwick West Sussex RH6 0PA Bankers National Westminster Bank Plc PO Box 113 Cavell House 2A Charing Cross Road, London

69 O

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH

OHE

OHE Committee Structure

BOARD OF Remit Formal role of overseeing the business, relying on existing
DIRECTORS mechanisms ofgovernance and accountability
Membership Anita Charlesworth (Chair), Richard Torbett, Paul Catchpole,
Margaret Kyle, Werner Brouwer, Patrick Holmes, Thomas Allvin, Ryan
Hollingsworth (Secretariat)
EDITORIAL PANEL Remit Acts as a guarantor of the quality of OHE’s publications output
Assures the OHE Research Board of Directors that OHE’s
publication quality is in line with its charitable objectives and
strategic purpose
Membership Martin Buxton, Martin Chalkley, Anita Charlesworth, Tony Culyer,
Mike Drummond, Nick Mays, Richard Norman, Pedro Pita Barros,
Julie Ratcliffe, Peter Zweifel
RESEARCH Remit •
Oversees OHE’s research
COMMITTEE •
Ensures the quality and independence of OHE’s research
programme
Assures the OHE Research Board of Directors that OHE’s research
output is meetingits charitable objects and strategic purpose
Membership (6+) Margaret Kyle (Chair),Tony Culyer, Patricia Danzon, Mike
Drummond, Hareth Al-Janabi, Donna Rowen, Katherine Payne, Luigi
Siciliani, Pedro Pita-Barros
Matthias Hofer (Secretariat)
Board of Anita Charlesworth(Chair), Richard Torbett, Paul Catchpole,
Directors are Margaret Kyle, Werner Brouwer, Patrick Holmes, Thomas Allvin, Ryan
invited to attend Hollingsworth (Secretariat)
as observers
POLICY COMMITTEE Remit Helps OHE to:
•
inform a policy agenda
•
identify areas of policymaking where OHE research can help
and inform decision-making
•
engage with the right people, in the right manner and at the
right time
improve OHE’s policy engagement work to ensure that maximum
impact of its research
Membership (6+) Anita Charlesworth(Health Foundation; Chair),
Elliot Dunster, Tom Easterling, Dr Koonal Shah, Daniel Ollendorf,
Jamie Munroe,Siva Anandaciva,Chris HenshallHelen Hayes
(Secretariat)
Board of
Directors are
invited to attend
as observers		 Anita Charlesworth(Chair), Richard Torbett, Paul Catchpole,
Margaret Kyle, Werner Brouwer,Patrick Holmes, Thomas Allvin,
Ryan Hollingsworth (Secretariat)

70 O

ohe.org

'. OFFICE OF HEALTH ECONOMICS : OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH hae CONTRACT RESEARCH

- OHE . 4 Appendices

ohe.org ohe.org

65 71

Review of OHE’s research programme in 2024

Executive summary

These papers summarise OHE’s research activity in 2024.

OHE’s research activity in 2024 was extensive and diverse. By the end of the year, ongoing research grant-funded projects had a total value of approximately £2.6 million, similar to 2023. The total value of new research grants awarded in 2024 was £0.9 million, with an additional £0.6 million in probability-adjusted funding in the pipeline. We continue to benefit from our success in securing the EU HORIZON HI-PRIX project and have been approached by various consortia. In 2024, we secured an additional HORIZON grant worth £0.28 million for developing a biomarker-based predictive tool for dementia. Furthermore, we obtained a Wellcome Trust grant in collaboration with LSTM and the Euro-Mediterranean Center on Climate Change (CMCC) to develop guidance on the economic evaluation of health impacts of climate change. Alongside these grant successes, we made significant efforts to secure major new contract research work, resulting in a portfolio of new contracts worth £3.5 million. Additionally, the probability-adjusted pipeline for contract research proposals under submission or preparation at the end of the year exceeded £1.4 million.

Research Outputs: Our research activities resulted in 39 publications in 2024, compared to 37 in 2023: 22 peer-reviewed journal articles, 6 non-peer-reviewed publications, and 14 OHE peer-reviewed publications. We continued to publish work funded through our core research grant, with core-funded research projects leading to 5 peer-reviewed publications in 2024, compared to 3 in 2023, alongside several additional submissions by year-end.

In terms of impact, we tracked citations for OHE journal articles published since 2019. As expected, citation counts increased with publication age. Between 2019 and 2023, we published 120 articles with at least 10 citations, of which: 9 articles received more than 50 citations; and 4 articles received more than 100 citations. Older publications naturally accrued a higher number of citations over time.

Engagement and Dissemination: OHE convened a significant number of research events in 2024: 9 roundtables; 4 brown-bag lunchtime seminars; 5 webinars; 2 workshops; and 2 externally focused events. Notably, four of our webinars were funded, representing a valuable opportunity to diversify OHE’s research income while expanding our audience reach. On average, our webinars attracted 412 attendees, with the audience predominantly comprising industry and academia. OHE colleagues delivered 93 external presentations in 2024, a significant increase from 68 in 2023.

1

Following OHE’s full website relaunch in 2023, minor disruptions and changes in analytics initially led to a slight decline in website visitors and downloads. However, 2024 saw an increase in both metrics. Our social media presence also expanded, particularly on LinkedIn, where our subscriber base grew by over 30%, from 9,000 to more than 12,749.

Impact Highlights: Beyond citations and research output metrics, OHE had a strong impact in 2024, particularly in five key areas:

Conclusion: Overall, 2024 was a successful year for OHE’s research, both in externally funded projects and core-funded initiatives. However, we remain committed to continuous improvement. While our performance in securing research grants has improved, further progress is needed to increase success rates. The Research Committee’s guidance has been and will continue to be instrumental in achieving this goal.

2

Table of Contents

REVIEW OF OHE’S RESEARCH PROGRAMME IN 2024 .................................................................................................................................. 1 EXECUTIVE SUMMARY ..................................................................................................................................................................................................... 1 TABLE OF CONTENTS ....................................................................................................................................................................................................... 3 RESEARCH PROGRAMME OUTPUT .................................................................................................................................................................. 4 RESEARCH GRANTS AND PROJECTS ............................................................................................................................................................................. 4 PUBLICATIONS .................................................................................................................................................................................................................. 8 CORE-FUNDED PROJECTS ............................................................................................................................................................................................. 17 OHE EVENTS ................................................................................................................................................................................................................... 25 Webinars ...................................................................................................................................................................................................................... 25 Sponsored Webinars ................................................................................................................................................................................................... 25 Roundtables ................................................................................................................................................................................................................. 25 OHE external events .................................................................................................................................................................................................... 26 Brown-bag lunch seminars .......................................................................................................................................................................................... 26 EXTERNAL IMPACT (BEYOND SCIENTIFIC CITATIONS) .................................................................................................................................. 28 SELECTION OF IMPACTFUL RESEARCH OUTPUTS ...................................................................................................................................................... 28 WEBSITE, INSIGHTS & SOCIAL MEDIA .......................................................................................................................................................................... 30 ADVISORY ROLES ............................................................................................................................................................................................................ 33 EXTERNAL PRESENTATIONS ......................................................................................................................................................................................... 37 APPENDIX CITATIONS OVER TIME – PRE-2024 ............................................................................................................................................. 61

3

Research Programme Output

In the following sections, we provide a list and some insights into 2024’s research outputs, including research funded grant projects, publications, corefunded projects and OHE organised events. In the appendix, we also provide a summary of the contract research projects as they have contributed to our research output.

Research grants and projects

The number and amount of live research grant funded projects in 2024 is higher than last year and amounts to £.5 million. See below: The pipeline and the research grant applications lost show that the year 2024 has been a very active year for collaboration with other European institutions applying to European HORIZON research grant calls. Although so far, the research funded grants won in 2024 amount £0.9 million.

2024 Live Research Grant Funded Projects

Projects won in 2024
Funder Project Title Theme Year won Project Budget
IFPMA 5607d – Extension of Socio-economic value of adult vaccination flu abstract VADM Apr-2024 £2598
Amicus Therapeutics 5853 - Diversityof supplyfor rare disease medicines EoI Oct-24 £84,513
Projects won in 2024 Projects won in 2024 Projects won in 2024 Projects won in 2024 Projects won in 2024
Funder Project Title Theme Year won Project Budget
IFPMA 5607d – Extension of Socio-economic value of adult vaccination flu abstract VADM Apr-2024 £2598
Amicus Therapeutics 5853 - Diversityof supplyfor rare disease medicines EoI Oct-24 £84,513
High Flow Therapy UK 5562 - High Flow Therapy Post AECOPD VADM Oct-24 £71,158
CML Advocates Network 5747 - CMLpatientpreference study MVO Jul-24 £377,578
Workgroup of European Cancer Patient
AdvocacyNetworks(WECAN)		 5780 - WECAN Patient Experience Data Course MVO Jan-24 £859
European Commission 5743 – EU HORIZON Predict FTD VADM Aug-24 £282,119
Wellcome Trust 5824 - Guidance on eval of health effects of climate change VADM Oct-24 £115,471
Total* £934,296

*by the end of 2024, we were told that we had one additional grant, NIHR, on Decarbonising the NHS that will kick start in 2025.

4

Projects wonprior to 2024 and still live Projects wonprior to 2024 and still live Projects wonprior to 2024 and still live Projects wonprior to 2024 and still live Projects wonprior to 2024 and still live
Funder Project Title Theme Year won Project Budget
Acute Leukemia Advocates Network 5362a - Patient preferences for leukaemia treatments: UK R/R
phases 5-6		 MVO 14-Jun-23 £73,788
Acute Leukemia Advocates Network 5362b - Patient preferences for leukaemia treatments: US/EU4 R/R
allphases		 MVO 04-Jan-23 £105,116
Acute Leukemia Advocates Network 5362c - Patient preferences for leukaemia treatments: UK/US/EU4 1L
allphases		 MVO 06-Nov-23 £210,477
Acute Leukemia Advocates Network 5627 - Acute leukaemia carer preference study MVO 06-Nov-23 £149,876
EuroQol Research Foundation 5437 - Estimating an EQ-5D-Y-3L value set in the United Kingdom MVO 19-Jul-23 £7,650
EuroQol Research Foundation 5479 - Bolt-on conceptual MVO 14-Sep-23 £32,599
European Commission 5443 - EU HORIZON HI-PRIX Project EoI 01-Mar-23 £354,263
EuroQol Research Foundation EE60 EQ-5D Bolt -Development VADM 01-Jan-18 £57,700
Health Foundation 5402 Efficiency and Labour Productivity in Primary Care POIHS 01-Apr-21 £410,325
EuroQol Research Foundation 5487 Exploring the use of the OPUF tool for valuing EQ-5D-Y-3L MVO 14-Mar-22 £63,310
EuroQol Research Foundation 5133 Development and testing of a hearing bolt-on MVO 01-Apr-21 £77,456
Total £1,542,560
Projects wonprior to 2024 closed in 2024 Projects wonprior to 2024 closed in 2024 Projects wonprior to 2024 closed in 2024 Projects wonprior to 2024 closed in 2024 Projects wonprior to 2024 closed in 2024
Funder Project Title Theme Year won Project Budget
Parkinson's UK 5378 - PWP mindfulness app VADM 15/11/2021 £15,318
Cancer Research (UK) 5617 Oncology TPPs EoI 13/02/2023 £66,406
Curta, Inc 5690 - Biosimilar Market Dynamics: A Review and Simulation Model EoI 03/04/2023 £25,237
Total £106,961
Grant Total Live £2,583,817

5

2024 Pipeline and Lost Grant Funded Projects

Projects in the Pipeliine(as of December 2024) Projects in the Pipeliine(as of December 2024) Projects in the Pipeliine(as of December 2024) Projects in the Pipeliine(as of December 2024) Projects in the Pipeliine(as of December 2024)
Funder Project Title Value Probability % Proj. Adj. Value
National Institute for Health Research (NIHR) 5869 - NIHR Global LMICs Partnership AIIG £500,000 15 £75,000
National Institute for Health Research (NIHR) 5870 - NIHR Global LMICs Partnership AMPATH £476,713 15 £71,506
European Commission 5863 – EU HORIZON TEN4CARE £294,790 25 £73,697
Wellcome Trust 5799 - Climate Impact Award £250,000 20 £50,000
The Fleming Initiative 5837 - AMR Strategic Policy TFI £150,000 50 £75,000
Acute Leukemia Advocates Network 5840 - Creating Opportunities to Hear the Patient Voice £89,994 40 £35,997
Innovate UK 5852 - Value of pharmacogenomics to the UK £79,931 75 £59,948
National Institutes of Health 5755 - ModEx £10,000 5 £10,000
Physicians Committee for Responsible Medicine 5791 - US impact of vegan diets £136,821 100 £136,821
EuroQol Research Foundation 5764 - OPUF bolt-on valuation £5,000 100 £5,000
EuroQol Research Foundation 5725 - Cognition bolt-on Hong Kong £2,254. 100 £2,254
£1,995,503 £595,223

6

Projects submitted and lost in 2024 so far Projects submitted and lost in 2024 so far Projects submitted and lost in 2024 so far
Funder Project Title Theme Value
Parkinson's UK 5378a - PwP Mindfulness app - dissemination VADM £7,000
Science for Africa 5788 - EPSILONScience for Africa POIHS £299,000
Scottish Consortium UKRI 5792 - Decarbonising H&SC POIHS £190,000
EuroQol Research Foundation 5133b - Sign language extension of Development and
testingof a hearingbolt-on		 MVO £36,629
European Commission 5678 - AI4Kidney VADM £150,000
National Institute for Health Research
(NIHR)		 5708 - NIHR i4i application VADM £81,870
European Commission 5726 - BIONICS EoI £250,000
National Institute for Health Research
(NIHR)		 5740 - Memory Tracks evaluation VADM £50,000
National Institute for Health Research
(NIHR)		 5757 - NIHR Global LMICs Partnership POIHS £2,930,000
EuroQol Research Foundation 5763 - Development and Evaluation of a Refined Version
of the OPUF Approach(OPUF 2.0)		 MVO £6,440
Bill & Melinda Gates Foundation 5773 - Bill & Melinda Gates Advance Women's Health
Innovation		 POIHS £150,000
National Institute for Health Research
(NIHR)		 5803 - Case study economic analyses VADM £49,880
The Health Foundation 5825 Productivity in healthcare POIHS £72,824
National Institute for Health Research
(NIHR)		 5827 - Spark i4i bid VADM £133,947
National Institute for Health Research
(NIHR)		 5842 - Increasing Vaccinations Low Uptake POIHS £152,244
National Institute for Health Research
(NIHR)		 5843 - Biomarkers for Polyps POIHS £35,000
European Union 5846 - EU HORIZON HEROSCAN VADM £307,925
National Institute for Health Research
(NIHR)		 5857 - Bilateral versus unilateral cochlear implants in
adults		 VADM £50,000
EuroQol Research Foundation 5133b - Sign language extension of Development and
testingof a hearingbolt-on		 MVO £36,629
EuroQol Research Foundation 5809 - Cognition and corona in Norway MVO £21,501
Total £5,010,889

7

Publications

We present our publications in three main groups: publications in external peer-reviewed journals; publications on OHE’s website (peer-reviewed by the OHE reviewing process); OHE reports; books and chapters; and working papers in external institutions.

EXTERNAL PEER-REVIEWED JOURNAL ARTICLES, SOURCE OF FUNDING, JOURNAL IMPACT FACTOR, AND CITATIONS (JANUARY TO DECEMBER 2024)

For external peer-reviewed journal articles, we provide information on the sources of financial support, number of citations, SJR indicator and ABS journal ranking.

NO. JOURNAL REFERENCE SOURCES OF
FINANCIAL
SUPPORT		 NUMBER OF
CITATIONS
(AS OF 1
DEC 2024)1
SJR
INDICAT
OR
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
1 Saber, W., Bansal, A., Li, L., Scott, B. L., Sangaralingham, L. R., Thao, V., Roth, J. A., Wright,
W., Steuten, L. M. G., Pidala, J. A., Mishra, A., Maziarz, R. T., Westervelt, P., McGuirk, J. P.,
Cutler, C., Nakamura, R., & Ramsey, S. D. (2024). Cost-effectiveness of reduced-intensity
allogeneic hematopoietic cell transplantation for older patients with high-risk
myelodysplastic syndrome: Analysis of BMT CTN 1102.JCO Oncology Practice,
OP2300413. Advance onlinepublication.https://doi.org/10.1200/OP.23.00413		 National Heart,
Lung, and
Blood Institute
grant
R01HL126589		 4 1.601 N/A
2 Elvidge, J., Hawksworth, C., Avşar, T. S., Zemplenyi, A., Chalkidou, A., Petrou, S., Petykó, Z.,
Srivastava, D., Chandra, G., Delaye, J., Denniston, A., Gomes, M., Knies, S., Nousios, P.,
Siirtola, P., Steuten, L., Wang, J., Dawoud, D., & CHEERS-AI Steering Group. (2024).
Consolidated health economic evaluation reporting standards for interventions that use
artificial intelligence (CHEERS-AI).Value in Health, 27(9), 1196–1205.
https://doi.org/10.1016/j.jval.2024.05.006		 N/A 8 1.507 N/A
3 Jofre-Bonet, M., Rossello-Roig, M., & Serra-Sastre, V. (2024). Intimate partner violence and None 3 1.586 N/A
children's health outcomes.SSM - Population Health, 25, 101611.
https://doi.org/10.1016/j.ssmph.2024.101611

8

NO. JOURNAL REFERENCE JOURNAL REFERENCE SOURCES OF
FINANCIAL
SUPPORT		 NUMBER OF
CITATIONS
(AS OF 1
DEC 2024)1
SJR
INDICAT
OR
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
4 McElwee, F., Cole, A., Garrison Jr, L. P., & Towse, A. (2024). Federal support should not be a
factor in determining pharmaceutical prices under the IRA.Health Affairs Forefront.
https://www.healthaffairs.org/content/forefront/federal-support-should-not-factor-
determining-pharmaceutical-prices-under-ira		 Contract
research
(PhRMA, via
Lou Garrison)		 1 N/A N/A
5 Paulden, M., Sampson, C., O’Mahony, J. F., Spackman, E., McCabe, C., Round, J., & Snowsill,
T. (2024). Decision makers should avoid the Health Years in Total (HYT) approach: A
response to Dr Basu.Value in Health. Advance online publication.
https://doi.org/10.1016/j.jval.2024.04.006
n/a		 1 1.507 N/A
6 Sampson, C., Parkin, D., & Devlin, N. (2024). Is anchoring at 'dead' a theoretical requirement
for health state valuation?Health Economics. Advance online publication.
https://doi.org/10.1002/hec.4863		 EuroQol
Research
Foundation		 1 1.144 3
7 Oliver, E., Kourouklis, D., & Jofre-Bonet, M. (2024). Do R&D tax credits impact
pharmaceutical innovation? Evidence from a synthetic control approach.Research Policy,
53(8),105053.https://doi.org/10.1016/j.respol.2024.105053		 Core funded
research		 0 3.219 4*
8 El Banhawi, H., Bell, E., Neri, M., Brassel, S., Chowdhury, S., & Steuten, L. (2024). A
structured narrative literature review of the broader value of adult immunisation
programmes.Vaccines,12(8),852.https://doi.org/10.3390/vaccines12080852		 Contract
research
IFPMA		 0 1.201 N/A
9 Hayes, H., Meacock, R., Stokes, J., & Sutton, M. (2024). The effect of local hospital waiting
times on GP referrals for suspected cancer.PLOS One, 19(5), e0294061.
https://doi.org/10.1371/journal.pone.0294061		 Core funded
research		 0 0.839 N/A
10 Hayes, H., Stokes, J., Sutton, M., & Meacock, R. (2024). How do hospitals respond to Core funded
research		 0 1.144 3
payment unbundling for diagnostic imaging of suspected cancer patients?Health
Economics. Advance onlinepublication. https://doi.org/10.1002/hec.4804

9

NO. JOURNAL REFERENCE SOURCES OF
FINANCIAL
SUPPORT		 NUMBER OF
CITATIONS
(AS OF 1
DEC 2024)1
SJR
INDICAT
OR
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
11 Kommandantvold, S. A., Lemenuel-Diot, A., Skedgel, C., Pitman, R., Rouse, P., Zaraket, H., &
Blanchet Zumofen, M. H. (2024). A cost-effectiveness analysis of reduced viral
transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and
pandemic influenza management in the United Kingdom.Expert Review of
Pharmacoeconomics & Outcomes Research. Advance online publication.
https://doi.org/10.1080/14737167.2024.2365421		 Internally
funded project
by Roche		 0 0.671 N/A
12 Jofre-Bonet, M., Rossello-Roig, M., & Serra-Sastre, V. (2024). Maternal labor supply and
children’s emotional well-being.Journal of Demographic Economics. Advance online
publication.https://doi.org/10.1017/dem.2024.19		 Core funded
research		 0 0.619 N/A
13 Mott, D. J., Hitch, J., Nier, S., Pemberton-Whiteley, Z., & Skedgel, C. (2024). Patient
preferences for treatment in relapsed/refractory acute leukemia in the United Kingdom: A
discrete choice experiment.Patient Preference and Adherence, 18, 1243–1255.
https://doi.org/10.2147/PPA.S442530		 Research-grant
funded		 0 N/A N/A
14 Neri, M., Cubi-Molla, P., & Cookson, G. (2024). A multi-dimensional framework of valued
output for primary care in England.Applied Health Economics and Health Policy. Advance
onlinepublication.https://doi.org/10.1007/s40258-024-00895-z		 Research grant
(the Health
Foundation)		 0 0.990 N/A
15 Radu, P., Kumar, G., Cole, A., Fameli, A., Guthrie, M., Annemans, L., Geissler, J., Italiano, A.,
O’Rourke, B., Xoxi, E., & Steuten, L. (2024). Evolving assessment pathways for precision
oncology medicines to improve patient access: A tumor-agnostic lens.The Oncologist.
Advance onlinepublication. https://doi.org/10.1093/oncolo/oyae060		 Contract
research EFPIA		 0 1.991 N/A
16 Skedgel, C., Mott, D. J., Elayan, S., & Cramb, A. (2024). A longer life or a quality death? A
discrete choice experiment to estimate the relative importance of different aspects of end-
of-life care in the United Kingdom.MDM Policy & Practice, 9(1), 23814683241252425.
https://doi.org/10.1177/23814683241252425		 NIHR-CLARHC
/ Core funded
research		 0 0.696 N/A
17 Steuten, L., Lothgren, M., Bruce, A., Campioni, M., & Towse, A. (2024). Proposal for a
general outcome-based value attribution framework for combination therapies.Value in
Health. Advance onlinepublication. https://doi.org/10.1016/j.jval.2024.07.019		 Contract
Research		 2 1.507 N/A

10

NO. JOURNAL REFERENCE SOURCES OF
FINANCIAL
SUPPORT		 NUMBER OF
CITATIONS
(AS OF 1
DEC 2024)1
SJR
INDICAT
OR
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
18 Henderson, N., Hodgson, S., Mulhern, B. et al. (2024). A qualitative systematic review of the
impact of hearing on quality of life_. Qual Life Res _https://doi.org/10.1007/s11136-024-
03851-5		 EuroQol
Research
Foundation		 1 1.299 N/A
19 Sampson, C., & Cookson, G. (2024). Marginal cost per QALY estimates: What are they good
for? Health Policy. Advance online publication.
https://doi.org/10.1016/j.healthpol.2024.105036
ABPI		 2 1.206 2
20 Bourke, S., Skedgel, C., Martí-Gil, Y., et al. (2024). Food for thought: More explicit guidance
for inclusion of caregiver perspectives in health technology assessment. International
Journal of Technology Assessment in Health Care,40(1),e77.https://		 0 0.846 N/A
21 Neri, M., Mewes, J. C., de Almeida, F. A., Stoychev, S., Minarovic, N., Charos, A., Shea, K. M.,
& Steuten, L. M. G. (2024). Impact of including productivity costs in economic analyses of
vaccines for C. difficile infections and infant respiratory syncytial virus, in a UK setting.
Cost effectiveness and resource allocation: C/E, 22(1), 34.
https://doi.org/10.1186/s12962-024-00533-4		 0 0.610 N/A
22 Gordon, J., Gheorghe, M., Harrison, C., Miller, R., Dennis, J., Steuten, L., Goldenberg, S.,
Gandra, S., & Al-Taie, A. (2024). Estimating the Treatment and Prophylactic Economic
Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for
Common Pathogens in the USA: A Population Modelling Study._PharmacoEconomic_s,
42(3), 329–341.https://doi.org/10.1007/s40273-023-01337-9		 2 1.517 N/A

1. Google Scholar. The number of citations for each article as of October 2024

2. SCImago Journal Rank (SJR) indicator (PDF), developed by SCImago from the widely known algorithm Google PageRank™. This indicator shows the visibility of the journals contained in the Scopus® database from 1996. SJR takes into account both the number of citations received by a journal and the prestige of the journal based on where those citations come from. The latest available year of indicators is 2022.

3. Chartered Association of Business Schools ('ABS'), UK: journal rankings go from 4* (highest) to 1 lowest). The latest available year of rankings in 2021.

11

Other external publications (non-peer-reviewed) Core, Grant, or Contract Research funded

  1. Henderson, N., & Sampson, C. (2024). The impact of higher uptake of plant-based diets in England: Model-based estimates of health care resource use and health-related quality of life. MedRxiv. doi: https://doi.org/10.1101/2023.12.26.23300536

  2. Ashton, C. (2024). How health economics is redefining climate-resilient healthcare. World Economic Forum. https://www.weforum.org/agenda/2024/06/how-health-economics-is-redefining-climate-resilient-healthcare/

  3. Cabling, M.L., Dawney,J., Naper, M., Marciniak Nuqui, Z., Olumogba, F., Kessler, L., Cole,A., Steuten, L., Marjanovic, S. (2004) Advancing the development and use of diagnostic target product profiles for cancer https://www.cancerresearchuk.orgsites/default/files/final_report_31may2024_final.pdf

  4. Steuten,L (2024) The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and -

Collaboration May 2024. https://globalcoalitiononaging.com/wp content/uploads/2024/05/GCOA_G7Governments_English_FINAL.pdf

  1. Barlow J, Havenaar E, Hofer M, 2024, 2024, The UK Biopharmaceutical Sector 2024 (not peer-reviewed) https://www.imperial.ac.uk/media/imperialcollege/research-centres-and-groups/centre-for-sectoral-economic-performance/Biopharmaceutical_Sector_2024_Brochure_Nov2024.pdf

  2. Pinto, C., Brown, J., Hurt, C., Norton, S., Stumpf, S., Volpato, R., Cubi-Molla, P., Chowdhury, S., McCracken, L., & Bogosian, A. (2024). Acceptability and feasibility randomized controlled trial of a digital psychological support intervention for people with Parkinson’s disease: trial protocol . Research Square . Preprint: https://doi.org/10.21203/rs.3.rs-3773762%2Fv1

Additionally, OHE published 22 insights or blogs on our website on various topics ranging from three of the series HTAs Around the World to Drug Shortages in the UK and their impact. See Inishgts - OHE for more detailed information.

12

Summary of Citations over time

Publication Year Publication Year Publication Year
Number of citations 2019 2020 2021 2022 2023 2024 Total
10+ 19 10 15 12 1 - 57
20+ 13 5 6 8 - - 32
50+ 4 3 - 2 - - 9
100+ - 2 - 2 - - 4

(See appendix for a list of all OHE publications and citations, 2019-2024).

Top 10 Most Cited Publications since 2019

1. 1,388 Citations

Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics . (Epub ahead of print). DOI: 10.1007/s10198-021-01426-6.

2. 278 Citations

Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., ReisFilho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. Nature Medicine. DOI: 10.1038/s41591-022-01717-2

  1. 169 Citations

13

Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, Feb;23(2):139-150. doi: 10.1016/j.jval.2020.01.001. PubMed PMID: 32113617.

4. 112 Citations

Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD, Steuten L, Fenwick E. (2020) Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health . Mar;23(3):277-286. doi:10.1016/j.jval.2020.01.004. PubMed PMID: 32197720.

5. 104 Citations

’ - Zamora, B., Maignen, F., O Neill, P., Mestre Ferrandiz, J. and Garau, M., 2019. Comparing access to orphan medicinal products in Europe. Orphanet Journal of Rare Diseases , 14(1), p.95. 10.1186/s13023-019-1078-5.

6. 85 Citations

Berdud M, Drummond M, and Towse A. (2020). Establishing a reasonable price for an orphan drug. Cost Effectiveness and Resource Allocation https://doi.org/10.1186/s12962-020-00223-x

7. 84 Citations

Steuten, L., Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology , (3), pp. 1-10. DOI: 10.1200/CCI.19.00002.

8. 76 Citations

Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., Mestre-Ferrandiz, J., Oortwijn, W. and Oosterwijk, C., Tunis, S., Zamora, B. 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems . Public Health Genomics , pp.1-8.

9. 69 Citations

Sampson, C.J., Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? PharmacoEconomics . DOI: 10.1007/s40273-019-00819-z.

10. 53 Citations

14

Mott DJ, Shah KK, Ramos-Goñi JM, Devlin NJ, Rivero-Arias O. (2021) Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? Medical Decision Making. DOI:10.1177/0272989X21999607

15

OHE Publications (Peer-Reviewed), Funding, and Number of Downloads

No. Publication Sources of financial support Number of
downloads
1 El Banhawi H., Chowdhury S., Neri M., Radu P., Besley S., Bell E., Brassel S., Steuten L., (2024) Socio-Economic Value of Adult
Immunisation Programmes. OHE Contract Research. Available from https://www.ohe.org/publications/the-socio-economic-value-
of-adult-immunisation-programmes/		 Contract funded (International
Federation of Pharmaceutical
Manufacturers and Associations)		 838
2 Hodgson S., Hayes H., Cubi-Molla P., Garau M. (2024) Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards
Greater Understanding. OHE Contract Research. Available from https://www.ohe.org/publications/inequalities-in-dementia		 Contract funded (Alzheimer’s
Society)		 194
3 Radu P. et. al., 2024 (2024) How Have HTA Agencies Evolved Their Methods Over Time?. OHE Contract Research. Available from
https://www.ohe.org/publications/how-have-hta-agencies-evolved-their-methods/		 Contract funded (Merck Sharp &
Dohme)		 207
4 Kumar G, Bray G, Pan J, Skedgel C, Dunton K, Fonseca Santos F, Genin P, Schroefel G. (2024) Incorporating the Patient Voice in
Health Technology Assessment. OHE Contract Research. Available from https://www.ohe.org/publications/patient-voice-in-hta		 Contract funded (Daiichi-Sankyo) 143
5 Napier M., Kourouklis D., Cole A., Cookson G (2024) The Dynamics of Drug Shortages. OHE Contract Research. Available from
https://www.ohe.org/publications/the-dynamic-of-drug-shortages		 Contract funded ( Organon
Pharma)		 145
6 Napier M., Sampson C., Cole A., Garau M. (2024) A Framework for Value-aligned Pricing of Combination Therapies. OHE Contract
Research. Available from https://www.ohe.org/publications/framework-for-value-aligned-pricing-of-combination-therapies/		 Contract funded ( Astellas
Pharma)		 117
7 Kumar G., Bray G., Steuten L. (2024) Unlocking the Value of Combination Therapies. OHE Contract Research. Available from
https://www.ohe.org/publications/unlocking-the-value-of-combination-therapies/		 Contract funded (The
Association of the British
Pharmaceutical Industry)		 68
8 Napier M., Berdud, M. and Cole A. (2024) The Cost of Drug Shortages. OHE Contract Research. Available from
https://www.ohe.org/publications/the-cost-of-drug-shortages/		 Contract funded ( Organon
Pharma)		 86
9 Henderson N, Bray G, Skedgel C (2024) Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During
Pregnancy. OHE Grant-Funded Research. Available from https://www.ohe.org/publications/impacts-anti-seizure-medicine-use-
during-pregnancy/		 Contract funded (The
Association of the British
Pharmaceutical Industry)		 40
10 Henderson N, Bray G, Skedgel C (2024) Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During
Pregnancy. OHE Grant-Funded Research. Available from https://www.ohe.org/publications/impacts-anti-seizure-medicine-use-
during-pregnancy/		 Research funded (Epilepsy
Society)		 40
11 Kumar G., Napier M., Neri M., Garau M., (2024) The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of
achieving the WHO elimination target?. OHE Contract Research. Available from https://www.ohe.org/publications/socioeconomic-
burden-of-cervical-cancer		 Contract funded (Merck Sharp &
Dohme)		 38*

16

Core-funded projects

Economics of innovation

Project Summary Investigators Update onprogress
Option Pricing The use of real options in relation to pharmaceutical pricing has been promoted by the ISPOR Special
Task Force on US Value Assessment Frameworks. How it can be calculated and used by payers in a way
that avoids double-counting and rewards/targets investment appropriately is still being thought about.
This core research project aims to move that thinking forwards via two invited editorials. The frst is for
Value in Health_and will review a paper to be published. It will focus on whether payers should pay for
option value. The second is for_Vaccine. It will argue for payers being willing to add an option value to
vaccine prices if this enables manufacturing capacity to be switched for use in a pandemic to be
maintained.		 Adrian Towse This is now closed . There were
two publications:
Newall AT, Beutels P, Kis Z,
Towse A, Jit M (2024). Placing a
value on increased fexible
vaccine manufacturing capacity
for future pandemics.Vaccine.
2024 Mar 2:S0264-
410X(23)00219-0. doi:
10.1016/j.vaccine.2024.02.065.
Epub ahead of print. PMID:
36870878; PMCID:
PMC9978930.
Towse, A. (2022). Real Option
Value: Should We Opt In or Out?
Commentary.Value in Health
Volume 25, Issue 11, 1818 –
1820
DOI:https://doi.org/10.1016/j.jval
.2022.09.004
The impact of R&D tax
credits on
pharmaceutical
innovation in the UK		 This project studies the impact of the Research and Development Expenditure Credit (RDEC) scheme,
designed to increase support for private research and development through tax credits. The use of R&D
tax credits is a well-recognised method for providing a fscal incentive that will reduce the cost of R&D;
however, the literature has struggled to properly estimate its effect on true innovation. In general, studies
fail to provide estimates on meaningful innovation and focusing on R&D spending means that results are
highly subject to varying efciencies between frms.
This research considers the treatment group to be the UK and the treatment itself to be the
implementation of the RDEC in 2013. However, the problem with causal inference in this kind of study is
that the counterfactual is unobservable and fnding another country that can act as a suitable control may
not be possible. The Synthetic Control Method (SCM), developed by Abadie and Gardeazabal (2003), will
allow us to estimate the treatment effect by comparing outcomes observed in the UK to a weighted
convex combination of the same outcome variables measured in other similar countries. By evaluating the
effectiveness of the RDEC policy in incentivising innovation, we can help countries such as the UK
evaluate its importance and therefore inform essential cost-beneft analysis. Understanding the impact of
the RDEC can also helpcountries like the UK assess itspotential use in drivinginnovation in specifc areas		 Edward Oliver,
Dimitrios
Kourouklis Mireia
Jofre-Bonet		 It was presented at AHEA 2022
and published in_Research Policy_
in 2024. The project is now
closed.

17

of health care that need it, such as genetic research, vaccinations, or other disease areas that face
scarcity in therapeutic options.
R&D competition &
diffusion of innovation
in the EU: the case of
Hepatitis C		 "The project seeks publication in a peer-reviewed journal of previous OHE Research work. We assessed
the impact of (i) intellectual property protection incentives for R&D, (ii) market competition, and (iii) other
factors, including healthcare policies, on access to Direct Acting Antivirals (DAAs) in Europe.
The study combined an economic framework with analyses of market shares and uptake of DAAs and
interviews with relevant stakeholders of six European Countries (France, Germany, Italy, Portugal, Spain
and the UK) to assess the degree and nature of market competition for DAAs between 2014Q1 and
2017Q2. The theoretical models show that current R&D incentives based on IP protection in the EU can
encourage in-patent competition. The uptake analyses showed that competition within the DAA class was
intense in European markets soon after the launch of the frst-in-class treatment. Evidence from our
interviews suggested that in-class competition improved access and uptake and provided bargaining
power to country payers. IP incentives for R&D may have encouraged a high degree of in-class
competition among DAAs. The in-class competition positively impacted the uptake and adoption of DAAs
in the top5 European countries.		 Mikel Berdud,
Martina Garau,
Margherita Neri,
Phill O’Neill, Chris
Sampson, Adrian
Towse		 Published as an OHE Research
Paper.Journal write-up has been
completed and the article was
rejected from_Applied Health_
Economics and Health Research.
A resubmission is planned.
Setting out the
conditions in which
risk-sharing schemes
improve value for
money		 Regulators have increasingly emphasised approving potentially important treatments rapidly, notably
through accelerated access schemes. As a consequence, there is a challenge for payers. Products are
launched with less evidence, creating greater uncertainty about their relative effectiveness and value for
money, Previous research focusing on the use of VoI approaches to conditional approval has looked only
at the case for only in-research (OIR) or only with research (OWR) and not considered risk sharing as an
additional option. The research question is, “when does risk-sharing improve outcomes for patients and
the health system –in terms of making cost-effective treatments available when they otherwise would be
delayed or not made available at all? Specifcally, the results should be robust to situations in which there
are differences of opinion between manufacturers and payers around the value of new technology to the
health system, which are unbiased (i.e., not negotiation posturing).		 Adrian Towse, Liz
Fenwick (Open
Health)		 We have a paper under review at
Value in Health_Towse A and
Fenwick E. It takes two to tango.
Setting out the conditions in
which performance-based risk
sharing arrangements work for
both parties. Under review at
_Value in Health. This is a journal
article version of a 2021 OHE
research paper Towse, A. and
Fenwick, E., 2021. It takes two to
tango: when do conditional
reimbursement risk-sharing
schemes work for both parties?
Setting out the conditions in
which risk sharing schemes
improve value for money.
Pharmaceutical policy
and access to
innovation in the United
Kingdom after Brexit		 Brexit was presented as an opportunity to promote innovation by breaking free from the European Union
regulatory framework. Since the beginning of 2021 the Medicines and Healthcare products Regulatory
Agency (MHRA) has operated as the independent regulatory agency for the United Kingdom.		 Matthias Hofer Collaboration with Imperial
College London Business School
didn’t progress in 2024. A new

18

This project aims to update the frst published analysis into the regulatory activity of the MHRA post
Brexit. The analysis of regulatory activity of the year 2021 found that the MHRA remained reliant on EU
regulatory decision-making for novel medicines and there were signifcant regulatory delays for a small
number of novel medicines in the UK, the reasons being so far unclear. The updated analysis should cover
a longer time frame and also look at access to medicines after MHRA approval.		 collaboration with LSE to be
established.

19

Value, affordability, and decision-making

Project Investigators Update on progress
ICER pricing,
bargaining, and Cost-
Effectiveness
Thresholds (CETs)		 The project seeks publication in a peer-review journal of previous OHE consulting work for Roche. A novel
supply and demand model of pharmaceutical markets is presented to analyse the relationship between
the value of the CET and the distribution of new medicines' health and economic value between
consumers (payers) and developers (life science industry). The model incorporates a bargaining process
and bargaining power distributed between the payer and the developers, which impacts the distribution of
the health and economic value of new medicines between the two parties.
One of the paper's key fndings is that, with a sufciently large payer’s bargaining power, an efcient CET
value could be higher than the supply-side CET used for decision making. This result has important policy
implications. For example, if market access for innovative medicines is based in HTA using CETs defned
by the health system opportunity costs, there would be circumstances under which some cost-effective
(in the long run) medicines would not be granted. This would result in reimbursement, and incentives for
investing in future innovation would be undermined. This would produce inefcient resource allocation in
thepresent,leadingto not optimal innovationproduction in the future.		 Mikel Berdud,
Adrian Towse		 Completed. Peer review
publication: Berdud, M., Ferraro,
J., & Towse, A. (2024). A theory
on ICER pricing and optimal
levels of cost-effectiveness
thresholds: a bargaining
approach.Frontiers in Health
Services, 3.
Value of life and health This paper follows up on a research project with Amgen and will be submitted for publication in 2021.
Government departments regularly monetise the value of a life for the purposes of informing resource
allocation. In many countries, guidance documents set out the manner in which economic evaluation
should be conducted, often specifying the precise values to be used for different impacts. However, we
fnd different values of life and health are used in analyses by departments despite commonality in
outcomes, giving rise to potential inconsistencies in decision-making and considering trade-offs within a
broader public sector spending budget. Our research intends to provide some evidence to better inform
the political process and raise a number of important issues on assessing the value of public expenditure
across different sectors. Our targeted literature review aimed to identify thresholds, explicitly or implicitly,
as observed in government-related publications, which we understand to represent the government’s
willingness topayfor healthgain.		 Patricia Cubi-
Molla, Martina
Garau, David Mott,
Nadine Henderson		 The paper received a reject and
resubmit from_Cost Effectiveness_
and Resource Allocation,
resubmitted in November 2024.
Defning Affordability The objectives of this project are to Identify how ‘affordability’ in healthcare has been defned, described
and implemented in the theoretical and empirical literature and in the UK policy debate. Propose a unifed
defnition of affordability across different levels of healthcare decision-making and Identify possible ways
to improve efciency and consistency in how health systems handle affordability concerns.		 Gayathri Kumar,
Patricia Cubi-
Molla, Martina
Garau, Gayathri
Kumar, Matthew
Napier, Phill O’Neill,
Chris Sampson,
George Bray		 paused.
ISPOR Task Force:
Antimicrobial
resistance (AMR)		 The objective is to describe and further develop emerging good practices for value assessment of
antimicrobials, including (but not limited to) in the context of a global pull incentive. The guide will improve
estimations of the signifcant and multifaceted wider value offered by new antimicrobials, beyond that
which has routinely been captured in value assessment to date. In doing so, the guide will also be relevant
to other technologies to tackle AMR, such as diagnostics, which face several of the		 Grace Hampson The proposal was submitted to
ISPOR and suggestions for
revisions were received

20

same challenges and offer a similar value profle to new antibiotics.1 It will provide overarching
recommendations on the approach(es) that should be taken and the criteria that should be considered
when designing and conducting value assessment of new antibiotics and related technologies.2 It will
also explore the implications of full quantitative assessment versus more pragmatic scoring approaches,
as have been proposed in some jurisdictions (NHS England, 2024). Appropriate value assessment, as
supported by the proposed guide to emerging good practices, will in turn support the
implementation of effectivepull incentives for the development of much-needed new antibiotics.
Around the world in
HTAs blog series		 In this Insights series, Around the World in HTAs, we shed light on HTA around the world. A general
overview of the health system in the country is given, followed by how health technologies are assessed.
Then some of the main challenges of the system are introduced and next steps for the future are
discussed. Each blog involves a collaboration with an external author/s		 Gayathri Kumar,
Patricia Cubi-
Molla, Martina
Garau, Gayathri
Kumar, Matthew
Napier, Phill O’Neill,
Chris Sampson,
George Bray		 In 2024, 3 additional HTAs
Around the World blogs were
published.

21

Policy, organisation, and incentives in health systems

Project Summary Investigators Update on progress
Primary Care Valued
Output		 This project aims to revise and resubmit a manuscript summarising the development of a framework to
measure the valued output of primary care in England. This manuscript represents the second
contribution of the Health Foundation-funded Efciency Research Programme grant.		 Margherita Neri,
Patricia Cubi-
Molla, Graham
Cookson		 Published on_Applied Health_
Economics and Health Policy,
2024.
The Effect of Distance
on Accident and
Emergency Department
Demand (new 2022)		 When individuals choose to attend a hospital accident and emergency department (AED), they must incur
both the time and fnancial costs of travel, which are both likely to increase with distance. The aim of this
research is to quantify the relationship between travel distance and emergency department demand using
area-level regression analysis. This research will also explore the extent to which the role distance
travelled plays in the decision to attend an AED is dependent on the severity of the individual’s condition.
This work builds upon research conducted by Sian Besley for her MSc Health Economics dissertation and
the fndings of thisproject will be submitted to a health economicsjournal.		 Sian Besley Sian is awaiting fnal analysis
results tables from her external
co-authors. Once the fnal tables
are available these will be added
to the manuscript draft which is
near completion.
GP demand response
to waiting times for
suspected cancer
patients		 Reducing waiting times is a priority in many public health systems. Efforts of healthcare providers to
shorten waiting times may be negated if they simultaneously induce increases in demand.
The existing health economics literature on the demand response to waiting times focuses on elective or
non-urgent care. This study adds to this literature by exploring this relationship for urgent diagnosis of
suspected cancer. Early detection of cancer is a key policy concern in the UK.		 Helen Hayes,
(Rachel Meacock,
University of
Manchester
Jonathan Stokes,
University of
Glasgow
Matt Sutton,
University of
Manchester)		 The paper is now published in
the_European Journal of Health_
Economics
The effects of payment
unbundling on the
utilisation of diagnostic
imaging scans for
suspected cancer
patients		 The overall aim of this study is to examine whether changes in the way that a hospital is reimbursed for
diagnostic testing affects utilisation of tests for suspected cancer patients. This study examines a policy
reform to the way that hospitals were reimbursed for diagnostic imaging scans, wherein a fee-for-service
element was separated from the DRG-based system for hospital reimbursement for outpatient scans,
also known as payment unbundling. This paper examines whether payment unbundling affected provider
utilisation of scans, and conducts further analysis to ascertain whether the recorded effects represent a
real change in the delivery of scans or a change in recording of scans.		 Helen Hayes,
(Rachel Meacock,
University of
Manchester
Jonathan Stokes,
University of
Glasgow
Matt Sutton,
University of
Manchester)		 Published in_Health Economics_

22

The effect of local
hospital waiting times
on GP referrals for
suspected cancer		 Reducing waiting times is a major policy objective in publicly-funded healthcare systems. However,
reductions in waiting times can produce a demand response, which may offset increases in capacity.
We used annual counts of referrals from all 6,667 general practices to all 185 hospital Trusts in England
between April 2012 and March 2018. Using a practice-level measure of local hospital waiting times based
on breaches of the two-week maximum waiting time target, we examined the relationship between waiting
times and urgent GP referrals for suspected cancer. To identify the sources of variation (between practices
or over time) that may drive this relationship, we estimated this using three regression models: pooled linear
regression, a between-practice estimator, and a within-practice estimator.		 Helen Hayes,
(Rachel Meacock,
University of
Manchester
Jonathan Stokes,
University of
Glasgow
Matt Sutton,
University of
Manchester)		 Published in_PLOS ONE_
Labour productivity and
efciency of general
practices in England		 This paper provides new evidence on labour productivity determinants and efciency variables of general
practices. The analysis used a longitudinal dataset of general practice-level, quarterly observations between
2018 and 2021, on a sample of 316 general practices in England. We estimated a general practice
production model using stochastic frontier analysis to evaluate the marginal productivities of general
practitioners (GPs) and nurses with respect to the volume of face-to-face, remote and total consultations
delivered; the substitution and complementarity between these roles; and the technical efciency of general
practices. The aim of this project is to complete a manuscript for submission to The European Journal of
Health Economics.		 Margherita Neri,
Graham Cookson,
(Eugenio Zucchelli,
Universita
autonoma de
Madrid, Bruce
Hollingsworth,
University of
Lancaster)		 Updating the paper for
resubmission
Development of a
synthetic index of
primary care output in
England: a feasibility
study		 In this project we explore potential methodologies for and the feasibility of creating a synthetic index
aggregating the indicators of valued output, developed as part of an OHE research grant funded by the
Health Foundation on primary care efciency. This index will capture the outcome produced by primary
care, with the aim of making the framework developed in our project available for actual use by researchers
or policymakers. The aim of this project is to complete a manuscript for submission to Applied Health
Economics and Health Policy.		 Patricia Cubi-Molla
Margherita Neri
Graham Cookson		 Completing the paper for journal
submission
Socioeconomic and
demographic
determinants of the
double burden of
malnutrition among
mother-child pairs in
Nigeria: overweight
mothers and stunted
children		 Nigeria has historically had a high burden of chronic undernutrition, but overweight and obesity rates are
increasing. This phenomenon, called the double burden of malnutrition (DBM), is increasingly observed in
low- and middle- income countries. At the household level the DBM can manifest as mother-child DBM
(MCDBM). This study aims to address the research gaps by exploring the distribution of and risk factors for
household-level DBM in Nigeria at the national level. Specifcally, study objectives are to: (1) estimate the
prevalence of MCDBM and its’ components (child stunting and maternal overweight/obesity); (2) describe
the percentage distribution of MCDBM and its’ components according to socioeconomic and demographic
factors; and (3) investigate the socioeconomic and demographic determinants of MCDBM in Nigeria.		 Hania El Banhawi,
(Neha Batura,
University College
London, Rolando
Leiva-Granados,
University College
London)		 Imputing missing data for
robustness and revising text for
journal submission

23

Measuring and valuing outcomes

Project Summary Investigators Update onprogress
Assessing the quality
of life of carers of
patients with cystic
fbrosis manuscript		 This project’s aim is to (modify and) publish the WIP manuscript for the CF Carer QOL project completed in
2020, contributing to the (sparse) evidence base of carer QOL for CF carers in the UK.		 David Mott,
Sulayman
Chowdhury		 The manuscript has been
submitted to_Quality of Life_
Research, still under review,
decision to be made very soon
early 2025

24

OHE events

The OHE run an array of educational virtual and face to face events with the new addition of hybrid events this year. These events include specialised webinars, workshops, parliamentary launches, and an annual lecture. This section provides an update on all of the OHE events held over 2024:

Webinars

  1. On January 31[st] , OHE streamed the 2023 Insights and Reflections webinar live to 373 registrants. The webinar explored which OHE research trends had the biggest impact in the previous year and discussed which emerging issues were identified for 2024. Key themes were prevention, sustainability, innovative outcome measures and key policy reforms.

  2. ‘The Future of NICE in a changing HTA Landscape’ webinar took place on March 27 and featured a series of short interviews capturing the most pressing issues and advancements in HTA. There were 491 registrations.

  3. On the 4[th of] September OHE led a webinar titled ‘Green Healthcare: Are We Asking the Right Questions’, which had 197 registrations. The webinar explored the pressing need for the healthcare sector to address its impact on climate change whilst balancing ever-growing financial constraints.

Sponsored Webinars

  1. OHE led a Takeda sponsored webinar titled ‘Efficiency and Labour Productivity of Primary Care in England’ on April 23[rd] . The webinar provided an outlook on the labour productivity and efficiency patterns of general practices in England and proposed how to improve measurement of efficiency. There were 253 registrations.

  2. Organon commissioned a webinar titled ‘Drug Shortages: What are the causes, consequences and pathways to a solution?’ on the 24[th of] September. The panel discussed the range of international government policy measures to secure sustainable and resilient medicine supply. There were 284 registrations.

Roundtables

  1. On the 19[th of] July, OHE led an advisory board on the macroeconomic benefits of Covid-19 vaccines. There were 12 attendees.

  2. On the 8[th of] August, OHE ran a roundtable in Brazil to gather country- specific insights to analyse and communicate the benefits of optimal HIV prevention in Brazil for government decision making. There were 20 participants.

  3. On the 28[th] November 2024, OHE convened an expert group comprised of HTA experts from Asian-Pacific countries and subject matter experts on the broader value of medicines for the ongoing BRAVER project. The meeting was virtual and had 24 participants in total. The BRAVER project aims to identify opportunities

25

and recommendations for the inclusion of broader value elements, including societal perspective, into HTA guidelines and decision making within the AsiaPacific region. The expected outcomes include a whitepaper report by OHE to be published in Q1 2025.

OHE external events

  1. On the 23[rd] January, OHE highlighted their recommendations from the report: ‘The Individual, Health System, and Societal Impacts of Anti-Seizure Medicine Use During Pregnancy’ in parliament. The report launch was convened alongside the Epilepsy Society and was supported by Caroline Nokes. Cross-party MPs (including the Minister for Disabled People), patient advocates, academics, media and industry convened in the House of Commons’ Pavilion.

  2. On the 24[th of] January, OHE attended a parliamentary event to coincide with Cervical Cancer Prevention Week. OHE presented the findings from the report: ‘The Socioeconomic Burden of Cervical Cancer in the UK: what are the benefits of achieving the WHO elimination target?’. OHE shared the platform with the Secretary of State for Health.

  3. On June 12[th] , OHE attended the Global Sustainable Development Congress, convened by The Times Higher Education in Thailand. OHE led a panel titled ‘Charting a Healthy Future: Health, climate, and the SDGs’. There were 75 live attendees.

  4. “On the 8[th] of July, OHE spoke at a parliamentary event in Ireland, showcasing the findings from the report, ’The Value of Adult Vaccination in Ireland”.

  5. 2024 Annual Lecture: On the 8[th] October, OHE brought Professor Andrew J Scott to the stage to give a talk titled ‘The Preventive Health Revolution: Live Longer, Live Better’. The lecture re-evaluated prominent perceptions of ageing and argues for the need to focus on a longevity society. 180 registrants attended the event, held at the prestigious One Birdcage Walk Lecture Hall. The lecture was followed by a drinks and networking reception in the Marble Gallery.

  6. On 18[th] November in Barcelona, OHE participated in a roundtable convened by AstraZeneca. The Access to Innovative Medicines in Cancer (AIMC) initiative roundtable was on ‘Improving Timely Access to Cancer Therapies: Addressing Uncertainty in Value Assessments’.

Brown-bag lunch seminars

Finally, we also hosted four different brown-bag lunch seminars:

  1. The relative value of health gains by age)- Ashwini De Silva

  2. C Health Inequalities: Under-treated Conditions and Unwarranted Treatment Variations - Collete Whitelegg 3. Severity Priority Setting in Norway - Dr Mathias Barra

26

  1. The role of gamification in combatting vaccine hesitancy and misinformation: evidence from a randomised controlled trial. - Sayuri Rentschler.

27

External impact (beyond scientific citations)

In this section we aim to provide an idea of the impact of OHE research that goes beyond the number of publications and/or scientific citations. We first present a selection of impactful outputs by other metrics, and, we illustrate some of this impact with some summary statistics of the downloads and visits to our website, as well as a list of our advisory roles and external presentations.

Selection of Impactful Research Outputs

In 2024, OHE’s research was impactful across many important topics. The following is a selection of the most notable, based on level of activity, digital channel metrics and broader coverage.

  1. Healthy vegan diets – The year started strongly with a great example of a small project with a big impact. Research commissioned by the Vegan Society, and timed to coincide with Veganuary, resulted in mainstream UK coverage in the Daily Mail, extensive social media engagement and a reaction piece in the Health Service Journal.

As the year has progressed, the results have been quoted in several national media articles (Independent and Independent), indicating that it has already become a key element of the evidence base for making decisions around health and a vegan diet.

The accompanying Insight was the most visited of 2024 with 1,395 views.

  1. Adult immunisation – Our most impactful project of 2024 was undoubtedly the research commissioned by IFPMA around the socio-economic value of adult immunisation programmes. This was a fantastic example of collaboration between OHE and a funder working closely to play to individual strengths. The total downloads were well above any other report in 2024 (see graphs below) and it was also hosted on the IFPMA website where it was downloaded 358 times.

Alongside UK national coverage (Daily Telegraph) there was a wide range of international coverage (inc STAT and Pink Sheet) and some high-profile paidfor opportunities (Politico). This was partly due to IFPMA mobilising the national organisations and their media relationships but also OHE’s own relationships.

The success of the report resulted in a follow-on project in Ireland which included an event in the Irish parliament and media coverage.

28

3. Leader in HTA

Notable mentions:

29

Website, Insights & Social Media

We have continued to have substantial activity on our website and our social media channels are growing. We have achieved the following reach as in 2024:

Our analytics are more conservative, as repeat views of the same page are now measured as a single ‘visit’, and users are also able to opt-out of monitoring of their visits and downloads for privacy reasons. Our website analytics also demonstrate the geographic reach of our website. We have over 42,144 users in 170 countries.

This year we continue the work to refine our mailing strategy, by removing duplicates, addresses sending bounce backs, and individuals who had not interacted with our last 15 emails. Furthermore, working on a more sustainable email strategy to drive engagement. Our total mailing list grown from 9,533 to 11,339. Our monthly newsletter operates on an ‘opt in’ basis and we circulate it to 5,355 people.

30

FIGURE 1 TOP 10 LOCATIONS FOR OHE WEBSITE USERS

FIGURE 2: TOP 5 DOWNLOADS OF 2024 OHE REPORTS IN THE YEAR 2024.

31

FIGURE 3: TOP 5 DOWNLOADS OF ALL OHE REPORTS IN THE YEAR 2024.

When looking at the top downloads in 2024, highest interest and impact is observed in OHE publications on adult vaccination and dementia, the evolvement of health technology assessment (HTA), the impact of patient voices, drug shortages and the improvement of the supply chain, green healthcare and sustainability and cost-effective thresholds and modifiers for HTA on the international level.

32

Advisory roles

The number of advisory roles held by OHE staff members has continued to grow, reflecting their strong influence on policy and their recognized contributions to the research and policy community. This impact aligns with OHE's charitable objective of steering health policy and decision-making in health economics and creating capacity by transferring health economics research capacity to students and other individuals at different stages of their careers.

OHE STAFF MEMBERSHIP OF ADVISORY PANELS, BOARDS AND COMMITTEES

Advisory Panels Health Foundation

HTAi

Interest Groups/Task Forces

AES

33

IMPACT-HTA

EuroQol

iHEA

ISPOR

Editorial Roles Applied Health Economics and Health Policy Journal

PharmacoEconomics

PLOS One

Grant Panel Advisory Groups

34

NICE

NIHR

Spanish Health Economics Association (AES)

Visiting Positions for OHE Staff

City, University of London

Fred Hutch Cancer Research Center, University of Washington

Imperial College Business School

Medical University of Vienna

Public University of Navarra

University College London (UCL)

35

University of East Anglia

University of Surrey

Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain

Memberships: Many OHE researchers are also members of associations such as ISPOR, IHEA, HESG, AES, EuroQoL,,and iHTA.

36

External presentations

Presentation Detail
1 Date: January 11, 2024
Presenter: Mireia Jofre-Bonet
Event: HESG Winter 2024
Location: Exeter
Presentation title: How Does Unexpected Demand Affect Queue Prioritisation
In Emergency Care?
What was your presentation about? I discussed a paper that analyses how unexpected demand shifts in Emergency Departments in England affect
prioritisation of patients and how these changes might affect differently protected characteristics of patients (age, biological sex at birth, etc.). The study
uses the Hospital Episodes Survey on patients visiting Emergency Departments between April 2017 and March 2018.
How many people were in the audience: 30
Authors: I. Francetic,R. Meacock,L. Siciliani,and M. Sutton
2 Date: 12th January 2024
Presenter: Chris Sampson
Event: HESG winter 2024
Location: Exeter
Presentation title: Discussion of 'Mobilising health economics research: priorities for action' by Rebecca Kandiyali
What was your presentation about? NA
How many people were in the audience (approx number): 60
Authors: NA
3 Date: 21stJanuary 2024
Presenter: Amanda Cole
Event: Podcast
What was your presentation about?
In this podcast episode produced byThe Evidence Base®, Amanda Cole, Emily Reuben OBE,Karen FaceyandMatt Hickeydiscussed the growing need
for managed-access agreements in the assessment and reimbursement of pharmaceuticals.
Amanda shared insights from research conducted in collaboration withRAND EuropeforCancer Research UK (CRUK)on outcome-based payment,
which aims to alignpayment withpatient value,address decision uncertainty,and allowpayment onlywhen the medicine works as intended.
4 Date: 23rdJanuary 2024
Presenter Nadine Henderson

37

Event What is the cost of a disability? (Epilepsy Society)
Location Thames Pavilion, Houses of Parliament, Westminster
Presentation Title Overview of OHE report "Individual, Health System, and Societal Impacts of Anti-seizure Medicines Use During Pregnancy"
What was your presentation about?
Prevention remains at the heart of our mission as we navigate through these critical issues. The insights presented at this event highlighted the
multifaceted benefits of proactively addressing health challenges.
How many people were in the audience: 50
Nadine Henderson,George Bray,Chris Skedgel
5 Date: 24th January 2024
Presenter: Gayathri Kumar
Event: Parliamentary event hosted by MSD and Evoke Incisive; sponsored by Jess Phillips MP and opening speech by Victoria Atkins MP, Secretary of
State for Health
Location: Houses of Parliament
Presentation title: The socioeconomic benefits of eliminating cervical cancer in the UK
What was your presentation about? Key findings from the OHE report on the socioeconomic benefits of eliminating cervical cancer in the UK. The
presentation outlined OHE’s research approach, the headline results and recommendations for accelerating the path to elimination.
How many people were in the audience (approx number): 50
Authors: Gayathri Kumar,Matthew Napier,Margherita Neri,Martina Garau
6 Date: 31st January 2024
Presenter: Margherita Neri
Event: Team Meeting of the Health Foundation REAL centre
Location: online
Presentation title: Efficiency and Labour Productivity of Primary Care in England
What was your presentation about? Presentation on the findings of an econometric analysis about the labour productivity and efficiency of general
practices in England.
How many people were in the audience (approx number)25
Authors: Margherita Neri,Graham Cookson,Eugenio Zucchelli,Bruce Hollingsworth
7 Date: 12thFebruary 2024
Presenter: Amanda Cole
Event: Guest Lecture for UCL's MBA in Health programme
Location: UCL, Marshgate East Campus
Presentation title: Adapting how we pay for innovative medicines in the life sciences industry.
What was the presentation about: Presentation on why we may need to change the way we pay, to adapt to the promise and challenge of new innovation
in treatments. The presentation focused on two examples - the cancer drugs fund / innovative medicines fund and outcome-based payment - and
described the role of real-world data in these envisioned solutions.

38

How many people were in the audience (approx number 40)
Authors: Amanda Cole
8 Date 16thFebruary 2024
Presenter: Lotte Steuten,
Event Roundtable: Virtual presentation
Presentation title “Discounting Practices in Public Decision-Making: Is the system fit For purpose?"
What was the presentation about?
The Case of cost-effectiveness analyses of Gene Therapies for Inherited Eye Disease Topic: discounting and gene therapies
How many people were in the audience (approx number)100
Authors: Lotte Steuten
9 Presenter Sian Besley,
Date: 17th February 2024
Event: International Conference on Duchenne and Becker Muscular Dystrophy
Location: Rome, Italy
Presentation title: The Race to Improve Assessment of Gene Therapies and Facilitate Patient Access
What was your presentation about? Our poster aimed to inform patients, their families, clinicians and other researchers about the challenges of HTA of
gene therapies and provided our recommendations for overcoming these challenges. The poster also demonstrated whether 9 European countries,
Australia and Canada were achieving these recommendations and discussed examples of best practice.
How many people were in the audience (approx number)
Authors: Sian Besley, Nadine Henderson, Matthew Napier, Amanda Cole and Grace Hampson (OHE) Lauren Diamond, Safiyya Gassman, David Fortier,
Ruth Kim(Pfizer,Inc).
10 Presenter Graham Cookson
Date: 21stFebruary
Event: Economist Thought Leadership Working Group/DLA Piper
Location: Washington
Presentation title: Evidence: Market Size and Investment in R&D, Working Group
What was your presentation about
Graham was invited by DLA Piper to join alongside a group of economists whose work already does, or has the potential to, affect drug pricing policy in
the U.S. The February meeting was a continuation of the October 2023 webinar focusing on the
the Inflation Reduction Act “Maximum Fair Price” provision and evidence that could be used to inform future changes to the law or new proposals to
expand price controls. The working group discussed a draft report that they had co-authored and discussed need areas of research and possible grant
programs to apply to
How many people were in the audience(50)
11 Presenter: Graham Cookson
Event Date: 21stFebruary2024

39

Location: Washington
Event We Work For Health CBO Roundtable Discussion
What was the event about
We Work For Health (WWFH) convened a roundtable discussion in response to the Congressional Budget Office (CBO) post from December 2023. The
roundtable explored the impacts of policy decisions have on the biopharmaceutical industry as well as ultimate patient outcomes and discuss
opportunities to help inform CBO as they review future policies under consideration.
How many people were in the audience(50)
12 Presenter: Graham Cookson
Event Date: 27thFebruary
Location London
Event: Association of British Insurers Annual Conference
Presentation title: "Invested in people and planet - Investing in healthy lives."
Graham joined as a speaker at the Association of British Insurers Annual Conference. The panel discussed how Healthy life expectancy has increased,
but not as much as life expectancy. The talk explored the socio-economic factors, behavioural aspects, and their complex interactions leading to health
inequalities. Graham focused on the changes in healthy life expectancy and health inequality. The presentation focused on the benefits of investing in
prevention-based research based on on OHE's 'Reimagining Prevention, for a Healthier, More Prosperous Society' research.
How many people were in the audience(200)
13 Date: 2ndMarch 2024
Presenter: Mireia Jofre-Bonet
Event: Warwick Women in Economics Society Conference - International Women's Day
Location: University of Warwick
Presentation title: Reflections on a career in Health Economics
What was your presentation about? About my career in economics as a woman and introduction to health economics
How many people were in the audience (approx. number) 75
Authors: Mireia Jofre-Bonet
14 Presenter: Lotte Steuten
Date: 12thMarch 2024
Event: World Evidence, Pricing and Access Congress
Location: Amsterdam
Presentation title: 'Novel payment models: is this where HTA and VBHC “meet in the middle”?
The session will cover the importance of implementing novel payment models to balance value, affordability and innovation of care. Lotte will address the
key challenges associated with implementing these models in practice and highlight how a shift towards value-based healthcare can help overcome
these challenges.
How many people were in the audience(30)

40

15 Presenter: Martina Garau
Date: 13thMarch 2024
Event: World Evidence, Pricing and Access Congress
Location: Amsterdam
Presentation title: NICE enough? Do NICE decision outcomes impact international HTA decision-making?
What was your presentation about: a study showing how NICE guidance and its supporting evidence have an impact on HTA decision-making in
countries beyond the UK.
How many people were in the audience (30)
Authors: Henderson N.,Brassel S.,O’Neill P.,Allen R.,Largeron N.,Garau M.
16 Date: 14thMarch 2024
Presenter: Mikel Berdud
Event: Lecture at MsC Health Economics programme at City, University of London
Location: City university of London, London, UK
Presentation title: Economics of Pharmaceutical Markets
What was your presentation about? About the R&D of new medicines' process and cost, market failures characterising the pharmaceutical markets,
mechanisms to fix market failures and incentives for innovation.
How many people were in the audience (20)
Authors: Mikel Berdud
17 Presenter: Graham Cookson
Date: 20thMarch 2024
Location: Washington
Event: Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma
Presentation title: We Work For Health Paths to Progress: Understanding Policy's Broader Impact on US Leadership in BioPharma
Graham was invited to join a moderated discussion in Washington exploring the impact policy decisions have on biopharmaceutical industry and
opportunities to help inform the congressional budget office (CBO) as it reviews future legislation. Speakers include Douh Holtz-Eakin (President of
American Action Forum) and former CBO Director; Duane Schulthess (CEO of vital Transformation); Ken Thorpe (Professor and the Department of Health
Policy and Management at Emory University)
How many people were in the audience(approx number 50)
18 Date: 21stMarch 2024
Presenters: Amanda Cole, Matthis Hofer, Helen Hayes, George Bray, Sulayman Chowdhury
Event: University of Southern California Doctoral Student Delegation visit to OHE
Location: OHE offices, London
Presentation title: Introduction to OHE; Reimagining Prevention; Combating AMR; The Carer Qaly Trap; Discounting: what can we learn from
environmental economics?

41

What was your presentation about? A showcase of our work to a delegation of 12 USC doctoral student and faculty members from the program
Regulatory Sciences in Europe and the Americas.
How many people were in the audience (approx number) 12
Authors: as above.
19 Date: 27thMarch 2024
Presenter: Charlotte Ashton
Event: Clinton Health Initiative Climate x Health SeminarLocation: Online
Presentation title: Change Initiative: Environmental Sustainability and the Global Healthcare Lifecycle
Presentation focused on the Initiative and our new membership of the Clinton Health Initiative Group
How many people were in the audience(approx number): 75
20 Date 16th April 2024
Presenter: Martina Garau
Location Brussels
EventEconomist Impact's 2nd Cell & Gene Therapy Summit
Presentation Title
The talk was around the need for innovative payment models to ensure access to CGTs
How many people were in the audience (approx number):
around 80
21 Date 16th April 2024
Presenter: Martina Garau
Location Brussels
EventEconomist Impact's 2nd Cell & Gene Therapy Summit
Presentation Title 'From theory to practice: the market impact of HTA legislation'
Martina moderated the session and provided an introduction on explain key concepts (such as JCA and PICO) and set up the access problem that many
ATMPs face in Europe (i.e. wide variation in access among countries and evidence availability at launch vs HTA agencies' evidence requirements).
Audience:
around80

42

22 Date: 16th April 2024
Presenter: Nadine Henderson
Event: Cell & Gene Collective's Patient Voice Summit
Location: Broadway House, Westminster, London
"Panel 2: Improving data collection to ensure cell and gene therapies deliver for patients"
Discussed the necessity of capturing long-term patient-relevant data, the involvement of patient organisation in developing standardised disease
registries and the importance of collaboration and education in data collection
How many people were in the audience: 50
N/A
23 Date: 19th April 2024
Presenter: Simon Brassel
Event: Economics of Longevity: Challenges and Opportunities
Location: Washington D.C.. UN Foundation
Presentation title: Socio-economic value of adult immunisation programs
What was your presentation about? I presented the results from our related project as a contribution to High-level event alongside the G20 Finance
Minister’s Meeting and World Bank Group and IMF Spring Meetings in Washington DC, USA.
How many people were in the audience (approx number)15
Authors: El Banhawi H.,ChowdhuryS.,Neri M.,Radu P.,BesleyS.,Bell E.,Brassel S.,Steuten L.
24 Date: 22nd April 2024
Presenter: Grace Hampson
Event World Federation of Hemophilia (WFH) Congress
Presentation : New Horizons: The Value of Continued Innovation in Hemophilia
Grace lead the discussion at Pfizer's satellite symposium on'New Horizons: The value of continued innovation in hemophilia'panel.
Speakers: moderated by Grace Hampson, Meryem Nimour, Daniel-Aníbal García Diego, Cedric HERMANS MD PhD FRCP (Lon,Edin), Lou Garrison and
Malcolm Qualie
This session focused on the recent progress, identifying remaining unmet needs, and exploring the next steps for innovation in this critical space.
How many people were in the audience (approx number)50
25 Date: 22nd April 2024
Presenter: Mikel Berdud
Event: II HI-PRIX Consortium Meeting
Location: Hamburg, Germany
Presentation title: Impact of innovative payment schemes on long-term competition in health
technologymarkets,inparticular thepharmaceutical market

43

What was your presentation about? About research methodology for a project assessing the impact of Innovative Payment Models on Long-term
competition in Pharmaceutical markets
How many people were in the audience (30)
Authors: Mikel Berdud,Amanda Cole,Mireia Jofre-Bonet
26 Date: 23rd April 2024
Presenter: Mikel Berdud
Event: II HI-PRIX Consortium Meeting
Location: Hamburg, Germany
Presentation title: Mapping of payment and pricing schemes for health innovation in the EU:
implementation, barriers and enablers
What was your presentation about? Preliminary results of a research on the costs and benefits, and the barriers and enablers for Innovative Payment
Models implementation
How many people were in the audience (30)
Authors: Mikel Berdud,Amanda Cole,Mireia Jofre-Bonet
27 Date: 24thApril 2024
Presenter – Lotte Steuten
Event: NHS Confederation –The Economic Benefit of Vaccines
Presentation Title: Are Vaccinations the shot in the arm the economy and health service need?
Tune in to the discussion on the broader impact of vaccinations beyond public health on the latest episode of Hosted by Matthew Taylor,this episode
featuresProf. Lotte Steuten, PhD andChristopher Thomasfrom the IPPR.
Find out more about the economic and societal benefits of vaccinations, including return on investment, elective recovery, presenteeism, and more.
Bow many people were in the audience(unknown)
28 Date: 30th April 2024
Presenter: Chris Sampson
Event: NICE Technical Forum
Location: Online
Presentation title: The future of the QALY: replacement or revision?
What was your presentation about?
The Quality-Adjusted Life Year (QALY) metric, pivotal in health care decision-making, faces increasing scrutiny due to methodological criticisms and anti-
rationing lobbying efforts. This Technical Forum will first explore various proposed alternatives to the QALY, such as Health Years in Total (HYT) and the
Equal Value of Life Years Gained (evLYG). We will assess the suitability of these metrics as replacements for the QALY. Second, the session will address
an important flaw in current approaches to the estimation of QALYs—specifically, the challenges in valuing 'dead' states—and argue for a fundamental
revision to the interpretation of QALYs. The discussion will underscore the irreplaceability of QALYs, while advocating for continuous methodological
revisions to the estimation of QALYs, refinement of their interpretation, and clarity on their role in decision-making.
How many people were in the audience(approx number): 70

44

Authors: Chris Sampson
29 Date: 1st May 2024
Presenter: Patricia Cubi-Molla
Event: Lecture as part of the module "Pharma and Economic Evaluation", for MSc in Health Management (City University of London)
Location: online
Presentation title: Measuring Health Outcomes
What was your presentation about? Basic introduction to health outcome measurement as part of the HTA in England
How many people were in the audience (approx number): 55
Authors: Patricia Cubi-Molla. Module leader: Charitini Stavropoulou
30 Date: 6th May 2024
Presenter: Tori Dawer (Mireia Jofre-Bonet, Alistair McGuire, Josh Roth, Sean Sullivan)
Event: ISPOR USA 2024
Location: Atlanta
Presentation title: A Targeted Literature Review to Identify the Dimensions of Sustainable Global Biosimilars Markets
What was your presentation about? How the entry of biosimilars in the USA pharmaceutical market have affected prices of both biosimilars and
originator products
How many people were in the audience 35
Authors: Tori Dawer(Mireia Jofre-Bonet,Alistair McGuire,Josh Roth,Sean Sullivan)
31 Date: 7th May 2024
Presenter: Amanda Cole
Event: ISPOR International 2024
Location: Atlanta
Presentation title: Value Assessment and Reimbursement of Early Treatment for Prevention of Chronic Progressive Diseases: Are Traditional Approaches
Up to the Task?
What was your presentation about? I described the challenges from a reimbursement perspective, drawing on examples from Alzheimer’s and gene
therapies, and demonstrating the role for innovative and outcome-based payment models to address uncertainty and manage budget impact.
Issue Panel presenters: Will Herring, Amanda Cole, Chuck Phelps, Boshen Jiao.
How many people were in the audience(approx number)1,000
32 Date: 7th May 2024
Presenter: Amanda Cole
Event: ISPOR International 2024
Location: Atlanta

45

Presentation title: How Elastic is Biopharmaceutical Innovation With Respect to Expected Reward? What Is Missing From Existing Literature on Elasticity
of Innovation?
What was your presentation about? I present a select set of existing empirical estimates of the elasticity of innovation from the literature and described
the strengths and weaknesses of the Congressional Budget Office (CBO) forecasts of the impact of policies that curb biopharmaceutical revenue (e.g. the
Inflation Reduction Act) on innovation.
Issue Panel presenters: Gunnar Esiason, Amanda Cole, Darius Lakdawalla, Peter Kolchinsky
How many people were in the audience(approx number)1,000
33 Date: 7th May 2024
Presenter: Matthias Hofer
Event: ISPOR International 2024
Location: Atlanta
Presentation title:
What was the presentation about: During the podium session starting at 13:45 EDT on 7 May, Matthias Hofer presented the analysis of the novel
antimicrobial subscription scheme in the UK and shared the answers to question 'Are proposals for a scheme to stimulate investment in critically needed
new antimicrobials fit for purpose?'.
How many people were in the audience?(60-70)
34 Date: 15th May 2024
Presenter Nadine Henderson
Event Title: Gesundheit Österreich GmbH / Austrian National Public Health Institute webinar: Greener Pharmaceuticals.
Presentation title: "The role of pharmaceuticals in achieving net zero: greener pharmaceuticals in the UK"
An overview of greener pharmaceuticals and health system from the UK perspective, presenting parts of the "Supporting the Era of Green
Pharmaceuticals" OHE Report.
How many people were in the audience: 50
35 Date: 24th May 2024
Presenter Chris Skedgel
Location : ,Philippine International Convention Center, Manila
Event: ASPIRE24, 23-26 May
Presentation Title: Unlocking the Value of Fertility Medicines Using Health Economic Studies' panel
Chris will take part in the company symposium 1 by Merck discussing ‘Unlocking the Value of Fertility Medicines Using Health Economic Studies'.
He will describe how "value" is assessed in fertility treatment and provide an overview of the evidence around the relative value of different therapies.
Speakers: chaired byRomerico Torres, David Humphreys and Michael Costello
How many people were in the audience(approx number)300

46

36 Date 30th May 2024
Presenter Lotte Steuten
Location: Geneva
Event Title: Demonstrating the full societal value of adult immunization: The importance of adopting a prevention-first mindset
Presentation title: Demonstrating the full societal value of adult immunization: The importance of adopting a prevention-first mindset'
OHE has published a report on the Socio-economic Value of Adult Immunization recently. This report discusses the role of adult vaccination programs in
health and societal challenges while aligning with global agendas like the UN Sustainable Development Goals and the WHO Immunisation Agenda 2030
(IA2030).
During the 'Demonstrating the full societal value of adult immunization: The importance of adopting a prevention-first mindset' Lotte will provide an
overview of the project, the objectives, and discuss the results, and recommendations.
Speakers: moderated by Lise Pedersen, Lotte Steuten, Stefania Maggi, Agnes Soares, Tania Cernuschi, Jane Barratt, and Christi G. Kelsey
How many people were in the audience(50)
37 Date: 10th June 2024
Presenter: Charlotte Ashton
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation Title: 'Delivering sustainable healthcare through effective collaboration and impactful outreach'
What was your presentation about? My presentation focused on measuring the success and impact of programmes on the overall health and well-being
of communities, from baseline surveys through to health indicators and tracking changes in specific health metrics e.g. vaccination rates. I also looked at
how it is essential to tailor programmes to address specific health needs across localities e.g. the EVIA programme and its effectiveness in sub-Saharan
Africa.
Approx. 150
N/A
38 Date: 11th June 2024
Presenter: Charlotte Ashton
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title 'Sustainable, resilient healthcare: What have we achieved so far?'
What was the presentation about:
My presentation explored the measures that are being used to improve access to healthcare, from HTS to value-based pricing. I also looked at the
barriers to sustainable healthcare access which included economic constraints, regulatory challenges and inequitable resource allocation, drawing on
lessons from existing healthcare interventions and cross-sector partnerships including the Access to Medicines Index and our own Change Initiative.
Approx. 50
N/A

47

39 Date: 12thJune 2024
Presenter: Grace Hampson
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title: Rethinking research and innovation for equitable healthcare
Approx 50
40 Date: 12th June 2024
Presenters: Charlotte Ashton and Grace Hampson
Location Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title:‘Charting a healthy future: Health, climate and the SDGs'
What was your presentation about?
During the presentation Grace and Charlotte shared their thoughts on ‘Charting a healthy future: Health, climate and the SDGs' discussion.’
Approx. 50
N/A
41 Date: 13thJune 2024
Presenter Grace Hampson
Location: Bangkok, Thailand
Event Title: Global Sustainable Development Congress
Presentation title: ‘The health workforce crisis: Ensuring a resilient workforce for resilient healthcare systems’
What was your presentation about?
Grace shared her research on how we can ensure a resilient workforce to provide a resilient healthcare system
Audience 50
42 Date: 12th June 2024
Presenter: Graham Cookson
Location Congressional Budget Office Washington
Event: Drug Innovation Modelling
Presentation title Modelling innovation in pharmaceutical markets.
Graham was invited to give a presentation to a mix of PhD economists and masters of public policy people at the CBO in Washington.
Audience 50
43 Date: 15 June 2024
Presenter: Martina Garau
Event: HTAi Workshop Characterizing why Rare Diseases Create Evidence Generation Challenges for HTA
Location: Seville

48

Presentation title: Economic modelling in rare diseases: insights from the literature and a survey.
What was your presentation about? Insights from a literature review as part of the Rare Disease Interest Group (RDIG) and the launch of a survey to HTAi
members
How many people were in the audience/online?: around 40 people
Authors: Farzana Malik and Martina Garau
44 Date: 15-19 June 2024
Presenter: Martina Garau
Event: HTAi virtual poster
Location: Virtual / Seville
Presentation title: Comparison of Health Technology Assessment Methodologies across Australia, Canada, New Zealand and the UK: Implications for
Future HTA Collaborations
What was your presentation about? Comparing method guides of a selection of HTA agencies to explore implications of international collaborations
How many people were in the audience/online? : unknown
Authors: Nadine Henderson, Claud Theakston, Simon Brassel, Martina Garau (OHE), Rachel Allen, Nathalie Largeron, Kinga Malottki Yuti Patel Kirsten
Garces Megan Coombes,Vanessa Xavier(Sanofi)
45 Date: 15-19 June 2024
Presenter: Martina Garau
Event: HTAi pre-recorded panel sessions
Location: Virtual / Seville
Presentation title: Economic Modelling For Rare Diseases: What Are The Challenges And How Can The HTA Community Overcome Them?
What was your presentation about? Exploring challenges and solutions of economic methods in rare diseases with a panel bringing different
perspectives (HTA, industry, health economists)
How many people were in the audience/online?: unknown
Authors: Farzana Malik,Saskia Knies,Jameel Nazir,Andrew Briggs,Martina Garau
46 Date: 16 June 2024
Presenter: Martina Garau
Event: HTAi Workshop Unlocking Rare Diseases Economic Modelling: Health Technology Assessment Implications, Methodological Standpoints, and
Multi-Perspective Solutions for Current Challenges
Location: Seville
Economic modelling in rare diseases: insights from the literature and a survey.
What was your presentation about? Insights from a literature review as part of the Rare Disease Interest Group (RDIG) and the launch of a survey to HTAi
members
How many people were in the audience/online?: around 40 people
Authors: Farzana Malik and Martina Garau

49

47 Date: 15-19 June 2024
Presenter: Martina Garau
Event: HTAi pre-recorded panel sessions
Location: Virtual / Seville
Presentation title: Innovation For Alzheimer’s Disease: How To Prepare For New Disease-Modifying Treatments Value Assessments?
What was your presentation about? Exploring challenges related to value assessment and provisions of Alzheimer’s treatments, bringing the HTA and the
patient perspectives.
How many people were in the audience/online?: unknown
Authors: Martina Garau,Jackie Glatter,Angela Bradshaw,Meindert Boysen
48 Date: 5th July 2024
Presenter: Chris Sampson
Event: Health Economists' Study Group
Location: University of Warwick
Presentation title: Discussion of 'Productivity and efficiency: measuring different things gives different results' by Daniel Howdon
What was your presentation about? NA
How many people were in the audience/online?: 40
Authors: NA
49 Date: 9th July 2024
Presenter: Sian Hodgson
Event: HSRUK Conference
Location: Oxford
Presentation title: Inequalities in Dementia in England, Wales and Northern Ireland: Unveiling the Evidence and Forging a Path Towards Greater
Understanding.
What was your presentation about? This poster was presented during a poster walkthrough session. The presentation and poster summarised the
findings of the OHE report, providing a summary of our key literature findings and case studies that assessed whether it is possible to measure
inequalities in dementia.
How many people were in the audience/online? (approx. number) 15
Authors: Sian Hodgson,Helen Hayes,Patricia Cubi-Molla,Martina Garau
57 Date: 9th July 2024
Presenter: Margherita Neri
Event: HSR UK Conference 2024
Location: Oxford
Presentation title: Efficiencyandproductivityofgeneralpractices in England

50

What was your presentation about? Results of an empirical analysis of efficiency across general practices in England and of the determinants of
productivity
How many people were in the audience/online? : 40
Authors: Margherita Neri,Bruce Hollingsworth,Eugenio Zucchelli,Graham Cookson
59 Date: 10 July 2024
Presenter: Lotte Steuten
Event: Ambrosetti Roundtable “The value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems”
Location: Brussels (I attended virtually)
Title: Value of Adult Vaccination
What was the presentation about: Socioeconomic value of adult vaccination
Audience: 150
Authors: Lotte Steuten,Simon Brassel
60 Date: 26 July 2024
Presenter: Martina Garau
Event: Cell and Gene Collective Commission: Session 1
Location: Virtual
Title: Value assessment of Cell & Gene Therapies: international practice and possible next steps in England.
What was the presentation about: Value assessment of Cell & Gene Therapies
Audience: closed meeting
Authors: NR
61 Date: 4 September 2024
Grace Hampson
Event: CER/WifOR hybrid discussion on 'EU fiscal policy: Is health a no-brainer public investment?'
Brussels
EU fiscal policy: Is health a no-brainer public investment
~40
62 Date: 11th September 2024
Presenter: Patricia Cubi-Molla
Event: Opening lecture - Inauguration of MSc/PhD in Quantitative Economics
Location: University of Alicante
Presentation title: "Health Economics for non-economist decision-makers"
What was your presentation about? How to bridge the evidence produced by health economic researchers ('idealism') with the practical realities faced by
stakeholders involved in real-world applications ('pragmatism')
How many people were in the audience/online: 60
Authors: Patricia Cubi-Molla

51

63 Date: 12th September 2024
Presenter: Chris Sampson
Event: IHEA Mental Health Economics SIG webinar - 'Quantifying mental health: research on measurement in mental health economics'
Location: Online
Presentation title: NA - I was just chairing the webinar
What was your presentation about?
How many people were in the audience/online? : 35
Authors: NA
64 Date: 16th September 2024
Presenter: Mikel Berdud
Event: IX Expert Program on Health Policy and Pharmacoeconomics
Location: Mallorca, Spain
Presentation title: " Prices and pharmaceuticals: is transparency good or bad for population health?"
What was your presentation about? Based on the results of the OHE research paper “The Future of Global Health Procurement: Issues around Pricing
Transparency” I discussed whether the price transparency can contribute to improve population health and reflected on some policy recommendations
separately for innovative medicines and generics/biosimilars. Themes I touched were: if transparency is a good in itself, how transparency of prices
relates to the risk of collusion, separating price transparency from process transparency, price transparency and bargaining power, differential pricing,
value-based pricing and competition.
How many people were in the audience/online?: 60
Authors: Mikel Berdud
65 Date: 16th September 2024
Keynote Speaker: Mireia jofre-Bonet
Event: IX Expert Program on Health Policy and Pharmacoeconomics
Location: Mallorca, Spain
Title: " The challenges for the pharmaceutical sector of providing healthcare systems under financial strain?"
What was your presentation about? This summarized the challenges that the pharmaceutical sector is facing due to the extreme financial pressures that
most health systems are experiencing due to pandemic shock in 2020-21, sociodemographic changes, and other causes.
How many people were in the audience/online?: 60
Authors: Mireia Jofre-Bonet
66 Date: 18th September 2024
Presenter: NA (our paper was discussed by someone else)
Event: EuroQol Plenary
Location: Noordwijk, Netherlands
Presentation title: MaryShelley’s Frankenstein: a metaphor for EuroQol instrument development and use

52

What was your presentation about? A discussion of the risks associated with the success of the EQ-5D and its adaptation and application in different
contexts.
How many people were in the audience/online? : 150
Authors: Paula Lorgellyand Chris Sampson
67 Date: 19thSeptember 2024
Presenter: Chris Skedgel
EventFT Live - "Improving ALM Care"
Location: Online
Presentation title: Discussing cost drivers in acute myeloid leukaemia
What was your presentation about? This Financial Times Digital Dialogue, held in partnership with Daiichi Sankyo Europe, brought together AML patient
advocates and carers, physicians, health system representatives and other leading AML experts to discuss what needs to be done to improve patient
care in AML, and the actions that can be taken to reduce the economic burden of the disease while improving outcomes for patients, families and
caregivers.
200 registered;84 online
68 Date: 30th September 2024
Presenter: Amanda Cole
Event:Cell & Gene Collective Commission on Tomorrow’s Science, Today’s NHS: Briefing for Evidence Session 2 – Reimbursement
Location: Virtual
Presentation title: Expert Witness statement and response to commissioners' questions.
What was your presentation about? Reimbursement - to consider optimal innovative finance models that, in the context of the Voluntary Pricing and
Growth Scheme (VPAG), can support the NHS to pay for and allow timely access to CGTs.
How many people were in the audience/online? : 12 (other expert witnesses, Commissioners, and the Cell & Gene Collective secretariat)
Authors: Amanda Cole
69 Date: 3rd October 2024
Presenter: Chris Sampson
Event: CEVR Health Policy Seminar
Location: Boston, MA
Presentation title: The future of the QALY: replacement or revision
What was your presentation about? The shortcomings of proposed alternatives to the QALY and the importance of improving QALY estimation.
How many people were in the audience/online? : 20 in person, 30 online
Authors: Chris Sampson
70 Date 17thOctober 204
Presenter: Simon Brassel

Event: Tagesspiegel Impfgipfel 2024

53

Location: Berlin, Germany
Presentation title: Der sozioökonomische Nutzen von (Erwachsenen)impfprogrammen.
What was your presentation about? I gave an impuls presentation laying out the broader value elements on immunisation programs,
before reporting on our IFMPA funded work on the socioeconomic value of adult immunisation and providing policy recommendations to
policymakers present. I then joined a panel discussion with representatives of academia, pharmaceutical industry and payers.
How many people were in the audience/online? : (approx. number) 40-50 in in the room, plus unknown number in a live stream plus later
audience as the video is published on their platform.
Authors: El Banhawi H.,ChowdhuryS.,Neri M.,Radu P.,BesleyS.,Bell E.,Brassel S.,Steuten L.,
71 Date: 29thOctober 2024
Presenter: Margherita Neri
Event: PROTECT-EUROPE Masterclass 8 - The Economic Case for HPV Vaccination: Securing Health, Saving Lives

Location: online
Presentation title: The socioeconomic benefits of eliminating cervical cancer in the UK
What was your presentation about? Presentation on socioeconomic burden of cervical cancer in the UK and the benefits of achieving the
WHO elimination target
How many people were in the audience/online?: 35
Authors: Gayathri Kumar,Matthew Napier,Margherita Neri,Martina Garau
72 Date 7thNovember 2024
Presenter: Lotte Steuten
Event HTAi Asia Pacific
Location: Seoul, S-Korea
Title: Going Braver: Towards a societal perspective in HTA
Topic: societal perspective in HTA
Lotte Steuten presented at the The Asia Policy Forum which is a leadership meeting for senior representatives from public and private
sector organizations using HTA from the Asia Pacific region. .
Audience: 50 Authors: Matthias Hofer,Claude Theakston,Martina Garau,Lotte Steuten
73 Date 12thNovember 2024
Presenter: Chris Sampson
Event: NCCN 2024 Global Academy for Excellence & Leadership in Oncology
Location: Online

54

Presentation title: Module II: The Role of Health Technology Assessment (HTA) and other Value Considerations
What was your presentation about? Discussion of HTA processes globally
How many people were in the audience/online? : 65
Authors: NA
74 Date: 13th November 2024
Presenter: Mireia Jofre-Bonet
Event: Lecture at St George's City, University of London
Location: London
Presentation title: The Pharmaceutical Market and Drug Pricing. Regulation, Market Dynamics, and Ethical Considerations
What was your presentation about? Landscape of the Pharmaceutical Market and Drug Pricing.
How many people were in the audience/online? : (approx. number) 25
Authors: n/a
76 Date: 17thNovember 2024
Presenter: Lotte Steuten
Event: ISPOR Short Course Programme
Location: Barcelona, Spain
Title: Concepts and Approaches to Early-Stage Health Technology Assessment”.
Lotte co led a short course to demystify the objectives of early-stage health technology assessment and the methods of translational health economics.
Students in the course gained a thorough understanding of available methods for early-stage technology assessment, the specific challenges and
solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and
reimbursement. The course utilised real-world examples and students had the opportunity to strategize about the creation of a research plan for their
purposes.
Faculty: Lotte Steuten, PhD, Office of Health Economics, London, LON, UK William Canestaro, PhD, MSc, Washington Research Foundation, Seattle, WA,
USA; Erik Landaas, PhD, MPH, W. L. Gore & Associates, Inc., Flagstaff, AZ, USA
Audience: 35
Authors: Lotte
77 Date 18thNovember
Presenter: Chris Skedgel
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life? What Difference Could It
Make to Decisions About Life-ExtendingTreatments?,

55

Chris Skedgel moderated an issues panel
78 Date 18thNovember 2024
Presenter: Chris Skedgel
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title Putting Breast Cancer into a Societal Perspective: How Can We Account for Its Full Impact in HTA?
Chris Skedgel moderated an issuespanel
79 Date: 18th November 2024
Presenter: Grace Hampson
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: Balancing Budgets and Breakthroughs: Does Budget Impact Analysis Systematically Disadvantage Gene Therapies?
What was your presentation about? Budget impact analysis for gene therapies
How many people were in the audience/online? : (approx. number) 300
Authors: Grace Hampson,Nadine Henderson,Paul Oyalo
79 Date: 18thNovember 2024
Presenter: Lotte Steuten
/Event: ISPOR Conference
Location: Barcelona, Spain
Title: Broader Value Elements: Methods to Quantify Each and Their Relevance for European Markets
Topic: Broader value elements
Audience: 150
Authors: Lotte
80 Date: 19thNovember 2024
Presenter: Lotte Steuten
Event: ISPOR Conference
Location: Barcelona, Spain
Title: From Research to Policy to Patients: Measuring the Impact of Health Economics and Outcomes Research
Lotte Steuten participated in the ISPOR Forum, "From Research to Policy to Patients: Measuring the Impact of Health Economics and Outcomes
Research (HEOR)."
OVERVIEW: Jan Hansen (Genentech) moderated this session and set the context by explaining global shifts in HEOR organization and investment. Rob
Abbott (ISPOR) presented the importance of measuring HEOR’s impact in the context of ISPOR’s Strategic Plan 2030.Laura Pizzi (ISPOR) discussed the
impact measures that ISPOR currently uses, and opportunities to improve them and Lotte Steuten (OHE) discussed ways to measure the impact of HEOR
on methodsguidelines,healthcarepolicies andpatients,usingthe example of an analysis with BMJ Impact Analytics that tracked the trajectoryand use

56

of HEOR research in real-time. James Chambers (Tufts University) discussed the impact of HEOR on coverage decisions using data from the Tufts
Medical Center Specialty Drug Evidence and Coverage (SPEC) Database. Drawing on these examples, panellists will debate the approaches to HEOR
impact measurement, including the role of data-driven methods and AI-tools, and establish a call to action for the use of these measures as well as
development of new measures.
Moderator: Jan E. Hansen, PhD, US Medical Affairs, Genentech, South San Francisco, CA, USA
Speakers: Rob Abbott, -, CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA; Laura Pizzi, PharmD, MPH, Chief Science Officer, ISPOR, Lawrence
Township, NJ, USA; Lotte Steuten, PhD, Office of Health Economics, London, LON, UK; James Chambers, PhD, MPharm, Center for the Evaluation of
Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Audience: 150
Authors: Lotte
81 Date: 19th November 2024
Presenter: Simon Brassel
Event: Politico Health Care Summit
Location: Brussels
Presentation title: Panellist on Panel discussing Health Care Systems resiliency and the health workforce
What was your presentation about? n/a
How many people were in the audience/online? : (approx. number) 448 audience / 53k+ views
Authors: n/a
82 Date 19thNovember 2024
Presenter: Chris Skedgel and Helen Hayes
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title Is NICE Too Severe With Severity? Exploring How Well Its Severity Modifier Aligns With UK Preferences, Helen Hayes & Chris Skedgel –
poster
83 Date: 19th November 2024
Presenter: Amanda Cole
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: [Issue Panel] Are There More Optimal Approaches to Managing Pricing and Reimbursement of Multi-Indication Medicines to Better
Facilitate Patient Access?
I provided an overview of the challenges and solutions from a broad, international perspective, highlighting the views of different stakeholders and
solutions implemented.
Audience: around 800
Panelists: Jens Grueger;Amanda Cole,Claudio Jommi;Julien Patris

57

84 Date: 19th November 2024
Presenter: Amanda Cole
Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: [Issue Panel] Challenges and Opportunities for Modeling the Impact of Cell and Gene Therapies in the Context of Evolving Regulatory
Environments
I moderated the session presented the background and context of evolving regulatory pathways that may influence and present challenges as well as
opporutnities for CGT modelling and uptake.
Audience: around 250
Panelists: Amanda Cole,Varun Ektare,Salah Ghabri,Indranil Bagchi
85 Date: 19th November 2024
Presenter: Grace Hampson

Event: ISPOR Europe 2024
Location: Barcelona
Presentation title: Lessons From Climate Change Models: What Can Health Economists Learn From Environmental Economists’ Modelling
Methodologies?
What was your presentation about? Environmental impacts in HTA
How many people were in the audience/online? : (approx. number) 250
Authors: Grace Hampson
86 Date: 20th November 2024
Presenter: Grace Hampson

Event: ISPOR Europe 2024
Location: Barcelona
Presentation title:
Taking the Greener Pill: A Case Study for Incorporating Carbon Footprint in Health Technology Assessment
What was your presentation about? Environmental impacts in HTA
How many people were in the audience/online? : (approx. number) 100
Authors: Grace Hampson
87 Date: Nov 20
Presenter: Lotte
Event: AZ Side Event to ISPOR
Location: Barcelona, Spain
Title: HTA in 2030: what have we solved, what are the new challenges?
Topic: HTA

58

Audience: 100
Authors: Lotte Steuten
88 Date: Nov 21
Presenter: Lotte
Event: Pfizer Side Event to ISPOR
Location: Barcelona, Spain
Title: Economic value of vaccines: summary of OHE's research for Pfizer
Topic: Economic value of vaccines
Audience: 120
Author: Lotte Steuten
89 Date: 3rdDecember 2024
Presenter: Grace Hampson
Event: Global AMR Concerns
Location: Brussels, Germany
Title: From UN Declaration to EU Action
Topic: POIHS - featuring keynote speaker Prof Dame Sally Davies. The event includes a panel discussion with Malin Grape, Grace Hampson, and
Aleksandra Opalska. https://womenat.com/w-at-ls-global-amr-concerns
Audience: N/A
Authors: Grace Hampson
90 Date: 04 Dec 2024
Presenter: Lotte Steuten
Event: Annual Business at OECD Health Forum
Location: Paris
Presentation title: Socio-economic value of adult vaccination
What was your presentation about? Socio-economic value of adult vaccination
How many people were in the audience/online? : 100
Authors: ChowdhuryS,El Banhawi H,Bell E,Neri M,Brassel S,Steuten L.
91 Date: 6th December 2024
Presenter: Patricia Cubi-Molla
Event: Guest lecture for module "Introduction to Economic Evaluation" for MSd Health Economics and MSc Economic Evaluation in Health Care at
City St George's, University of London
Location: City St George's, University of London
Presentation title: On HTA reforms,severitymodifiers,and resource allocation

59

What was your presentation about? Part 1 was on HTA reforms: An international comparison and drivers for changes. Part 2 was on Severity modifiers:
NICE HTA methods guidelines: key points and discussion on modifiers. Part 3 presented Resource Allocation in Public Sector Programmes: Does the
Value of a Life Differ Between Governmental Departments?
How many people were in the audience/online? : 5
Authors: Patricia Cubi-Molla
92 Date: 17th December 2024
Presenter: Amanda Cole
Event: All Party Parliamentary Group (APPG) on Genetic, Rare and Undiagnosed Conditions
Location: Portculis House, Westminster
Presentation title: [no title]
What was your presentation about? I presented my personal and professional views on the most pressing need for change in the support of rare disease
patients: better access to diagnosis, better coordinated care, better data sharing, and better opportunities to contribute to research. The objective was to
increase awareness in parliament among MPs and peers of these issues, to support a long-term strategy for the UK.
How many people were in the audience/online? : 30
Authors: Amanda Cole
93 Date: 18th December 2024
Presenter: Amanda Cole
Event: AstraZeneca Value Strategy Pathway Key Opinion Leader event
Location: Virtual
Presentation title: Indication-based pricing: research and progress
What was your presentation about? Summarising our research on IBP, its implementation, and current policy discussions in the UK. Presenting to
AstraZeneca leads in Italy and key opinion leaders from academia, payer, regulatory, modelling experts and hospital pharmacists.
How many people were in the audience/online? : 20
Authors: Amanda Cole

60

Appendix

Citations over time – pre-2024

NO. JOURNAL REFERENCE Sources of financial support NUMBER OF
CITATIONS (AS
OF 1 OCT
2024)1
SJR
Indicator
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
2023
1 Laliotis, I., Shaikh, M., Stavropoulou, C. and Kourouklis, D., 2023. Retirement and Household Expenditure in Turbulent
Times.Journal of Family and Economic Issues.
https://link.springer.com/article/10.1007/s10834-022-09884-7
DOI: 10.1007/s10834-022-09884-7		 Unfunded 0 0.722 2
2 Di Fusco, M.; Mendes, D.; Steuten, L.; Bloom, D.E.; Drummond, M.; Hauck, K.; Pearson-Stuttard, J.; Power, R.; Salisbury,
D.; Towse, A.; Roiz, J.; Szabo, G.; Yang, J.; Marczell, K. The Societal Value of Vaccines: Expert-Based Conceptual
Framework and Methods Using COVID-19 Vaccines as a Case Study. Vaccines 2023, 11, 234.
https://doi.org/10.3390/vaccines11020234
https://www.mdpi.com/2076-393X/11/2/234		 Unfunded 7 1.201 N/A
3 "Zamora, B. and Towse, A., 2023. The Cost-Per-QALY Threshold In England: Addressing Structural Uncertainty In The
Estimates. Frontiers in Health Services.
https://www.frontiersin.org/articles/10.3389/frhs.2022.936774
DOI: 10.3389/frhs.2022.936774		 ABPI 2 N/A N/A
4 "Yaman, F., Cubí‑Mollá, P. and Ungureanu, S., 2023. Which Decision Theory Describes Life Satisfaction Best?
Evidence from Annual Panel Data. Journal of Happiness Studies
https://link.springer.com/article/10.1007/s10902-023-00627-5
DOI: 10.1007/s10902-023-00627-5		 Core funded 4 1.480 1
5 Skedgel, C., Cubi-Molla, P., Mott, D., Gameiro, S., Boivin, J., Al-Janabi, H., Brazier, J., Markert, M., Andersson, F. L., Jofre-
Bonet, M., 2023. Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the
Value of Treatments for Infertility. PharmacoEconomics – Open.
https://link.springer.com/article/10.1007/s41669-023-00402-5
DOI: 10.1007/s41669-023-00402-5		 Ferring
P21B		 3 0.658 2
6 Banal-Estañol, A., Jofre-Bonet, M., Lor,G.,Maynou, L., Tumminello,M., Vassallo,P.,
Performance-based research funding: Evidence from the largest natural experiment worldwide, Research Policy,
Volume 52, Issue 6,2023,104780,
ISSN 0048-7333,
https://doi.org/10.1016/j.respol.2023.104780.		 Unfunded 11 3.219 4*

61

NO. JOURNAL REFERENCE Sources of financial support NUMBER OF
CITATIONS (AS
OF 1 OCT
2024)1
SJR
Indicator
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
7




 Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., & Towse, A. (2023). The Allocation of the Economic Value
of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United
Kingdom. Value in Health, 26(3), 328-335.
https://www.sciencedirect.com/science/article/abs/pii/S1098301523000402
DOI: 10.1016/j.jval.2022.11.022		 Contract funded (Johnson & Johnson) 3 1.507 N/A
8





 Newall AT, Beutels P, Kis Z, Towse A, Jit M (2023). Placing a value on increased flexible vaccine manufacturing
capacity for future pandemics. Vaccine. 2023 Mar 2:S0264-410X(23)00219-0. doi: 10.1016/j.vaccine.2023.02.065.
Epub ahead of print. PMID: 36870878; PMCID: PMC9978930.
https://www.sciencedirect.com/science/article/pii/S0264410X23002190?via%3Dihub
doi: 10.1016/j.vaccine.2023.02.065
PMID: 36870878		 4 1.342 N/A
9

 Jofre-Bonet M, Kamara J, Mesnard A (2023) Corruption and informal sector households’ participation in health
insurance in Sierra Leone. PLoS ONE 18(4): e0281724. https://doi.org/10.1371/journal.pone.0281724		 Unfunded 6 0.839 N/A
10




 Ramsey, S. D., Bansal, A., Li, L., O'Donnell, P. V., Fuchs, E. J., Brunstein, C. G., Eapen, M., Thao, V., Roth, J. A., & Steuten, L.
(2023). Cost-Effectiveness of Unrelated Umbilical Cord Blood vs. HLA Haploidentical Related Bone Marrow Transplant:
Evidence from BMT CTN 1101. Transplantation and cellular therapy, S2666-6367(23)01257-5.
https://www.sciencedirect.com/science/article/abs/pii/S2666636723012575?via%3Dihub
https://doi.org/10.1016/j.jtct.2023.04.017
PMID: 37120135
Grant funded (NIH National Heart, Lung,
and Blood Institute)		 2 1.602 N/A
11


 Neri, M., Brassel, S., Schirrmacher, H., Mendes, D., Vyse, A., Steuten, L. and Hamson, E., 2023. Vaccine-Preventable
Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?. Vaccines, 11(5), p.945.
https://www.mdpi.com/2076-393X/11/5/945
DOI: 10.3390/vaccines11050945		 Contract funded (Pfizer) 2 1.201 N/A
12



 Shafrin J., Lakdawalla D., Doshi J.A., Garrison L.P., Malani A., Neumann P.J., Phelps C.E., Towse A., and Willke R.J.
(2023). A Strategy For Value-Based Drug Pricing Under The Inflation Reduction Act. Health Affairs Forefront, May 4,
2023. DOI: 10.1377/forefront.20230503.153705
https://www.healthaffairs.org/content/forefront/strategy-value-based-drug-pricing-under-inflation-reduction-act
10.1377/forefront.20230503.153705		 Core funded 8 N/A N/A
13




 Firth, I., Hitch, J., Henderson, N. and Cookson, G., Moving towards a More Environmentally Sustainable Pharmaceutical
Industry: Recommendations for Industry and the Transition to Green HTA. Expert Review of Pharmacoeconomics &
Outcomes Research.
https://www.tandfonline.com/doi/full/10.1080/14737167.2023.2214730
DOI: 10.1080/14737167.2023.2214730
PubMed PMID: 37191398		 Core funded 2 0.671 N/A
14


 Garrison L.P. and Towse A. The IRA’s Request For Product-Specific R&D Cost Information: Short-Sighted And
Irrelevant. Health Affairs Forefront, June 5, 2023. DOI: 10.1377/forefront.20230602.550273. Available at
https://www.healthaffairs.org/content/forefront/ira-s-request-product-specific-r-d-cost-information-short-sighted-and-
irrelevantDOI: 10.1377/forefront.20230602.550273		 Core funded 4 N/A N/A
15

 Neri M, Brassel S, Akerjord S, Charos A, Schley K, Steuten L, Recognising the broader value of meningococcal
vaccination: a matter of evidence, ability or willingness?, Value in Health (2023), doi:
https://doi.org/10.1016/j.jval.2023.06.011.		 Contract funded (Pfizer) 1 1.507 N/A

62

NO. JOURNAL REFERENCE Sources of financial support NUMBER OF
CITATIONS (AS
OF 1 OCT
2024)1
SJR
Indicator
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
16 Hafidz F and Sampson C (2023) Editorial: Insights in cost and resource allocation: 2022. Front. Health Serv. 3:1254318.
doi: 10.3389/frhs.2023.1254318		 Unfunded 0 N/A N/A
17 Berdud M, Ferraro J, Towse A. 2023. A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a
bargainingapproach. Frontiers in Health Services Volume 3		 Core Funded 8 N/A N/A
18 Mott, D. J., Schirrmacher, H., Al-Janabi, H., Guest, S., Pennington, B., Scheuer, N., Shah, K. K., & Skedgel, C. (2023).
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap. PharmacoEconomics.
https://doi.org/10.1007/s40273-023-01316-0
https://link.springer.com/article/10.1007/s40273-023-01316-0
DOI: 10.1007/s40273-023-01316-0
PMID: 37659032		 Grant Funded 4 1.517 2
19 Brassel, S., Al Taie, A. and Steuten, L., 2023. Value assessment of antimicrobials using the STEDI framework–How
steady is the outcome?. Health Policy, 136, p.104892.
https://www.sciencedirect.com/science/article/pii/S016885102300177X
https://doi.org/10.1016/j.healthpol.2023.104892
PMID: 37632993		 Contract Funded (Pfizer) 3 1.206 2
20 Hayes, H., Meacock, R., Stokes, J. and Sutton, M., 2023. How do family doctors respond to reduced waiting times for
cancer diagnosis in secondary care?. The European Journal of Health Economics, pp.1-16.
https://link.springer.com/article/10.1007/s10198-023-01626-2
https://doi.org/10.1007/s10198-023-01626-2		 Core funded 1 1.080 2
21 Jakubczyk, M., Schneider, P., Lipman S.A., and Sampson, C., 2023. This dead or that dead: framing effects in the
evaluation of health states. Value in Health.
https://www.valueinhealthjournal.com/article/S1098-3015(23)06155-7/fulltext
10.1016/j.jval.2023.10.009
PMID 37913922		 Grant funded research (EuroQol
Research Foundation)		 2 1.507 N/A
22 Harding S, Alshukri A, Appelbe D, Broadbent D, Burgess P, Byrne P,... Sampson, C. et al. Individualised variable-interval
risk-based screening in diabetic retinopathy: the ISDR research programme including RCT. Programme Grants Appl
Res 2023;11(6) https://www.journalslibrary.nihr.ac.uk/pgfar/HRFA3155 (I'm in the 'et al.')
DOI: 10.3310/HRFA3155 PubMed PMID: 37943975		 n/a old project 0 N/A N/A
23 Gordon, J., Gheorghe, M., Harrison, C. et al. Estimating the Treatment and Prophylactic Economic Value of New
Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A
Population ModellingStudy. PharmacoEconomics(2023). https://doi.org/10.1007/s40273-023-01337-9		 Core funded 0 1.517 2
24 Paulden, M., Sampson, C., O’Mahony, J.F., Spackman, E., McCabe, C., Round, J. and Snowsill, T. 2023. Logical
inconsistencies in the health years in total and equal value of life years gained. Value in Health.
https://doi.org/10.1016/j.jval.2023.11.009		 Unfunded 2 1.507 N/A
25 Hampson, G and Steuten, L. 2023. Netflix and pill: is there a role for volume delinked subscription-style payments
beyond antimicrobials?’ Expert Review of Pharmacoeconomics & Outcomes Research, DOI:
10.1080/14737167.2023.2271171		 Unfunded 2 0.671 N/A
26 Sampson, C., Leech, A., and Garcia-Lorenzo, B. 2023. Opportunity costs in health care: cost-effectiveness thresholds
and beyond. Frontiers in Health Services https://doi.org/10.3389/frhs.2023.1293592		 Unfunded 2 N/A N/A

63

NO. JOURNAL REFERENCE Sources of financial support NUMBER OF
CITATIONS (AS
OF 1 OCT
2024)1
SJR
Indicator
(2023)2		 ABS
JOURNAL
RANKING
(2021)3
27
 Wahlberg K, Winblad B, Cole A, Herring WL, Ramsberg J, et al. People get ready! A new generation of Alzheimer's
therapies may require new ways to deliver and pay for healthcare. J Intern Med. 2023; 00: 1–1		 Grant funded (paid for my travel to
attend and contribute to workshop).
Think Tank; Innovative Payment Models
in Alzheimer's Disease, Stockholm,
Sweden. The Swedish Innovation
Agency (Vinnova), grant number 2021-
02680.
 8 2.895 N/A
28

 Cubi-Molla, P., Mott, D., Henderson, Nadine.,Zamora, Bernarda & Grobler, Mendel & Garau, Martina. (2023). Resource
allocation in public sector programmes: does the value of a life differ between governmental departments?. Cost
Effectiveness and Resource Allocation. 21. 10.1186/s12962-023-00500-5.		 8 0.610 N/A

64

NO. JOURNAL REFERENCE SOURCES OF FINANCIAL SUPPORT NUMBER
OF
CITATIONS
(AS OF
OCT 24)1
SJR
INDICATOR
(2022)2
ABS
JOURNAL
RANKING
(2021)3
2022
1 Bell, E., Brassel, S., Oliver, E., Schirrmacher, H.,Arnetorp, S., Berg, K., Darroch-Thompson, D., Pohja-Hutchison,
P., Mungall, B., Carroll, S., Postma, M. andSteuten, L., 2022. Estimates of the Global Burden of COVID-19 and
the Value of Broad and Equitable Access to COVID-19 Vaccines._Vaccines._DOI: 10.3390/vaccines10081320		 Contract Funded (AstraZeneca) 16 1.201 N/A
2 Bell, E., Neri, M., & Steuten, L.2022. Towards a Broader Assessment of Value in Vaccines: The BRAVE Way
Forward._Applied Health Economics and healthpolicy. _DOI: 10.1007/s40258-021-00683		 Funded Research (Pfizer) 31 0.990 N/A
3 Brassel, S., Neri, M., Schirrmacher, H., Steuten, L., 2022. The Value of Vaccines in Maintaining Health System
Capacityin England._Value in Health._DOI: 10.1016/j.jval.2022.06.018		 Consulting (ABPI) 6 1.507 N/A
4 El-Shal, A.,Cubi-Molla, P. andJofre-Bonet, M., 2022. Discontinuation of performance-based financing in
primary health care: impact on family planning and maternal and child health.International Journal of Health
_Economics and Management._DOI: 10.1007/s10754-022-09333-w		 Unfunded 5 0.541 2
5 Fernandes, S., Pinto, M., Barros, L., Lopes Moreira, M.E., Velho Barreto de Araújo, T., Maciel Lyra, T., Valongueiro,
S.,Jofre-Bonet, M.,Kuper, H. 2022. The economic burden of Congenital Zika Syndrome in Brazil: overview at 5
and 10years._BMJ Global Health._DOI: 10.1136/bmjgh-2022-008784		 Unfunded 4 2.449 N/A
6 Hernandez-Villafuerte, K.,Zamora, B., Feng, Y.Towse, A. et al. 2022. Estimating health system opportunity
costs: the role of non-linearities and inefficiency.Cost Effectiveness and Resource Allocation. DOI:
10.1186/s12962-022-00391		 ABPI 4 0.61 N/A
7 Horgan, D., Borisch, B., Cattaneo, I., Caulfield, M., Chiti, A., Chomienne, C.,Cole, A., et al., 2022. Factors Affecting
Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare.
International Journal of Environmental Research and Public Health. DOI: 10.3390/ijerph19031674		 8 0.808 N/A
8 Husereau, D.,Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the
CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation
Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic
evaluations.European Journal of Health Economics.(Epub ahead ofprint). DOI: 10.1007/s10198-021-01426-6.		 Unfunded 1163 1.080 2
9 Husereau, D.;Steuten, L.; Muthu, V.; Thomas, D.M.; Spinner, D.S.; Ivany, C.; Mengel, M.; Sheffield, B.; Yip, S.;
Jacobs, P.; Sullivan, T. 2022. Effective and Efficient Delivery of Genome-Based Testing- What Conditions Are
Necessary for Health System Readiness?Healthcare 2022. DOI: 10.3390/healthcare10102086		 Amgen Canada, Inc.; AstraZeneca
Canada Inc.; Eli Lilly Canada, Inc.; GSK
Canada Inc.; Hoffmann-La Roche
Canada, Inc. (Diagnostics Division);
Janssen (J&J) Canada Inc.; Pfizer
Canada Inc.; Thermo Fisher Scientific
(Canada)		 5 0.863 N/A
10 Kourouklis, D., Berdud, M., Jofre-Bonet, M.andTowse, A., 2022. Alternative funding models for medical
innovation: the role of product development partnerships in product innovation for infectious diseases.Applied
_Economics Letters._DOI: 10.1080/13504851.2022.2095335		 Core research grant 8 0.376 1
11 Kourouklis, D.and Gandjour, A., 2022. Pharmaceutical Spending and Early-Stage Innovation in EU
countries.Industry and Innovation. DOI: 10.1080/13662716.2021.2021864		 Unfunded 4 1.262 3
12 Kourouklis, D., Sampson, C., Berdud, M. andSkedgel, C.2022. Building Cost-Effectiveness Thresholds for the
Future. _Value & Outcomes Spotlight._DOI: 10.1007/s10198-021-01426-6		 Contract Funded (ABPI) 2 N/A N/A

65

NO. JOURNAL REFERENCE JOURNAL REFERENCE SOURCES OF FINANCIAL SUPPORT NUMBER
OF
CITATIONS
(AS OF
OCT 24)1
SJR
INDICATOR
(2022)2
ABS
JOURNAL
RANKING
(2021)3
13 Kreimeier, S.,Mott, D.,Ludwig, K., Greiner, W., & IMPACT HTA HRQoL Group. 2022. EQ-5D-Y Value Set for
Germany._PharmacoEconomics._DOI: 10.1007/s40273-022-01143-9		 Funded research (EuroQol) 28 1.517 2
14 Mateo, J.,Steuten, L.,Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I.,
Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision
Oncologyto Patients with Cancer._Nature Medicine._DOI: 10.1038/s41591-022-01717-2		 Unfunded 245 19.045
N/A
15 Mott, D. J., Devlin, N. J., Kreimeier, S., Norman, R.,Shah, K. K., & Rivero-Arias, O. 2022. Analytical Considerations
When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-
Y-3L._PharmacoEconomics._DOI: 10.1007/s40273-022-01214-x		 Funded research (EuroQol) 6 1.517 2
16 Mott, D., Ternent, L., & Vale, L. 2022. Do preferences differ based on respondent experience of a health issue
and its treatment? A case study using a public health intervention.The European Journal of Health
_Economics._DOI:10.1007/s10198-022-01482-		 Funded research (Health Foundation) 5 1.080 2
17 Mulhern, B.J.,Sampson, C., Haywood, P., Addo, R., Page, K.,Mott, D.,Shah, K., Janssen, M.F. andHerdman, M.,
2022. Criteria for Developing, Assessing and Selecting Candidate EQ-5D Bolt-Ons.Quality of Life Research.
DOI: 10.1007/s11136-022-03138-7		 Funded research (EuroQol) 11 1.299 N/A
18 Pouwels, X.G.L.V.,Sampson, C.J., and Arnold, R.J.G., 2022. Opportunities and Barriers to the Development and
Use of Open Source Health Economic Models: A Survey._Value in Health._DOI: 10.1016/j.jval.2021.10.001		 Unfunded 21 1.507 N/A
19 Ramos-Goñi, J. M., Estévez-Carrillo, A., Rivero-Arias, O., Rowen, D.,Mott, D., Shah, K., & Oppe, M. 2022. Does
Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based
Valuation Studies Affect Health Preferences?_Value in Health._DOI: 10.1016/j.jval.2022.03.001		 Funded research (EuroQol) 11 1.507 N/A
20 Rodes-Sanchez, M., Spencer, J., Tantri, A., Mitrovich, R., Rachev, B., Sharma, I.,Towse, A., Steuten, L.2022.
Working Towards a Sustainable, Healthy Market for Vaccines: A Framework to Support Evidence-Based
Policymaking._Vaccine 2022._DOI:10.1016/j.vaccine.2022.05.054		 Contract Funded (Merck Sharp & Dohme) 0 1.342 N/A
21 Sampson, C., Zamora, B., Watson, S., Cairns, J., Chalkidou, K.,Cubi-Molla, P., Devlin, N., García-Lorenzo, B.,
Hughes, D.A., Leech, A.A. and Towse, A., 2022. Supply-Side Cost-Effectiveness Thresholds: Questions for
Evidence-Based Policy._Applied Health Economics and Health Policy. _DOI: 10.1007/s40258-022-00730-3		 Contract Funded (ABPI) 21 0.990 N/A
22 Sampson, C.NICE and the EQ-5D-5L: Ten Years Trouble. PharmacoEconomics Open 6, 5–8 (2022).
https://doi.org/10.1007/s41669-021-00315-1		 Unfunded 0 0.658 2
23 Skedgel, C., Henderson, N., Towse, A., Mott, D.,& Green, C. 2022. Considering Severity in Health Technology
Assessment: Can We Do Better?_Value in Health._DOI: 10.1016/j.jval.2022.03.001		 Contract Funded (Biogen) 24 1.507 N/A
24 Towse, A.2022. Real Option Value: Should We Opt in
_Health._DOI: 10.1016/j.jval.2022.09.004		 or out? Commentary.Value in Core research grant 2 1.507 N/A
25 Towse, A. and Silverman Bonnifield, R. 2022. An Ambitious USG Advanced Commitment for Subscription-Based
Purchasing of Novel Antimicrobials and Its Expected Return on Investment.CGD Policy Paper 277. Washington,
_DC: Center for Global Development._https://www.cgdev.org/publication/ambitious-usg-advanced-
commitment-subscription-based-purchasing-novel-antimicrobials
Unfunded		 7 N/A N/A
26 Treibich, C.,Bell, E., Blanc, E., Lepine, A., 2022. From a drought to HIV: An analysis of the effect of droughts on
transactional sex and sexually transmitted infections in Malawi.SSM - Population Health.
DOI: 10.1016/j.ssmph.2022.101221		 Unfunded 8 1.586 N/A

66

NO. JOURNAL REFERENCE SOURCES OF FINANCIAL SUPPORT NUMBER
OF
CITATIONS
(AS OF
OCT 24)1
SJR
INDICATOR
(2022)2
ABS
JOURNAL
RANKING
(2021)3
27 Vass, C., Boeri, M., Karim, S., Marshall, D., Craig, B., Ho, K.-A.,Mott, D.,Ngorsuraches, S., Badawy, S. M.,
Mühlbacher, A., Gonzalez, J. M., & Heidenreich, S. 2022. Accounting for Preference Heterogeneity in Discrete-
Choice Experiments: An ISPOR Special Interest GroupReport._Value in Health._DOI: 10.1016/j.jval.2022.01.012		 Core research grant 43 1.507 N/A
28 Yaman, F.,Cubi-Molla, P. and Plagnol, A.C., 2022. Why do immigrants become less happy? Explanations for the
decrease in life satisfaction of immigrants in Germany over time._Migration Studies._DOI:
10.1093/migration/mnac034		 Unfunded 11 0.732 N/A

67

JOURNAL REFERENCE NUMBER OF
CITATIONS (AS OF
OCT 23)1
 SJR INDICATOR
(2022)2		 ABS JOURNAL
RANKING
(2021)3
2021
1 Bogosian, A, Hurt, C.S, Hindle, J.V, McCracken, L.M, Vasconcelos e Sa, D.A., Axell, S, Tapper, K, Stevens, J, Hirani, P.S, Salhab, M, Ye, W. and
Cubi-Molla, P.(2021) Acceptability and Feasibility of a Mindfulness Intervention Delivered via Videoconferencing for People With
Parkinson’s._Journal of Geriatric Psychiatry and Neurology. _DOI: 10.1177/08919887209881901		 28 1.014 N/A
2 El-Shal, A,Cubi-Molla, P. and Jofre-Bonet, M. (2021) Accreditation as a quality-improving policy tool: family planning, maternal health, and
child health in Egypt._The European Journal of Health Economics._DOI: 10.1007/s10198-020-01240-6		 11 1.080 2
3 Sampson, C, Zhang, K., Parkin, D. andHampson, G.(2021b) Exclusive human milk diet for very preterm babies in England: protocol for a
cost-effectiveness and budget impact analysis._F1000Research._DOI:10.12688/f1000research.22450.1		 2 N/A N/A
4 Kourouklis, D., 2021.Public subsidies for R&D and public sector pharmaceutical innovation.Applied Economics, 53(32), pp.3759–3777.
DOI: 10.1080/00036846.2021.1885614.		 15 0.590 2
5 Latimer,N,R., Towse, A., and Henshall, C (2021) Not cost-effective at zero price: valuing and paying for combination therapies in cancer,
Expert Review of Pharmacoeconomics&Outcomes _Research_DOI:10.1080/14737167.2021.1879644		 11 0.671 N/A
6 Sampson C, Firth I, Towse A.(2021) Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.:Medical Decision
Making. DOI: 10.1177/0272989x20987211		 2 1.165 N/A
7 Skedgel C, Ralphs E, Finn E, et al. (2021) Is the public supportive and willing to pay for a national assistive reproductive therapies
programme? Results from a multi-countrysurvey._BMJ Open, _11:e044986. DOI: 10.1136/bmjopen-2020-044986		 8 0.971 N/A
8 Mott DJ,Shah KK, Ramos-Goñi JM, Devlin NJ, Rivero-Arias O. (2021) Valuing EQ-5D-Y-3L Health States Using a Discrete Choice
Experiment: Do Adult and Adolescent Preferences Differ?Medical Decision Making. DOI:10.1177/0272989X21999607		 49 1.165 N/A
9 Zamora B., Garrison L.P., Unuigbe A., andTowse A. (2021). Reconciling ACEA and MCDA: is there a way forward for measuring cost-
effectiveness in the USS healthcare setting?Cost Effectiveness and Resource Allocation. DOI: 10.1186/s12962-021-00266-8		 8 0.61 N/A
10 Pearson S.D.,Towse A., Lowe M., Segel C.S., and Henshall C. (2021) Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and 13 0.579 N/A
utilisation managementpolicies forpharmaceuticals.Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0027
11 Brassel, S, Neri, M, O’Neill, P. and Steuten, L.(2021) Realising the Broader Value of Vaccines in the UK_. Vaccine: X, p.100096._DOI:
10.1016/j.jvacx.2021.100096		 19 0.682 N/A
12 Jofre-Bonet, M. (2021) Invited Tribune: COVID-19 and vaccines: Learning by Doing- Estudios sobre la Economía Española, 2021/04
Aspectos Económicos de la crisis del COVID-19. Boletín de Seguimiento no. 10. Fundación de Estudios de Economía Aplicada (FEDEA).
https://documentos.fedea.net/pubs/eee/eee2021-14.pdf		 N/A N/A N/A
13 Jofre-Bonet, M. (2021) About economic research that does not involve money_. Societat Catalana d’Economia - 5centims.cat._
https://www.5centims.cat/sobre-la-recerca-economica-que-no-va-de-diners/		 N/A N/A N/A
14 Latimer N, Pollard P,Towse A,Henshall C, Sansom L, Ward R, Bruce A, and Deakin C. (2021) Challenges in valuing and paying for
combination regimens in oncology: reporting the perspectives of a multistakeholder, international workshop.BMC Health Services
Research 21:412. DOI: 10.1186/s12913-021-06425-0		 23 1.029 3
15 Towse A.,Chalkidou K.,Firth I., Kettler H., and Silverman R. (2021) How Should the World Pay for a Coronavirus Disease (COVID-19)
Vaccine?Value in Health. DOI: https://doi.org/10.1016/j.jval.2020.12.008		 22 1.507 N/A
16 Mott, D.J., Leslie, I., Shah, K., Rowell, J. & Scheuer, N. (2021) Impact of Including Carer Information in Time Trade-Off Tasks: Results from a
Pilot Study._PharmacoEconomics - open._DOI: 10.1007/s41669-021-00270-x
1		 0.658 2
17 Zhang K,Kumar G, Skedgel C. (2021) Towards a New Understanding of Unmet Medical Need.Applied Health Economics and Health Policy.
DOI: 10.1007/s40258-021-00655-3
11		 0.990 N/A

68

18 Cubi-Molla P,Buxton M, Devlin N. (2021) Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform
Decisions in the UK and Elsewhere?Applied Health Economics and Health Policy. Jun 9:1-0. DOI:10.1007/s40258-021-00648-2		 Cubi-Molla P,Buxton M, Devlin N. (2021) Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform
Decisions in the UK and Elsewhere?Applied Health Economics and Health Policy. Jun 9:1-0. DOI:10.1007/s40258-021-00648-2		 Cubi-Molla P,Buxton M, Devlin N. (2021) Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform
Decisions in the UK and Elsewhere?Applied Health Economics and Health Policy. Jun 9:1-0. DOI:10.1007/s40258-021-00648-2		 21 0.990 N/A
19 Neri, M., Cubi-Molla, P. & Cookson, G. (2021) Approaches to Measuring Efficiency in Primary Care: A Systematic Literature Review.
Applied Health Economics and Health Policy. DOI: 10.1007/s40258-021-00669-x		 13 0.99 N/A
20 El-Shal, A., Cubi-Molla, P. and Jofre-Bonet, M. (2021) Are us
and child health services_. Economic Analysis and Policy. _DOI:		 er fees in health care always evil? Evidence from family planning, maternal,
10.1016/j.eap.2021.08.009		 7 1.597 1
21 Bell. E., Neri. M, and Steuten. L. (2021) Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward.Applied Health
Economics and Health Policy. 23:1–13. DOI:10.1007/s40258-021-00683-z.		 31 0.990 N/A
22 Payne, H., Robinson, A., Rappe, B., Hilman, S., De Giorgi, U., Joniau, S., Bordonaro, R., Mallick, S., Dourthe, L.-M., Flores, M. M., Gumà, J.,
Baron, B., Duran, A., Pranzo, A., Serikoff, A.,Mott, D.J., Herdman, M., Pavesi, M., & De Santis, M. (2021) A European, prospective,
observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE_. International Journal of_
Cancer. DOI: 10.1002/ijc.33845		 15 2.131 N/A
23 Flood, C., Behn, N., Marshall, J., Simpson, A., Northcott, S., Thomas, S., Goldsmith, K., McVicker, S.,Jofre-Bonet, M.and Hilari, K., 2021. A
pilot economic evaluation of a feasibility trial for SUpporting wellbeing through PEeR-Befriending (SUPERB) for post-stroke aphasia.
_Clinical Rehabilitation._DOI: 10.1177/02692155211063554		 1 0.949 N/A
24 Bajre MK,Towse A, Stainthorpe A, Hart J., 2021. Results from an Early Economic Evaluation of the use of A Novel Point of Care Device for
Diagnosis of Suspected Acute Coronary Syndrome Patient Within an Emergency Department in the National Health Service in
England._Cardiology and Cardiovascular Medicine._DOI: 10.26502/fccm.92920228		 0 N/A N/A
25 Sampson, C, Bell, E., Cole, A.,Miller, C.B., Marriott, T., Williams, M. and Rose, J., 2021. Digital cognitive behavioural therapy for insomnia
andprimarycare costs in England: an interrupted time series analysis_. BJGP Open._DOI: 10.3399/BJGPO.2021.0146		 12 N/A N/A
26 Skedgel, C., Ralphs, E., Finn, E., Markert, M., Samuelsen, C. & Whitty, J. 2021. How Do People with Experience of Infertility Value Different
Aspects of Assistive Reproductive Therapy?_The Patient – Patient Centred Outcomes Research._DOI: 10.1007/s40271-021-00563-7		 7 N/A N/A
27 Skedgel, C. 2021. Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain. Pharmacoeconomics.
DOI: 10.1007/s40273-021-01119-1.
0		 1.517 2
2020
1 Fenwick E,Steuten L, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of
Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good
Practices Task Force._Value in Health,_Feb;23(2):139-150. doi:10.1016/j.jval.2020.01.001. PubMed PMID: 32113617.		 154 1.507 N/A
2
Garrison, L.,Zamora, B., Li, M., andTowse, A. (2020). Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value
Assessment—Rationale and Empirical Support.Journal of Managed Care & Specialty Pharmacy,26(4), pp.400-406.		 28 0.766 N/A
3 Herdman, M., Kerr, C., Pavesi, M., Garside, J., Lloyd, A.,Cubi-Molla, P. and Devlin, N., (2020). Testing the validity and responsiveness of a
new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.Journal
of Patient-Reported Outcomes,4(1), pp.1-12.		 16 N/A N/A
4 Hilari, Katerina, Nicholas Behn, Jane Marshall, Alan Simpson, Shirley Thomas, Sarah Northcott, Chris Flood,Mireia Jofre-Bonet, et al.
(2020) Adjustment with Aphasia after Stroke: Study Protocol for a Pilot Feasibility Randomised Controlled Trial for Supporting Wellbeing
through PEeR Befriending (SUPERB)._Pilot and Feasibility Studies_5,no. 1: 14.https://doi.org/10.1186/s40814-019-0397-6.		 35 0.568 N/A
5 J Costa-Font,M Jofre-Bonet. (2020). Is the Intergenerational Transmission of Overweight ‘Gender Assortative’?Economics & Human
Biology,100907.		 11 0.916 2
6 Lorgelly, P., Pollard, J.,Cubi-Molla,P.,Cole, A., Sim, D. and Sussex, J., (2020). Outcome-Based Payment Schemes: What Outcomes Do
Patients with Cancer Value?The Patient-Patient-Centered Outcomes Research, pp.1-12.		 16 N/A N/A
7 Mott, D.J.,Chami, N. & Tervonen, T. (2020) Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit
Patient Preferences.Value in Health. 23(8),979–984.		 20 1.507 N/A

69

8 Mott, D.J., Hampson, G.,Llewelyn, M.J., Mestre-Ferrandiz, J. & Hopkins, M.M. (2020) Authors’ Reply to Hays: ‘A Multinational European
Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance’.Applied Health Economics and Health Policy. 18
(3),459–460.		 0 0.990 N/A
9 Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD,Steuten L, Fenwick E. (2020) Value of
Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.Value in
Health. Mar;23(3):277-286. doi:10.1016/j.jval.2020.01.004. PubMed PMID: 32197720.		 105 1.507 N/A
10
Shaikh, M., Del Giudice, P. andKourouklis, D., (2020). Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D
Investment.Applied Health Economics and Health Policy. 10.1007/s40258-020-00601-9.		 18 0.990 N/A
11 DeVolder, R., Serra-Sastre, V. andZamora, B.,(2020). Examining the variation across acute trusts in patient delayed discharge.Health
Policy.		 7 1.206 2
12 Chalkidou K,Towse A,Silverman R,Garau M, Ramakrishnan G. (2020). Market-driven, value-based, advance commitment (MVAC):
acceleratingthe development of apathbreakinguniversal drugregimen to end TB.BMJ Global Health;5: e002061.		 7 2.449 N/A
13 Berdud M,Drummond M, andTowse A.(2020). Establishing a reasonable price for an orphan drug.Cost Effectiveness and Resource
_Allocation_https://doi.org/10.1186/s12962-020-00223-x		 80 0.61 N/A
14 Costa-Font, J.,Jofre-Bonet, M., J. Legrand (2020) Vertical Transmission of Overweight: Evidence from a sample of English Adoptees,
forthcoming Food Policy.		 4 2.116 3
2019
1 Broadbent, D.,Sampson, C.J., Wang, A., Howard, L., Williams, A., Howlin, S., Appelbe, D., Mott, T., Cheyne, C., Rahni, M., Kelly, J., Collins,
J., García-Fiñana, M., Stratton, I., James, M., and Harding, S. 2019. Individualised Screening for Diabetic Retinopathy: the ISDR study.
Rationale, design and methodology for a randomised controlled trial comparing annual and personalised variable-interval risk-based
screening.BMJ Open. 9(e025788). DOI:10.1136/bmjopen-2018-025788.		 27 0.971 N/A
2 Cubi-Molla, P.,Shah, K., Garside, J., Herdman, M. and Devlin, N., 2019. A note on the relationship between age and health-related quality
of life assessment.Quality of Life Research, 28(5), pp.1201-1205. DOI: 10.1007/s11136-018-2071-5.		 11 1.299 N/A
3 Drummond, M. andTowse, A., 2019. Is rate of return pricing a useful approach when value-based pricing is not appropriate?A. Eur J
Health Econ (2019)20: 945.https://doi.org/10.1007/s10198-019-01032-7		 30 1.080 2
4 Li, A., Manohar, P.M., Garcia, D.A., Lyman, G.H. andSteuten, L.M.2019. Cost effectiveness analysis of direct oral anticoagulant (DOAC)
versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.Thrombosis Research, (180), pp. 37-24.
DOI:https://doi.org/10.1016/j.thromres.2019.05.012.		 27 1.098 N/A
5 Lopez-Picado, A., Barrachina, B., Remon, M. andErrea, M., 2019. Cost benefit analysis of the use of tranexamic acid in total replacement
hip surgery._Journal of Clinical Anesthesia._Vol. 57(in progress. November 2019), pp. 124-128.		 20 1.082 N/A
6 Mewes, J.C., Pulia, M.S., Mansour, M.K., Broyles, M.R., Nguyen, B. andSteuten, L., 2019. The cost impact of PCT-guided antibiotic
stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health
economic model analysis.PLOS ONE. DOI:https://doi.org/10.1371/journal.pone.0214222.		 43 0.839 N/A
7 Murad, Z., Stavropoulou, C., andCookson, G.2019. Incentives and gender in a multi-task setting: An experimental study with real-effort
tasks,PLOS ONE, 14(3), e0213080. DOI:https://doi.org/10.1371/journal.pone.0213080.		 13 0.885 N/A
8 Sanchez-Iriso, E.,Errea, M., Cabases, J.M., 2019. Valuing Health using EQ-5D: The impact of chronic diseases on the stock of health.
Health Economics. DOI: https:/A/doi.org/10.1002/hec.3952		 9 2.440 3
9 Sampson, C.J., Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W.,
Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how?PharmacoEconomics. DOI:
10.1007/s40273-019-00819-z.		 63 1.517 2

70

10 Steuten, L., Garmo, V., Phatak, H., Sullivan, S.D., Ngheim, P. and Ramsey, S.D. 2019. Treatment patterns, overall survival, and total
healthcare costs of advanced Merkle cell carcinoma in the USA.Applied Health Economics and Health Policy, pp. 1-8. DOI:
https://doi.org/10.1007/s40258-019-00492-5.		 11 0.990 N/A
11 Steuten, L., Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients
with advanced non-small-cell lungcancer.Journal of Clinical Oncology,(3), pp. 1-10. DOI: 10.1200/CCI.19.00002.		 77 10.639 N/A
12 Zamora, B., Gurupira, M.,Rhodés Sánchez, M., Feng, Y., Hernandez-Villafuerte, K., Brown, J. and Shah, K., 2019. The value of international
volunteers experience to the NHS.Globalization and Health, 15(31). DOI: https://doi.org/10.1186/s12992-019-0473-y.		 13 2.668 N/A
13 Zamora, B.,Maignen, F.,O’Neill, P.,Mestre-Ferrandiz, J. andGarau, M., 2019. Comparing access to orphan medicinal products in Europe_.
_Orphanet Journal of Rare Diseases, 14(1), pp.95.		 99 1.182 N/A
14 Davillas, A.and Pudney, S. (2019) Biomarkers as precursors of disability._Economics & Human Biology_Available online 10 September
2019, 100814. https://www.sciencedirect.com/science/article/pii/S1570677X18300959?via%3Dihub		 18 0.916 2
15 Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., Mestre-Ferrandiz, J., Oortwijn, W. and
Oosterwijk, C., Tunis, S.,Zamora, B.2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to
Facilitate BringingThis Technologyinto Healthcare Systems_. Public Health Genomics_, pp.1-8.		 69 0.349 N/A
16 Mott, D.J., Hampson, G.,Llewelyn, M., Mestre-Ferrandiz, J. and Hopkins, M.M. A Multinational European Study of Patient Preferences for
Novel Diagnostics to Manage Antimicrobial Resistance.Applied Health Economics and Health Policy. doi: 10.1007/s40258-019-00516-0		 8 0.990 N/A
17 Hilari, K., Behn, N., Marshall, J., Simpson, A., Thomas, S., Northcott, S., Flood, C., McVicker, S.,Jofre-Bonet, M.,Moss, B., James, K. and
Goldsmith, K., 2019. Adjustment with aphasia after stroke: study protocol for a pilot feasibility randomised controlled trial for Supporting
wellbeingthrough PEeR Befriending (SUPERB).Pilot and Feasibility Studies, 5(1), p.14.		 35 0.568 N/A
18 Kuper, H., Lyra, T.M., Moreira, M.E.L., de Albuquerque, M. do S.V., de Araújo, T.V.B., Fernandes, S.,Jofre-Bonet, M., Larson, H., Lopes de
Melo, A.P., Mendes, C.H.F., Moreira, M.C.N., do Nascimento, M.A.F., Penn-Kekana, L., Pimentel, C.,Pinto, M., Simas, C. and Valongueiro, S.,
2019. Social and economic impacts of congenital Zika syndrome in Brazil: Study protocol and rationale for a mixed-methods study.
Wellcome Open Research, 3, p.127		 40 1.104 N/A
21 Carrieri, V.,Davillas, A., Jones, A.M. (2019). A latent class approach to inequity in health using biomarker data. Health, Econometrics and
Data Group(HEDG)WorkingPapers 19/22, HEDG, c/o Department of Economics, Universityof York.		 31 N/A N/A
22 Garrison L andTowse A.(2019) A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and
Precision Medicine. Journal of Managed Care and SpecialityPharmacy. 2019;25(10):1082-87		 27 0.766 N/A
23 Pearson SD, Segel C,Cole A,Henshall C, andTowse A. 2019. Policy perspectives on alternative models for pharmaceutical rebates: a
report from the Institute for Clinical and Economic Review Policy Summit. Journal of Comparative Effectiveness Research 10.2217/cer-
2019-0094 C		 4 0.579 N/A
23 Towse A., and Fenwick E. (2019) Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different
About a One-Off Treatment? Value in Health. 2019; 22(6):677–683.		 40 1.507 N/A

71

Contract research projects that were won in 2024 (live and closed)

Project Funder Project Title Research
Theme		 Project
Status		 Year Won Project
Budget
The London School of Economics and
Political Science(LSE)		 5813 - LSE Market Access Academy (2024) VADM Closed 12-Apr-24 £1,500
The London School of Economics and
Political Science(LSE)		 5813a - Extension of LSE Market Access Academy June 2024 VADM Closed 16-Jul-24 £1,500
The London School of Economics and
Political Science(LSE)		 5813b - Extension LSE MAA sept 2024 VADM Closed 02-Sep-24 £750
Astrazeneca UK Limited 5815 - Patient Voice event MVO Closed 22-May-24 £2,500
GSK 5779a - Extension of Value of Vaccination Ireland VADM Closed 15-Mar-24 £2,832
GSK 5779c - Extension of Value of Vaccination Ireland VADM Closed 27-Jun-24 £8,263
M&F Health Communications 5500 - Burden of CSU VADM Closed 04-Apr-24 £29,750
Merck PTE Ltd 5409d - HTA reforms - OHE report VADM Closed 06-Feb-24 £20,746
Merck PTE Ltd 5776 - Health economics of infertility MVO Closed 05-Apr-24 £5,399
Pfizer Inc 5456f - Extension of HTA for GTx VADM Closed 05-Feb-24 £3,777
Pfizer 5485a Extension of Broad Value Meningitis Vx VADM Closed 26-Nov-24 £48,396
Pfizer Inc 5769a - Extension of Value of innovation EoI Closed 15-Oct-24 £9,976
The Janssen Pharmaceutical
Companies of Johnson & Johnson		 5702a - Extension of Discounting Panel - ISPOR 2023 VADM Closed 16-Feb-24 £1,458
IFPMA 5607d Extension of Socio-economic value of adult vaccination Flu Abstract VADM Closed 10-Apr-24 £2,598
Evoke incisive health 5704a - Extension of SE benefits of eliminating cervical cancer in the UK POIHS Closed 19-Jan-24 £2,226
Total won in 2024 and closed £141,671
Astellas Pharma US Inc 5784 - Combination-based pricing VADM Live 09-Feb-24 £78,137
Astrazeneca UK Limited 5785a - Extension of APACE collaboration VADM Live 24-Jun-24 £71,071
Astrazeneca UK Limited 5807- Broader value of breast cancer treatment MVO Live 03-Jun-24 £91,416

72

Astrazeneca UK Limited 5855 - Tumour Agnostic Treatment Access VADM Live 14-Oct-24 £62,694
BioLife Plasma Services LP 5758a - Circular economy WP2+3 VADM Live 28-May-24 £267,305
Biomerieux 5849 - STEDI for AMR Diagnostics VADM Live 10-Dec-24 £127,163
Chiesi 5841 - economic model pMDI VADM Live 05-Sep-24 £106,191
Daiichi Sankyo 5864 - Severity Modifier Roundtable VADM Live 20-Sep-24 £3,259
Grunenthal Pharma 5591d - Extension of Patient preferences in OA pain (2x Abstract/Posters) MVO Live 25-Jul-24 £14,375
GSK 5672b - Extension of Extension of Vacci-Nation: the Value of Vaccines to the
NHS		 VADM Live 15-Jan-24 £3,621
GSK 5777 - Vaccination Landscape POIHS Live 25-Jan-24 £82,457
GSK 5777a - Extension of Vaccination Landscape POIHS Live 09-May-24 £7,793
GSK 5839 - value of long-acting therapies VADM Live 18-Sep-24 £77,145
GSK 5839a - Extension of value of long-acting therapies VADM Live 30-Oct-24 £9,202
IFPMA 5607c - Extension of Socio-economic value of adult vaccination VADM Live 22-Jan-24 £25,457
Janssen Asia Pacific 5812b Extension of Going Braver - APAC VADM Live 27-Sep-24 £32,413
MSD Asia-Pacific 5812 - Going BRAVER - APAC VADM Live 23-Jul-24 £44,705
MSD Switzerland 5785 - APACE collaboration VADM Live 24-Jun-24 £71,071
Organon & Co. 5646c - Dissemination - The dynamics of drug shortages EoI Live 18-Jun-24 £49,904
Pfizer Limited 5865 - Employer costs from respiratory infections POIHS Live 24-Oct-24 £70,654
PhRMA 5822 The Innovation Ecosystem EOI Live 22-May-24 £104,000
PhRMA 5876 - CBO 2025 Critique EOI Live 11-Dec-24 £10,325
Pfizer Limited 5834 - Eliciting STEDI decision weights MVO Live 24-Oct-24 £68,683
Pfizer Inc 5823a - Pfizer Vaccines Summit Barcelona 2024 POIHS Live 12-Dec-24 £5947
Pfizer Inc 5833 - AIR OA - Alliance in RSV VADM Live 02-Jul-24 £11,920
Pfizer Inc 5829a - BRAVO-Vax (Sweden) VADM Live 18-Nov-24 £51,943
Pfizer Inc 5769b - Reporting extension of Value of innovation EOI Live 21-Nov-24 £29,998
Roche Singapore Pte. Ltd 5812a - Extension of Going BRAVER - APAC VADM Live 19-Aug-24 £51,830

73

Sanofi Pasteur SA 5868 - HRQoL in E. Coli Sepsis MVO Live 26-Nov-24 £106,306
Sanofi UK 5632c - Extension of Extension of International Collaborations in HTA VADM Live 15-Mar-24 £4,370
Sanofi UK 5858 - Commonwealth collaboration in HTA - 2024 update VADM Live 15-Oct-24 £48,296
The Janssen Pharmaceutical
Companies of Johnson & Johnson		 5820 - BIA for GTx VADM Live 27-Jun-24 £110,349
The Janssen Pharmaceutical
Companies of Johnson & Johnson		 5820a - Rountable Extension of BIA for GTx VADM Live 05-Sep-24 £71,445
UCB 5729a - Extension of Value frameworks VADM Live 06-Mar-24 £21,163
ViiV Healthcare 5698d - Extension of HIV Fiscal Health Modeling VADM Live 08-Jan-24 £4,792
ViiV Healthcare 5698f - Extension of HIV Fiscal Health Modeling VADM Live 03-Oct-24 £24,911
ViiV Healthcare 5783 - Ending HIV (Phase A) POIHS Live 11-Apr-24 £126,568
ViiV Healthcare 5783a - Ending HIV (Phase B) POIHS Live 18-Sep-24 £107,991
ViiV Healthcare 5783c - Ending HIV (Phase A Extension ) POIHS Live 25-Jul-24 £47235
ViiV Healthcare 5783d - Ending HIV (Phase A Extra Interviews) POIHS Live 24-Oct-24 £20,640
Alzheimer’s Society 5671b - Inequalities in dementia: amplification POIHS Live 29-Feb-24 £14,202
Cell and Gene Therapy Catapult 5819 - Macro benefits of CGT VADM Live 04-Jul-24 £296,850
Pfizer 5816 - Combo-Vx FHM POIHS Live 24-Jun-24 £201,570
Pfizer 5823 - Immunisation Budgets POIHS Live 04-Jul-24 £178,125
Pfizer Inc 5829 - BRAVO-Vax VADM Live 02-Aug-24 £366,379
UCB 5729c - Extension of Value frameworks VADM Live 30-Oct-24 £139,110
Total won in 2024 and still live in 2024 £3,520,981
Total won in 2024(live or closed) £3,662,652
Amgen AU 5610a - Extension of Combi Rx Roundtable and VSL VADM Live 01-Apr-23 £35,000
Compass Pathways 5707a - Extension of Consultancy Compass VADM Live 16-May-23 £468
Grunenthal Pharma 5591 - Patient preferences in OA pain MVO Live 23-Feb-23 £330,582
GSK 5672a - Extension of Vacci-Nation: the Value of Vaccines to the NHS VADM Live 30-Nov-23 £4,900

74

GSK 5733 - Pharmacy-based vaccination in England POIHS Live 08-Dec-23 £60,131
Moderna 5746 - COVID-19 Macroeconomics VADM Live 02-Nov-23 £360,551
Moderna 5746a - Extension of COVID-19 Macroeconomics VADM Live 29-Nov-24 £39,257
Roche Pharma (Schweiz) AG 5701 - cCDP endpoint in MS MVO Live 07-Aug-23 £192,315
Sanofi UK 5403f - Extension of Extension of Impact of NICE decisions VADM Live 17-May-23 £5,844
UCB 5729 - Value frameworks VADM Live 18-Oct-23 £124,162
ViiV Healthcare 5698 - HIV Fiscal Health Modeling VADM Live 22-Jul-23 £351,221
ViiV Healthcare 5698a - Extension of HIV Fiscal Health Modeling VADM Live 10-Oct-23 £2,366
Alzheimer’s Research UK 5625 - Dementia research investment case EoI Live 26-Jan-23 £53,419
Clifford Chance 5589e - Extension of Further Extension of Playdoh - Additional Trial Time VADM Live 04-Dec-23 £4,253
Big Health 5715 - Sleepio and Daylight employer analyses VADM Live 06-Nov-23 £59,703
Ondine Biomedical Inc 5508b - Extension of Steriwave UK report (stakeholder engagement) VADM Live 09-Oct-22 £31,485
PhRMA 5616a Inflation reduction Act Effects EoI Live 17-Dec-23 £20,000
Total won prior to 2024 still live £1,675,657

75

Project Funder Project Title Research
Theme		 Project
Status		 Year Won Project value
Amgen AU 5610 - Combi Rx Roundtable and VSL VADM Closed 17-Oct-22 £75,041
Astrazeneca UK Limited 5760 - Updating the AZ VBA narrative EoI Closed 18-Oct-23 £78,945
BioLife Plasma Services LP 5758 - Circular economy POIHS Closed 30-Dec-23 £110,778
Chiesi 5768 - Sustainability roundup ISPOR POIHS Closed 29-Nov-23 £12,752
Daiichi Sankyo 5420a - Extension of Priority roadmap & PVD VADM Closed 11-Sep-23 £9,591
Global Health Economics, LLC 5771 - Support for PHRMA work on IRA EoI Closed 23-Nov-23 £20,000
GSK 5405a - White Paper Extension of Early Global Value Proposition ABx VADM Closed 08-Dec-22 £19,856
GSK 5405c - Early Global Value Proposition ABx - Market Access Primer -
Enhancements		 VADM Closed 17-Sep-23 £43,175
GSK 5779 - Value of Vaccination Ireland VADM Closed 20-Dec-23 £58,595
Merck PTE Ltd 5409b - Mapping HTA changes dissemination activities VADM Closed 13-Apr-23 £60,261
Merck PTE Ltd 5409c - Mapping HTA changes - Phase 2 - MER interviews VADM Closed 13-Apr-23 £27,733
Novartis, Inc 5761 - Taiwan HTA workshop - Amanda EoI Closed 09-Nov-23 £4,000
Ondine Biomedical Inc 5508a - Extension of Steriwave UK report VADM Closed 31-Aug-22 £15,000
Organon & Co. 5646b - Estimating the cost of drug shortages EoI Live 17-Oct-23 £138,716
Organon & Co. 5646a - Dynamics of drug shortages dissemination EoI Closed 04-Sep-23 £34,306
Pfizer Inc 5384 - Educational Course Vaccine Economics VADM Closed 04-Jan-22 £255,429
Pfizer Inc 5552 - COVID-19 MASTERS MVO Closed 28-Apr-22 £10,747
Pfizer Inc 5769 - Value of innovation EoI Live 29-Nov-23 £138,970
PhRMA 5616 Inflation reduction Act Effects EoI , Live 26-Feb-23 £341,949
Reneo Pharmaceuticals 5781 - Reneo Ad Board VADM Closed 04-Dec-23 £1,689
Roche Diagnostic 5466b - Extension of Diagnostics for AMR VADM Closed 28-Mar-23 £15,000
Roche Pharma (Schweiz) AG 5556a - Extension of Role of Caregivers in HTA decision making MVO Closed 01-Dec-22 £16,096
Roche Pharma (Schweiz) AG 5731 - Case studies of RWE in EUnetHTA VADM Closed 16-Oct-23 £39,994
Roche Products Limited 5488 - Exploring issues in the modelling of carer quality of life MVO Closed 15-Dec-21 £143,226
Roche Products Limited , 5641 - Innovative Payment models - system readiness EOI Closed , 18-May-23 ,£95,438
Sanofi 5632 - International Collaborations in HTA VADM Closed 05-Jun-23 £27,915
Sanofi 5632b - Extension of International Collaborations in HTA VADM Closed 04-Oct-23 £23,842
Takeda 5502b - Extension of Value of NGS in Lung cancer (dissemination) VADM Closed 30-Mar-23 £33,451

76

The Janssen Pharmaceutical
Companies of Johnson & Johnson		 5702 - Discounting Panel - ISPOR 2023 VADM Closed 10-Sep-23 £61,696
The Janssen Pharmaceutical
Companies of Johnson & Johnson		 5766 - SE-Asia Speaking Tour VADM Closed 06-Nov-23 £10,720
Clifford Chance 5589d - Further Extension of Playdoh - Trial Processes VADM Closed 01-Dec-23 £96,633
Pfizer Limited 5095h - Extension of Impact of vaccines on productivity and health
servicepressure		 VADM Closed 29-Apr-22 £24,314
IFPMA 5607 Socio-economic value of adult vaccination VADM Closed 01-Nov-24 £467,373
Total won prior to 2024 but live for part of 2024 but now closed £2,417,793
Project Funder Project Title Research
Theme		 Project
Status		 Year Won Project value
Amgen AU 5610 - Combi Rx Roundtable and VSL VADM Closed 17-Oct-22 £75,041
Astrazeneca UK Limited 5760 - Updating the AZ VBA narrative EoI Closed 18-Oct-23 £78,945
BioLife Plasma Services LP 5758 - Circular economy POIHS Closed 30-Dec-23 £110,778
Chiesi 5768 - Sustainability roundup ISPOR POIHS Closed 29-Nov-23 £12,752
Daiichi Sankyo 5420a - Extension of Priority roadmap & PVD VADM Closed 11-Sep-23 £9,591
Global Health Economics, LLC 5771 - Support for PHRMA work on IRA EoI Closed 23-Nov-23 £20,000
GSK 5405a - White Paper Extension of Early Global Value Proposition ABx VADM Closed 08-Dec-22 £19,856
GSK 5405c - Early Global Value Proposition ABx - Market Access Primer -
Enhancements		 VADM Closed 17-Sep-23 £43,175
Total won prior to 2024 now closed £370,138

77

Contract research potential projects pipeline

Project Funder Project Name Theme Budget
Alzheimer’s Society 5671c - Extension of Inequalities in dementia POIHS £35,577
Astrazeneca UK Limited 5862 - Implementation of IBP EoI £131,400
Brunswickgroup 5851 - Earlycancer care impact VADM £120,820
Gilead Sciences Europe Ltd 5838 - CGT HTA Learnings Paper VADM £157,000
Gilead Sciences Europe Ltd 5727 - Gilead - HIV innovation spillovers and the IRA EOI £112,996
Grunenthal Pharma 5591c - Extension of Patientpreferences in OApain(Manuscript) MVO £34,207
Grunenthal Pharma 5591a - Extension of Patientpreferences in OApain(EU4 Launch) MVO £115,202
Grunenthal Pharma 5591b - Extension of Patientpreferences in OApain(US Launch) MVO £27,760
Grunenthal Pharma 5591c - Extension of Patient preferences in OA pain (Manuscript) MVO £34,207
GSK 5672d - Publication of Vacci-Nation: the Value of Vaccines to the NHS VADM £32,872
GSK 5733a - Extension of Pharmacy-based vaccination in England POIHS £17,514
GSK 5777b - Extension of Vaccination Landscape POIHS £9,987
GSK 5847 - GSK - Novel Access Models for Anti-infectives EOI £199,588
Guardant 5631a - Extension of UK Diagnostic Test Market Access VADM £61,011
Moderna 5746 - COVID-19 Macroeconomics VADM £36,661
Novartis Pharma Schweiz AG 5804 - Introduction to Utilities MVO £32,701
Organon £193,619
5873 - Evidencing the policy features of sustainable markets for
biosimilars		 EOI
Organon 5646d - Extension of Dissemination - The dynamics of drugshortages EOI £31,650
Pfizer 5866 - International accesspolicylandscape analysis EoI £129,772
Pfizer Inc 5829 - BRAVO-Vax VADM £58,395
Pharmaceutical Research and Manufacturers of America 5822a - Extension of The Innovation Ecosystem EoI £31,042
Roche Products Limited 5705 - ValuingcarerQALYs MVO £219,443
Shionogi Inc. 5647a - Extension of Antifungal Pull EoI £11,885
The Janssen Pharmaceutical Companies of J&J 5766a - Extension of SE-Asia Speaking Tour VADM £20,838
Vertex Pharmaceuticals(Europe)Ltd 5828 - Value ofpain management interventions VADM £0
ViiV Healthcare 5698c - Extension of HIV Fiscal Health Modeling VADM £31,319
ViiV Healthcare 5698e - Extension additional expert meetings Chile HIV Fiscal Health Modeling VADM £42,852
Potentialprojectpipeline total £1,930,318

78

About us

With over 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organisation. Every day we work to improve health care through pioneering and innovative research, analysis, and education.

As a global thought leader and publisher in the economics of health, health care, and life sciences, we partner with Universities, Government, health systems and the pharmaceutical industry to research and respond to global health challenges.

----- Start of picture text -----
OFFICE OF HEALTH ECONOMICS
CONTRACT RESEARCH
2024 REPORT ANNUAL CHARITY
----- End of picture text -----

As a government-recognised Independent Research Organisation and not-for-profit, our international reputation for the quality and independence of our research is at the forefront of all we do. OHE provides independent and pioneering resources, research and analyses in health economics, health policy and health statistics. Our work informs decision-making about health care and pharmaceutical issues at a global level.

All of our work is available for free online at www.ohe.org .

ohe.org

The Office of Health Economics A Company Limited by Guarantee of Registered No.09848965 OHE Consulting Ltd Registered Company No.09853113 OHE is a Charity Registration No.1170829 Registered Office ohe.org 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

Registered number: 09848965 Charity number: 1170829

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2024

Trustees Ms A R Charlesworth, Trustee
Dr R D Torbett, Trustee
Mr W P Holmes, Trustee
Ms M K Kyle, Trustee (resigned 31 December 2024)
Mr W B F Brouwer, Trustee
Mr P Catchpole, Trustee
Mr T E Allvin, Trustee (appointed 23 February 2024)
Company registered
number
09848965
Charity registered
number
1170829
Registered office
2nd Floor Goldings House
Hay's Galleria
2 Hay's Lane
London
SE1 2HB
Company secretary
R Hollingsworth
Chief executive officer
Prof G Cookson
Independent auditors
BDO LLP
Statutory Auditor & Chartered Accountants
2 City Place
Beehive Ring Road
Gatwick
West Sussex
RH6 0PA

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONTENTS
Page
Trustees' Report 1 - 7
Independent Auditors' Report 8 - 12
Consolidated Statement of Financial Activities 13
Consolidated Balance Sheet 14
Company Balance Sheet 15 - 16
Consolidated Statement of Cash Flows 17
Notes to the Financial Statements 18 - 32

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, ‘The Office of Health Economics’ ("OHE", "the charitable company", "the charity" or "the company") (charity number 1170829) (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2024.

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019.

As stated in Note 19 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The registered address of the ABPI is 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019 ("Charities SORP FRS 102").

Objectives and activities

The Office of Health Economics’ objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy.

Activities in furtherance of this include, in particular, but not exclusively:

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care.

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public.

Page 1

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE’s work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic activities. OHE’s consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity.

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI.

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2024, research funding was 117% of target and consultancy income was 105% of target. Operating expenditure in 2024 was 97% of the budget target. Overall, the company made a net operating loss, before receipt of Gift Aid from OHE Consulting Limited, as it made significant investments in charitable work, including the development of Third Edition of The Health Economics Dictionary which required significant staff input and constrained the organisation’s capacity to deliver against the full consultancy target for the year.

Financial review

a. Going concern

After making appropriate enquiries, and getting confirmation of on going support from ABPI (Note 18), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

The Trustees are aware that the operational and financial implications of the conflict between Ukraine and Russia as well as the Gaza war, have been considered by the Governance Committee of OHE’s ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

Page 2

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Financial review (continued)

b. Reserves policy

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources.

The group’s reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The charity reserves was £1,567,558 (2023 - £1,092,664 ) as at the year ended 31 December 2024. The Trustees have agreed with the ABPI that the research grant will in principle be a fixed amount each year, to help enable OHE to record an operating profit each year and build its own financial reserves.

The group's reserves target is 6 months of payroll expenditure. For 2025, that would be a target of £1,856,000. the group continue to work towards this by preparing a budget that delivers a 5% surplus to steadily increase the total reserves which the Trustees and Executive Management Team believe is sustainable. This has been possible over the past several years with the exception of 2023. We suggest that generating a surplus which is too significant would not be inline with delivering on our Charitable Objects.

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not-for-profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments.

c. Work programmes and funding

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, as well as the Health Foundation, European Commission, and a number of charitable and other organisations.

d. Results for the year

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £1,614,938 ( 2023 - £676,952 ) and made a gift aid payment for this amount to its parent company, the OHE.

The company made an operating loss of £1,194,790 ( 2023 - £807,403 ) prior to the gift aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2024 of £474,894 ( 2023 - loss of £130,451 ).

e. Fundraising

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fundraising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants.

Page 3

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management

a. Constitution and legal structure

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015.

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel.

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co opted under the terms of the Memorandum of Association.

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity.

c. Policies adopted for the induction and training of Trustees

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets.

d. Pay policy for key management personnel

Two Trustees (2023: Two) received fees for services during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements.

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends.

Page 4

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management (continued)

e. Organisational structure and decision-making policies

The company is governed by the Board of Trustees. The Trustees of the company during the period were as follows:

Ms A Charlesworth, Trustee Mr R D Torbett, Trustee Mr W P Holmes, Trustee Ms K Kyle, Trustee (resigned 31 December 2024) Mr W B F Brouwer, Trustee Mr P Catchpole, Trustee Mr T E Allvin, Trustee (appointed 23 February 2024)

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by an Editorial Committee, a Research Committee and a Policy Committee. Each Committee is Chaired by a Trustee and provides regular reports to the entire Board.

The Executive Management Team during the period were as follows:

Prof G Cookson (Chief Executive) Prof L Steuten (Deputy Chief Executive) Prof M Jofre Bonet (Chief Research Officer and Head of Education)

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. Transactions with other related parties are disclosed in Note 18.

As per the company Articles, the ABPI is entitled to appoint a majority of the Trustees (4/7), one of which is the Chief Executive of the ABPI.

f. Risk management

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks.

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff.

Plans for future periods

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as a newly established charity, OHE will be developing evidence based policy positions, which it will advocate by engaging with a wide range of stakeholders via events, media commentaries, and publications.

Page 5

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Statement of Trustees' responsibilities

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

Page 6

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Auditors

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). The registered office is 2 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies.

This report was approved by the Trustees, and signed on their behalf by:

Trustee Trustee

Date: 24-Jun-2025 | 11:05 BST Date: 23-Jun-2025 | 12:00 BST

Page 7

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

Opinion

In our opinion the financial statements:

We have audited the financial statements of The Office of Health Economics (“the Parent Charitable Company”) and its subsidiaries (“the Group”) for the year ended 31 December 2024 which comprise the consolidated statement of financial activities (incorporating income and expenditure account), the consolidated and charity balance sheets, the consolidated statement of cash flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Page 8

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Other Companies Act 2006 reporting

In our opinion, based on the work undertaken in the course of the audit:

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion;

Page 9

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Responsibilities of Trustees

As explained more fully in the Statement of Trustees’ responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the Parent Charitable Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations

Based on:

we considered the significant laws and regulations to be UK Companies Act, Charities Act 2011, and relevant UK tax legislation.

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be employment law, data protection and health and safety legislation.

Page 10

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Our procedures in respect of the above included:

Fraud

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

Based on our risk assessment, we considered the areas most susceptible to fraud to be posting of inappropriate journal entries and management bias in income recognition.

Our procedures in respect of the above included:

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Page 11

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Use of our report

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

David Wildey (Statutory Auditor)

For and on behalf of BDO LLP, Statutory Auditor Gatwick, UK

Date: 24 June 2025

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

Page 12

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2024

Note
Income from:
Donations and research grant
Charitable activities
Other trading activities
Interest receivable
Total income
Expenditure on:
Costs of other trading activities
4
Charitable activities
4
Total expenditure
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward		 Unrestricted
funds
2024
205,484
855,987
4,204,016
16,745
5,282,232
2,609,887
2,197,451
4,807,338
474,894
1,092,664
474,894
1,567,558		 Total
funds
2024
205,484
855,987
4,204,016
16,745
5,282,232
2,609,887
2,197,451
4,807,338
474,894
1,092,664
474,894
1,567,558		 Total
funds
2023
211,216
697,957
3,545,831
9,405
4,464,409
2,876,291
1,718,569
4,594,860
(130,451)
1,223,115
(130,451)
1,092,664

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 18 to 32 form part of these financial statements.

Page 13

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2024

2024 2024 2023
Note
Fixed assets
Tangible assets 9 17,220 33,115
17,220 33,115
Current assets
Debtors 10 2,724,920 1,879,379
Cash at bank and in hand 694,601 659,393
3,419,521 2,538,772
Creditors: amounts falling due within one
year 11 (1,869,183) (1,479,223)
Net current assets 1,550,338 1,059,549
Total assets less current liabilities 1,567,558 1,092,664
Net assets excluding pension asset 1,567,558 1,092,664
Total net assets 1,567,558 1,092,664
Charity funds
Restricted funds - -
Unrestricted funds 1,567,558 1,092,664
Total funds 1,567,558 1,092,664

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf by:

Trustee Trustee Date: 24-Jun-2025 | 11:05 BST Date: 23-Jun-2025 | 12:00 BST

The notes on pages 18 to 32 form part of these financial statements.

Page 14

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET AS AT 31 DECEMBER 2024

Note
Fixed assets
Tangible assets
9
Investments
Current assets
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
Net current assets
Total net assets less current liabilities
Charity funds
Unrestricted funds
Total funds		 2,067,875
305,491
2,373,366
(823,029)		 2024
17,220
1
17,221
1,550,337
1,567,558
1,567,558
1,567,558		 1,715,883
130,616
1,846,499
(786,951)		 2023
33,115
1
33,116
1,059,548
1,092,664
1,092,664
1,092,664

Page 15

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The profit after tax after gift aid of the parent Company for the year was £474,894 (2023 - loss after tax after gift aid £130,451).

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf by:

Trustee Trustee

Date: 24-Jun-2025 | 11:05 BST Date: 23-Jun-2025 | 12:00 BST

The notes on pages 18 to 32 form part of these financial statements.

Page 16

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2024

Cash flows from/(used in) operating activities
Net cash generated from/(used in) operating activities (note 14)
Cash flows from/(used in) investing activities
Purchase of tangible fixed assets
Net cash provided by/(used in) investing activities
Cash flows from financing activities
Interest received
Net cash provided by financing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
The notes on pages 18 to 32 form part of these financial statements		 2024
18,463
-
-
16,745
16,745
35,208
659,393
694,601		 2023
(371,764)
(15,895)
(15,895)
9,405
9,405
(378,254)
1,037,647
659,393

Page 17

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Statement of Financial Activities (SOFA) and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements.

The net income and expenditure for the period dealt with in the accounts of the parent company, after receipt of gift aid, was a net income of £474,894 (2023 - net expenditure of £130,451) .

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered the ongoing support from the ABPI, the evaluation of the conflicts around the world, inflation and interest rate rises, and concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. The ABPI has confrmed its support and provided a letter confirming this.

There is no indication that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. We have come to this conclusion following a review of the liabilities and cash flow over the next 12-18 months.

1.2 Company Status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 5. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Page 18

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Consultancy and research project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Deferred Income) to the extent that these have not been earned in the period. Project income yet to be invoiced has been accrued within Debtors (Accrued Income).

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

1.6 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Page 19

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.6 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

IT Software

33% straight line

1.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.8 Cash and Cash Equivalents

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.10 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments.

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Page 20

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.11 Foreign currencies

The company's and group's functional and presentational currency is Pounds Sterling.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account.

1.12 Pensions

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year.

Page 21

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

2. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

(a) Impairment of trade and other debtors

The company makes a judgement of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 11 for the net carrying amount of debtors.

(b) Accrued and deferred income

The group reviews the amount of any income generated but not invoiced to customers at the year end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end.

Page 22

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

3. Analysis of expenditure by activities

Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2024
Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2023		 Activities
undertaken
directly
2024
1,989,101
-
-
1,989,101
Activities
undertaken
directly
2023
1,612,284
-
-
1,612,284		 Support
costs
2024
-
114,027
94,323
208,350
Support
costs
2023
-
31,110
75,175
106,285		 Total
funds
2024
1,989,101
114,027
94,323
2,197,451
Total
funds
2023
1,612,284
31,110
75,175
1,718,569

Included within Direct charitable expenditure are staff costs totalling £1,225,077 ( 2023 - £961,939 ). A further £2,145,635 ( 2023 - £2,226, 206) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £3,370,712 ( 2023 - £3,188,1 45), is provided in Note 6.

Page 23

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

3. Analysis of expenditure by activities (continued)

Analysis of support costs

Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2024
Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2023		 Governance
2024
84,554
29,473
-
-
-
-
114,027
Governance
2023
7,619
23,491
-
-
-
-
31,110		 General
2024
-
-
26,582
3,767
21,035
42,939
94,323
General
2023
-
-
21,184
3,003
16,765
34,223
75,175		 Total
funds
2024
84,554
29,473
26,582
3,767
21,035
42,939
208,350
Total
funds
2023
7,619
23,491
21,184
3,003
16,765
34,223
106,285

Page 24

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

4. Analysis of expenditure by expenditure type

5. Other costs
2024		 Other costs
2023
OHE Consulting trading activities £
2,609,887		 £
2,876,291
Direct charitable expenditure 1,989,101 1,612,284
General support costs 94,323 75,175
Charitable activities 2,083,424 1,687,459
Expenditure on governance 114,027 31,110
2,197,451 1,718,569
Total Expenditure 4,807,338 4,594,860
Auditors' remuneration
Fees payable to the company's auditor and its associates in respect of:
Audit-related assurance services		 2024
10,000		 2023
9,000

6. Staff costs Staff costs, including key management personnel (see Note 7), were as follows:

Wages and salaries
Social security costs
Contribution to defined contribution pension
schemes (Note 17)		 Group
2024
2,845,429
332,758
192,525
3,370,712		 Group
2023
2,693,492
317,736
176,917
3,188,145		 Company
2024
1,034,880
129,120
61,077
1,225,077		 Company
2023
811,280
93,346
57,313
961,939

Page 25

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

6. Staff costs (continued)

The average number of persons employed by the company during the year was as follows:

Key management personnel
Administrative staff
The number of higher paid employees was:
In the band £60,001 - £70,000
In the band £70,001 - £80,000
In the band £80,001 - £90,000
In the band £90,001 - £100,000
In the bank £100,001 - £110,000
In the band £110,001 - £120,000
In the band £120,001 - £130,000
In the band £140,001 - £150,000
In the band £160,001 - £170,000
In the band £220,001 - £230,000
In the band £240,001 - £250,000
In the band £350,001 - £360,000		 Group
2024
No.
3
33
36		 Group
2023
No.
3
33
36		 Company
2024
No.
3
33
36
Group
2024
No.
2
3
4
3
1
1
1
1
1
-
1
1		 Company
2023
No.
3
33
36
Group
2023
No.
5
6
2
1
2
-
-
1
-
1
-
1

Page 26

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

7. Key management personnel

Wages and salaries
Social security costs
Cost of defined contribution scheme (Note 17)		 2024
771,027
106,402
19,721
897,150		 2023
719,995
93,199
25,270
838,464

In addition to the Board of Trustees, there were 3 ( 2023 - 3 ) key management personnel, 2 ( 2023 - 2 ) of which accrued benefits under another group entity's defined contribution pension scheme during the period.

8. Trustees' fees

Fees for services provided (see below)
Reimbursed travel expenses paid to 1 trustee		 2024
26,470
269
26,739		 2023
26,555
-
26,555

The highest paid Trustee received remuneration of £NIL ( 2023 - £NIL ).

A Charlesworth, Trustee, received fees for services provided during the period of £13,606 ( 2023 - £14,065 ).

M Kyle, Trustee, received fees for services provided during the period of £12,864 ( 2023 - £12,490 ).

The fees paid to the two Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its' objectives.

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party.

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period.

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association.

Page 27

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

9. Tangible fixed assets Group and Company

Cost or valuation
At 1 January 2024
At 31 December 2024
Depreciation
At 1 January 2024
Charge for the year
At 31 December 2024
Net book value
At 31 December 2024
At 31 December 2023		 IT software
47,685
47,685
14,570
15,895
30,465
17,220
33,115

10. Debtors

Due within one year
Trade debtors
Amounts owed by group undertakings
Other debtors
Prepayments and accrued income		 Group
2024
2,010,319
-
54,249
660,352
2,724,920		 Group
2023
1,220,246
-
-
659,133
1,879,379		 Company
2024
185,788
1,597,341
54,249
230,497
2,067,875		 Company
2023
60,386
1,315,578
-
339,919
1,715,883

Page 28

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

11. Creditors: Amounts falling due within one year

Trade creditors
Amounts owed to group undertakings
Other taxation and social security
Other creditors
Accruals and deferred income
Deferred income at the beginning of the year
Resources deferred during the year
Amounts released from previous periods
Deferred income at the end of the year		 Group
2024
61,287
578,890
4,678
43,000
1,181,328
1,869,183
Group
2024
581,655
880,844
(581,655)
880,844		 Group
2023
32,821
591,930
-
-
854,472
1,479,223
Group
2023
594,710
581,655
(594,710)
581,655		 Company
2024
47,657
517,369
4,678
2,310
251,015
823,029
Company
2024
57,369
111,904
(57,369)
111,904		 Company
2023
30,393
577,359
-
-
179,199
786,951
Company
2023
244,756
57,369
(244,756)
57,369

12. Financial instruments

Financial assets
Financial assets measured at fair value
through income and expenditure
Financial assets measured at amortised cost
Financial liabilities
Financial liabilities measured at cost less
impairment		 Group
2024
694,601
2,012,754
2,707,355
Group
2024
988,339		 Group
2023
659,393
1,820,128
2,479,521
Group
2023
897,568		 Company
2024
305,491
1,785,564
2,091,055
Company
2024
711,125		 Company
2023
130,616
1,656,632
1,787,248
Company
2023
729,582

Page 29

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

12. Financial instruments (continued)

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents.

Financial assets measured at amortised cost compromise of debtors falling due within one year, excluding prepayments.

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income.

13. Reconciliation of net movement in funds to net cash flow from/(used in) operating activities

Net surplus/(deficit) for the year (as per Statement of Financial Activities)
Adjustments for:
Depreciation charges
Increase in debtors
Increase in creditors
Interest received
Net cash provided by/(used in) operating activities		 Group
2024
474,894
15,895
(845,541)
389,960
(16,745)
18,463		 Group
2023
(130,451)
14,570
(334,374)
87,896
(9,405)
(371,764)

14. Cash and cash equivalents

Cash at bank and in hand
Total cash and cash equivalents		 Group
2024
694,601
694,601		 Group
2023
659,393
659,393

Page 30

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

15. Analysis of changes in net debt (Group)

Cash at bank and in hand At 1
January
2024
659,393
659,393		 Cash flows
35,208
35,208		 At 31
December
2024
694,601
694,601

16. Pension commitments

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable to the fund, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £192,525 (2023 - £176,917) for the group and £61,077 ( 2023 - £57,313 ) for the company.

17. Related party transactions

During the period two Trustees received fees for services totalling £26,470 ( 2023 - £26,555 ) (refer to Note 8 for details). At the balance sheet date, no amount ( 2023 - £Nil ) of this was outstanding.

During the period the company received research grants totalling £150,000 ( 2023 - £200,000 ) from the ABPI.

During the period, the group and company incurred support costs totalling £443,280 and £208,350 respectively ( 2023 - £368,280 and £106,285 ), which were recharged by the ABPI (refer to Note 19 below).

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred via Gift Aid (refer to Note 19 below).

18. Ultimate parent undertaking and controlling party

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB.

Page 31

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

19. Principal subsidiaries

The following was a subsidiary undertaking of the company:

Name Country of Incorporation Principal activity Holding
OHE Consulting Limited United Kingdom Provision of policy and 100%
strategic expertise on
healthcare and related
matters.

During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £4,204,016 ( 2023 - £3,5 45,831), and incurred expenditure totalling £2,602,333 ( 2023 - £2,876, 291), plus interest received of £13,255 (2023 - £7,412), generating profits for the period of £1,614,938 ( 2023 - £ 676,952). OHE Consulting Limited elected to transfer its profits, by Gift Aid, to the company leaving aggregated assets in OHE Consulting Limited of £1 at the period end.

20. Post balance sheet events

There have been no significant events affecting the group since the year-end.

Page 32

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

Registered number: 09848965 Charity number: 1170829

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2024

Trustees Ms A R Charlesworth, Trustee
Dr R D Torbett, Trustee
Mr W P Holmes, Trustee
Ms M K Kyle, Trustee (resigned 31 December 2024)
Mr W B F Brouwer, Trustee
Mr P Catchpole, Trustee
Mr T E Allvin, Trustee (appointed 23 February 2024)
Company registered
number
09848965
Charity registered
number
1170829
Registered office
2nd Floor Goldings House
Hay's Galleria
2 Hay's Lane
London
SE1 2HB
Company secretary
R Hollingsworth
Chief executive officer
Prof G Cookson
Independent auditors
BDO LLP
Statutory Auditor & Chartered Accountants
2 City Place
Beehive Ring Road
Gatwick
West Sussex
RH6 0PA

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONTENTS
Page
Trustees' Report 1 - 7
Independent Auditors' Report 8 - 12
Consolidated Statement of Financial Activities 13
Consolidated Balance Sheet 14
Company Balance Sheet 15 - 16
Consolidated Statement of Cash Flows 17
Notes to the Financial Statements 18 - 32

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, ‘The Office of Health Economics’ ("OHE", "the charitable company", "the charity" or "the company") (charity number 1170829) (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2024.

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019.

As stated in Note 19 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The registered address of the ABPI is 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019 ("Charities SORP FRS 102").

Objectives and activities

The Office of Health Economics’ objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy.

Activities in furtherance of this include, in particular, but not exclusively:

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care.

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public.

Page 1

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE’s work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic activities. OHE’s consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity.

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI.

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2024, research funding was 117% of target and consultancy income was 105% of target. Operating expenditure in 2024 was 97% of the budget target. Overall, the company made a net operating loss, before receipt of Gift Aid from OHE Consulting Limited, as it made significant investments in charitable work, including the development of Third Edition of The Health Economics Dictionary which required significant staff input and constrained the organisation’s capacity to deliver against the full consultancy target for the year.

Financial review

a. Going concern

After making appropriate enquiries, and getting confirmation of on going support from ABPI (Note 18), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

The Trustees are aware that the operational and financial implications of the conflict between Ukraine and Russia as well as the Gaza war, have been considered by the Governance Committee of OHE’s ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

Page 2

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Financial review (continued)

b. Reserves policy

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources.

The group’s reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The charity reserves was £1,567,558 (2023 - £1,092,664 ) as at the year ended 31 December 2024. The Trustees have agreed with the ABPI that the research grant will in principle be a fixed amount each year, to help enable OHE to record an operating profit each year and build its own financial reserves.

The group's reserves target is 6 months of payroll expenditure. For 2025, that would be a target of £1,856,000. the group continue to work towards this by preparing a budget that delivers a 5% surplus to steadily increase the total reserves which the Trustees and Executive Management Team believe is sustainable. This has been possible over the past several years with the exception of 2023. We suggest that generating a surplus which is too significant would not be inline with delivering on our Charitable Objects.

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not-for-profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments.

c. Work programmes and funding

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, as well as the Health Foundation, European Commission, and a number of charitable and other organisations.

d. Results for the year

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £1,614,938 ( 2023 - £676,952 ) and made a gift aid payment for this amount to its parent company, the OHE.

The company made an operating loss of £1,194,790 ( 2023 - £807,403 ) prior to the gift aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2024 of £474,894 ( 2023 - loss of £130,451 ).

e. Fundraising

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fundraising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants.

Page 3

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management

a. Constitution and legal structure

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015.

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel.

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co opted under the terms of the Memorandum of Association.

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity.

c. Policies adopted for the induction and training of Trustees

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets.

d. Pay policy for key management personnel

Two Trustees (2023: Two) received fees for services during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements.

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends.

Page 4

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management (continued)

e. Organisational structure and decision-making policies

The company is governed by the Board of Trustees. The Trustees of the company during the period were as follows:

Ms A Charlesworth, Trustee Mr R D Torbett, Trustee Mr W P Holmes, Trustee Ms K Kyle, Trustee (resigned 31 December 2024) Mr W B F Brouwer, Trustee Mr P Catchpole, Trustee Mr T E Allvin, Trustee (appointed 23 February 2024)

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by an Editorial Committee, a Research Committee and a Policy Committee. Each Committee is Chaired by a Trustee and provides regular reports to the entire Board.

The Executive Management Team during the period were as follows:

Prof G Cookson (Chief Executive) Prof L Steuten (Deputy Chief Executive) Prof M Jofre Bonet (Chief Research Officer and Head of Education)

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. Transactions with other related parties are disclosed in Note 18.

As per the company Articles, the ABPI is entitled to appoint a majority of the Trustees (4/7), one of which is the Chief Executive of the ABPI.

f. Risk management

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks.

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff.

Plans for future periods

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as a newly established charity, OHE will be developing evidence based policy positions, which it will advocate by engaging with a wide range of stakeholders via events, media commentaries, and publications.

Page 5

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Statement of Trustees' responsibilities

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

Page 6

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Auditors

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). The registered office is 2 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies.

This report was approved by the Trustees, and signed on their behalf by:

Trustee Trustee

Date: 24-Jun-2025 | 11:05 BST Date: 23-Jun-2025 | 12:00 BST

Page 7

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

Opinion

In our opinion the financial statements:

We have audited the financial statements of The Office of Health Economics (“the Parent Charitable Company”) and its subsidiaries (“the Group”) for the year ended 31 December 2024 which comprise the consolidated statement of financial activities (incorporating income and expenditure account), the consolidated and charity balance sheets, the consolidated statement of cash flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Page 8

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Other Companies Act 2006 reporting

In our opinion, based on the work undertaken in the course of the audit:

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion;

Page 9

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Responsibilities of Trustees

As explained more fully in the Statement of Trustees’ responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the Parent Charitable Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations

Based on:

we considered the significant laws and regulations to be UK Companies Act, Charities Act 2011, and relevant UK tax legislation.

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be employment law, data protection and health and safety legislation.

Page 10

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Our procedures in respect of the above included:

Fraud

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

Based on our risk assessment, we considered the areas most susceptible to fraud to be posting of inappropriate journal entries and management bias in income recognition.

Our procedures in respect of the above included:

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Page 11

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Use of our report

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

David Wildey (Statutory Auditor)

For and on behalf of BDO LLP, Statutory Auditor Gatwick, UK

Date: 24 June 2025

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

Page 12

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2024

Note
Income from:
Donations and research grant
Charitable activities
Other trading activities
Interest receivable
Total income
Expenditure on:
Costs of other trading activities
4
Charitable activities
4
Total expenditure
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward		 Unrestricted
funds
2024
205,484
855,987
4,204,016
16,745
5,282,232
2,609,887
2,197,451
4,807,338
474,894
1,092,664
474,894
1,567,558		 Total
funds
2024
205,484
855,987
4,204,016
16,745
5,282,232
2,609,887
2,197,451
4,807,338
474,894
1,092,664
474,894
1,567,558		 Total
funds
2023
211,216
697,957
3,545,831
9,405
4,464,409
2,876,291
1,718,569
4,594,860
(130,451)
1,223,115
(130,451)
1,092,664

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 18 to 32 form part of these financial statements.

Page 13

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2024

2024 2024 2023
Note
Fixed assets
Tangible assets 9 17,220 33,115
17,220 33,115
Current assets
Debtors 10 2,724,920 1,879,379
Cash at bank and in hand 694,601 659,393
3,419,521 2,538,772
Creditors: amounts falling due within one
year 11 (1,869,183) (1,479,223)
Net current assets 1,550,338 1,059,549
Total assets less current liabilities 1,567,558 1,092,664
Net assets excluding pension asset 1,567,558 1,092,664
Total net assets 1,567,558 1,092,664
Charity funds
Restricted funds - -
Unrestricted funds 1,567,558 1,092,664
Total funds 1,567,558 1,092,664

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf by:

Trustee Trustee Date: 24-Jun-2025 | 11:05 BST Date: 23-Jun-2025 | 12:00 BST

The notes on pages 18 to 32 form part of these financial statements.

Page 14

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET AS AT 31 DECEMBER 2024

Note
Fixed assets
Tangible assets
9
Investments
Current assets
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
Net current assets
Total net assets less current liabilities
Charity funds
Unrestricted funds
Total funds		 2,067,875
305,491
2,373,366
(823,029)		 2024
17,220
1
17,221
1,550,337
1,567,558
1,567,558
1,567,558		 1,715,883
130,616
1,846,499
(786,951)		 2023
33,115
1
33,116
1,059,548
1,092,664
1,092,664
1,092,664

Page 15

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The profit after tax after gift aid of the parent Company for the year was £474,894 (2023 - loss after tax after gift aid £130,451).

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf by:

Trustee Trustee

Date: 24-Jun-2025 | 11:05 BST Date: 23-Jun-2025 | 12:00 BST

The notes on pages 18 to 32 form part of these financial statements.

Page 16

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2024

Cash flows from/(used in) operating activities
Net cash generated from/(used in) operating activities (note 14)
Cash flows from/(used in) investing activities
Purchase of tangible fixed assets
Net cash provided by/(used in) investing activities
Cash flows from financing activities
Interest received
Net cash provided by financing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
The notes on pages 18 to 32 form part of these financial statements		 2024
18,463
-
-
16,745
16,745
35,208
659,393
694,601		 2023
(371,764)
(15,895)
(15,895)
9,405
9,405
(378,254)
1,037,647
659,393

Page 17

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Statement of Financial Activities (SOFA) and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements.

The net income and expenditure for the period dealt with in the accounts of the parent company, after receipt of gift aid, was a net income of £474,894 (2023 - net expenditure of £130,451) .

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered the ongoing support from the ABPI, the evaluation of the conflicts around the world, inflation and interest rate rises, and concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. The ABPI has confrmed its support and provided a letter confirming this.

There is no indication that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. We have come to this conclusion following a review of the liabilities and cash flow over the next 12-18 months.

1.2 Company Status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 5. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Page 18

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Consultancy and research project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Deferred Income) to the extent that these have not been earned in the period. Project income yet to be invoiced has been accrued within Debtors (Accrued Income).

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

1.6 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Page 19

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.6 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

IT Software

33% straight line

1.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.8 Cash and Cash Equivalents

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.10 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments.

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Page 20

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.11 Foreign currencies

The company's and group's functional and presentational currency is Pounds Sterling.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account.

1.12 Pensions

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year.

Page 21

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

2. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

(a) Impairment of trade and other debtors

The company makes a judgement of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 11 for the net carrying amount of debtors.

(b) Accrued and deferred income

The group reviews the amount of any income generated but not invoiced to customers at the year end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end.

Page 22

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

3. Analysis of expenditure by activities

Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2024
Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2023		 Activities
undertaken
directly
2024
1,989,101
-
-
1,989,101
Activities
undertaken
directly
2023
1,612,284
-
-
1,612,284		 Support
costs
2024
-
114,027
94,323
208,350
Support
costs
2023
-
31,110
75,175
106,285		 Total
funds
2024
1,989,101
114,027
94,323
2,197,451
Total
funds
2023
1,612,284
31,110
75,175
1,718,569

Included within Direct charitable expenditure are staff costs totalling £1,225,077 ( 2023 - £961,939 ). A further £2,145,635 ( 2023 - £2,226, 206) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £3,370,712 ( 2023 - £3,188,1 45), is provided in Note 6.

Page 23

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

3. Analysis of expenditure by activities (continued)

Analysis of support costs

Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2024
Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2023		 Governance
2024
84,554
29,473
-
-
-
-
114,027
Governance
2023
7,619
23,491
-
-
-
-
31,110		 General
2024
-
-
26,582
3,767
21,035
42,939
94,323
General
2023
-
-
21,184
3,003
16,765
34,223
75,175		 Total
funds
2024
84,554
29,473
26,582
3,767
21,035
42,939
208,350
Total
funds
2023
7,619
23,491
21,184
3,003
16,765
34,223
106,285

Page 24

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

4. Analysis of expenditure by expenditure type

5. Other costs
2024		 Other costs
2023
OHE Consulting trading activities £
2,609,887		 £
2,876,291
Direct charitable expenditure 1,989,101 1,612,284
General support costs 94,323 75,175
Charitable activities 2,083,424 1,687,459
Expenditure on governance 114,027 31,110
2,197,451 1,718,569
Total Expenditure 4,807,338 4,594,860
Auditors' remuneration
Fees payable to the company's auditor and its associates in respect of:
Audit-related assurance services		 2024
10,000		 2023
9,000

6. Staff costs Staff costs, including key management personnel (see Note 7), were as follows:

Wages and salaries
Social security costs
Contribution to defined contribution pension
schemes (Note 17)		 Group
2024
2,845,429
332,758
192,525
3,370,712		 Group
2023
2,693,492
317,736
176,917
3,188,145		 Company
2024
1,034,880
129,120
61,077
1,225,077		 Company
2023
811,280
93,346
57,313
961,939

Page 25

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

6. Staff costs (continued)

The average number of persons employed by the company during the year was as follows:

Key management personnel
Administrative staff
The number of higher paid employees was:
In the band £60,001 - £70,000
In the band £70,001 - £80,000
In the band £80,001 - £90,000
In the band £90,001 - £100,000
In the bank £100,001 - £110,000
In the band £110,001 - £120,000
In the band £120,001 - £130,000
In the band £140,001 - £150,000
In the band £160,001 - £170,000
In the band £220,001 - £230,000
In the band £240,001 - £250,000
In the band £350,001 - £360,000		 Group
2024
No.
3
33
36		 Group
2023
No.
3
33
36		 Company
2024
No.
3
33
36
Group
2024
No.
2
3
4
3
1
1
1
1
1
-
1
1		 Company
2023
No.
3
33
36
Group
2023
No.
5
6
2
1
2
-
-
1
-
1
-
1

Page 26

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

7. Key management personnel

Wages and salaries
Social security costs
Cost of defined contribution scheme (Note 17)		 2024
771,027
106,402
19,721
897,150		 2023
719,995
93,199
25,270
838,464

In addition to the Board of Trustees, there were 3 ( 2023 - 3 ) key management personnel, 2 ( 2023 - 2 ) of which accrued benefits under another group entity's defined contribution pension scheme during the period.

8. Trustees' fees

Fees for services provided (see below)
Reimbursed travel expenses paid to 1 trustee		 2024
26,470
269
26,739		 2023
26,555
-
26,555

The highest paid Trustee received remuneration of £NIL ( 2023 - £NIL ).

A Charlesworth, Trustee, received fees for services provided during the period of £13,606 ( 2023 - £14,065 ).

M Kyle, Trustee, received fees for services provided during the period of £12,864 ( 2023 - £12,490 ).

The fees paid to the two Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its' objectives.

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party.

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period.

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association.

Page 27

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

9. Tangible fixed assets Group and Company

Cost or valuation
At 1 January 2024
At 31 December 2024
Depreciation
At 1 January 2024
Charge for the year
At 31 December 2024
Net book value
At 31 December 2024
At 31 December 2023		 IT software
47,685
47,685
14,570
15,895
30,465
17,220
33,115

10. Debtors

Due within one year
Trade debtors
Amounts owed by group undertakings
Other debtors
Prepayments and accrued income		 Group
2024
2,010,319
-
54,249
660,352
2,724,920		 Group
2023
1,220,246
-
-
659,133
1,879,379		 Company
2024
185,788
1,597,341
54,249
230,497
2,067,875		 Company
2023
60,386
1,315,578
-
339,919
1,715,883

Page 28

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

11. Creditors: Amounts falling due within one year

Trade creditors
Amounts owed to group undertakings
Other taxation and social security
Other creditors
Accruals and deferred income
Deferred income at the beginning of the year
Resources deferred during the year
Amounts released from previous periods
Deferred income at the end of the year		 Group
2024
61,287
578,890
4,678
43,000
1,181,328
1,869,183
Group
2024
581,655
880,844
(581,655)
880,844		 Group
2023
32,821
591,930
-
-
854,472
1,479,223
Group
2023
594,710
581,655
(594,710)
581,655		 Company
2024
47,657
517,369
4,678
2,310
251,015
823,029
Company
2024
57,369
111,904
(57,369)
111,904		 Company
2023
30,393
577,359
-
-
179,199
786,951
Company
2023
244,756
57,369
(244,756)
57,369

12. Financial instruments

Financial assets
Financial assets measured at fair value
through income and expenditure
Financial assets measured at amortised cost
Financial liabilities
Financial liabilities measured at cost less
impairment		 Group
2024
694,601
2,012,754
2,707,355
Group
2024
988,339		 Group
2023
659,393
1,820,128
2,479,521
Group
2023
897,568		 Company
2024
305,491
1,785,564
2,091,055
Company
2024
711,125		 Company
2023
130,616
1,656,632
1,787,248
Company
2023
729,582

Page 29

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

12. Financial instruments (continued)

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents.

Financial assets measured at amortised cost compromise of debtors falling due within one year, excluding prepayments.

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income.

13. Reconciliation of net movement in funds to net cash flow from/(used in) operating activities

Net surplus/(deficit) for the year (as per Statement of Financial Activities)
Adjustments for:
Depreciation charges
Increase in debtors
Increase in creditors
Interest received
Net cash provided by/(used in) operating activities		 Group
2024
474,894
15,895
(845,541)
389,960
(16,745)
18,463		 Group
2023
(130,451)
14,570
(334,374)
87,896
(9,405)
(371,764)

14. Cash and cash equivalents

Cash at bank and in hand
Total cash and cash equivalents		 Group
2024
694,601
694,601		 Group
2023
659,393
659,393

Page 30

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

15. Analysis of changes in net debt (Group)

Cash at bank and in hand At 1
January
2024
659,393
659,393		 Cash flows
35,208
35,208		 At 31
December
2024
694,601
694,601

16. Pension commitments

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable to the fund, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £192,525 (2023 - £176,917) for the group and £61,077 ( 2023 - £57,313 ) for the company.

17. Related party transactions

During the period two Trustees received fees for services totalling £26,470 ( 2023 - £26,555 ) (refer to Note 8 for details). At the balance sheet date, no amount ( 2023 - £Nil ) of this was outstanding.

During the period the company received research grants totalling £150,000 ( 2023 - £200,000 ) from the ABPI.

During the period, the group and company incurred support costs totalling £443,280 and £208,350 respectively ( 2023 - £368,280 and £106,285 ), which were recharged by the ABPI (refer to Note 19 below).

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred via Gift Aid (refer to Note 19 below).

18. Ultimate parent undertaking and controlling party

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB.

Page 31

Docusign Envelope ID: A3461AC3-4702-4E8B-8578-30DEC99706DF

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

19. Principal subsidiaries

The following was a subsidiary undertaking of the company:

Name Country of Incorporation Principal activity Holding
OHE Consulting Limited United Kingdom Provision of policy and 100%
strategic expertise on
healthcare and related
matters.

During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £4,204,016 ( 2023 - £3,5 45,831), and incurred expenditure totalling £2,602,333 ( 2023 - £2,876, 291), plus interest received of £13,255 (2023 - £7,412), generating profits for the period of £1,614,938 ( 2023 - £ 676,952). OHE Consulting Limited elected to transfer its profits, by Gift Aid, to the company leaving aggregated assets in OHE Consulting Limited of £1 at the period end.

20. Post balance sheet events

There have been no significant events affecting the group since the year-end.

Page 32